File Name,Date of Petition,Date Comments,Identity of Submitting Entity,Representation Details,Cited Statutes or Regulations,FDA Action Commented On,Requested Action,Justification for Request,Status of Review,Review Comments
FDA-2018-P-0033-0001_Citizen_Petition_from_Hyman__Phelps___McNamara.pdf,1/2/2018,,"Hyman, Phelps & McNamara, P.C.
",Not mentioned.,"- Section 505(j) of the Federal Food, Drug and Cosmetic Act (FDC Act)
- 21 C.F.R. §§ 10.20, 10.30, 314.3, 25.31
- 57 Fed. Reg. 17,950 (Apr. 28, 1992)
- Orange Book Preface (37th ed. 2017)","FDA’s policy and designation practices for Reference Listed Drugs (RLDs) in the Orange Book, specifically regarding the lack of RLD designation for RASUVO (methotrexate) Injection under NDA 205776.","- Designate NDA 205776 (RASUVO) as a Reference Listed Drug (RLD) in the Orange Book.
- Determine and assign a RASUVO dosage strength as the Reference Standard.","- RASUVO is a single-source product with no pharmaceutical equivalence to the currently listed RLD (OTREXUP).
- No RLD exists for RASUVO’s ten dosage strengths, preventing ANDA submissions.
- RASUVO has significant market share, justifying RLD designation.",FALSE,"Missing in original spreadsheet, so completed in full here."
FDA-2018-P-0034-0001_Citizen_Petition_from_Hyman__Phelps___McNamara.pdf,1/2/2018,,"Hyman, Phelps & McNamara, P.C.
",Not mentioned.,"- Federal Food, Drug, and Cosmetic Act (FDC Act) § 505(j)
- 21 C.F.R. §§ 10.25(a), 10.30, 314.3, and 25.31
- FDA Draft Guidance for Industry: Referencing Approved Drug Products in ANDA Submissions (Jan. 2017)","FDA’s selection of Reference Standards (RS) in the Orange Book. The petition addresses the need to designate a new RS for Ranitidine Hydrochloride Capsules due to unavailability of the current RS.
","Designate Ranitidine Hydrochloride Capsules, 300 mg (ANDA 075742) as a new Reference Standard (RS) in the Orange Book, replacing the current RS under ANDA 074655
","- The existing RS (ANDA 074655) is increasingly difficult to obtain in the U.S., obstructing the ability to conduct bioequivalence studies.
- ANDA 075742 is an appropriate substitute, and designating it as RS would promote generic competition and efficiency
",FALSE,"Missing in original spreadsheet, so completed in full here."
FDA-2018-P-0097-0001_Citizen_Petition_from_Hyman__Phelps___McNamara.pdf,1/5/2018,,"Hyman, Phelps & McNamara, P.C.
",Not mentioned.,"- Federal Food, Drug, and Cosmetic Act (FDC Act) § 505(j)
- 21 C.F.R. §§ 10.25(a), 10.30, 25.31, 314.3
- FDA Draft Guidance for Industry: Referencing Approved Drug Products in ANDA Submissions (Jan. 2017)","FDA’s designation of Reference Standards (RS) in the Orange Book, specifically the absence of RS designation for Amicar Tablets, 500 mg despite being listed as a Reference Listed Drug (RLD).
","Designate Amicar (aminocaproic acid) Tablets, 500 mg, approved under NDA 015197, as a Reference Standard (RS) in the Orange Book","- The current RS (aminocaproic acid tablets, 1 g, NDA 015197) is increasingly difficult to obtain in the U.S.
- Though Amicar 500 mg is listed as an RLD, it lacks RS status, effectively shielding it from generic competition.
- RS designation would support generic entry",FALSE,"Missing in original spreadsheet, so completed in full here."
FDA-2018-P-0097-0004_Withdrawal__of_Petition_from_Hyman__Phelps___McNam.pdf,12/11/2018,,"Hyman, Phelps & McNamara, P.C.
",Not mentioned.,Not applicable.,Not applicable.,"Withdrawal of the previously submitted citizen petition.

","No justification for the withdrawal is provided in the letter. It states that a formal FDA response is no longer necessary.

",FALSE,
FDA-2018-P-0098-0001_Citizen_Petition_from_Lachman_Consultant_Services_.pdf,1/8/2018,,"Lachman Consultant Services, Inc.",Representing an unnamed client.,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. § 10.30
- 21 C.F.R. § 25.31 (Environmental Impact exclusion)","- FDA’s approval process for Abbreviated New Drug Applications (ANDA) where the proposed drug differs in strength from the Reference Listed Drug (RLD)
- The petition comments on the policy of allowing a change in strength of the RLD to be considered in an ANDA filing without raising new questions of safety or efficacy","The petitioner requests that FDA declare Zonisamide Capsules USP, 150 mg, 200 mg, and 300 mg as suitable for submission in an ANDA, even though they differ in strength from the existing 100 mg listed RLD (Zonegran Capsules by Sunovion Pharmaceuticals Inc.). This includes:
- Adding 150 mg, 200 mg, and 300 mg strengths
- Referencing the 100 mg, 25 mg, and 50 mg RLD capsules","- The proposed drug product uses the same dosage form (capsules) and active ingredient (zonisamide) as the RLD.
- The requested strengths (150/200/300 mg) are contemplated in the labeling of the RLD and support existing clinical dosing practices.
- Provides more convenient dosing for patients already stabilized on higher doses.
- No safety or efficacy issues are introduced.
- Includes draft labeling consistent with the RLD, and no change in intended use.
- Environmental exclusion is claimed under 21 C.F.R. § 25.31",FALSE,"Missing in original spreadsheet, so completed in full here."
FDA-2018-P-0130-0001_Citizen_Petition_from_Lachman_Consultant_Services_.pdf,1/8/2018,,"Lachman Consultant Services, Inc.",Representing an unnamed client.,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. § 10.30
- 21 C.F.R. § 25.31 (Environmental Impact exclusion)
- Pediatric waiver requested under PREA (Pediatric Research Equity Act)","- FDA’s procedure for approving ANDAs for drug products with different dosage strengths and dosage forms than those of the reference listed drug (RLD).
- Specifically, the policy of allowing such changes if no safety/efficacy issues arise and labeling is consistent","FDA should declare Zonisamide Tablets in strengths of 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, and 300 mg suitable for submission as an ANDA, even though the RLD is a capsule formulation (Zonegran Capsules, 100 mg by Sunovion). The request includes a change in dosage form (capsule → tablet) and additional strengths
","- Proposed strengths and form are clinically justified and already implied in the RLD’s labeling and dosing range.
- No safety or efficacy concerns are raised; labeling changes are minimal (strength/form only).
- Pediatric waiver requested due to minimal pediatric use and known risks (e.g., metabolic acidosis, oligohidrosis).
- Environmental exclusion claimed under 21 C.F.R. § 25.31",FALSE,"Missing in original spreadsheet, so completed in full here."
FDA-2018-P-0131-0001_Citizen_Petition_from_Lachman_Consultant_Services_.pdf,1/8/2018,,"Lachman Consultant Services, Inc.",Representing an unnamed client.,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. § 10.30 (Citizen Petition requirements)
- 21 C.F.R. § 25.31 (Environmental Impact exclusion)
- Pediatric waiver under PREA (Pediatric Research Equity Act)","FDA’s policy on the acceptance of Abbreviated New Drug Applications (ANDAs) for drug products that differ in strength and dosage form from the Reference Listed Drug (RLD), specifically changes from capsule to orally disintegrating tablet (ODT) and addition of new strengths
","FDA should declare Zonisamide Orally Disintegrating Tablets (ODTs) in 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, and 300 mg strengths as suitable for submission in an ANDA, despite the RLD (Zonegran) being a capsule formulation. This includes both a dosage form change (capsule → ODT) and strength additions
","- RLD (Zonegran) labeling supports a wide dosing range (up to 600 mg/day), implying higher strengths like 150–300 mg are clinically reasonable.
- An ODT formulation offers dosing flexibility, convenience, and potential compliance improvements.
- Labeling changes are minimal, and the proposed product maintains same indications and directions for use.
- Pediatric use is minimal, and the product carries known risks (e.g., oligohidrosis, metabolic acidosis), justifying a full pediatric waiver.
- Environmental impact exclusion claimed under 21 C.F.R. § 25.31
",FALSE,"Missing in original spreadsheet, so completed in full here. Similar to FDA-2018-P-0130-0001_Citizen_Petition_from_Lachman_Consultant_Services_.pdf, but slightly different."
FDA-2018-P-0258-0001_Citizen_Petition_from_Gilman_Cheese_Corporation.pdf,1/1/2018,"Letterhead dated January 1, but stamp reflects January 10.","Gilman Cheese Corporation
",Not mentioned.,"- 21 C.F.R. §§ 133.169 and 133.170 – Standards of identity for “Pasteurized Process Cheese”
- 21 C.F.R. §§ 25.30(h) and 25.32(a) – (for Environmental Impact exclusion)",FDA’s regulations specifying the name “Pasteurized Process Cheese” in 21 C.F.R. Parts 133.169 and 133.170. The petition comments on the use of that terminology and its implications for consumer perception and industry competition,"Amend 21 C.F.R. Parts 133.169 and 133.170 to:
- Replace all instances of the term “Pasteurized Process Cheese” with “Blended Cheese”, including in the part titles and body text.
- This would change the official designation of the cheese product to reflect a more neutral and modern term","- The term “Pasteurized Process Cheese” is misleading and unfairly associates high-quality cheese with lower-quality processed foods due to the word “process”.
- A PPC contains approximately 98% all-natural ingredients, is closer in composition to natural cheeses like Cheddar than to other “process cheese food” products.
- The term “Blended Cheese” is more accurate, free of negative consumer bias, separates it from lower-quality products, and is market-neutral and innovative",FALSE,"Missing in original spreadsheet, so completed in full here."
FDA-2018-P-0266-0001_Citizen_Petition_from_Arent_Fox_LLP.pdf,1/16/2018,,Arent Fox LLP,Representing an unnamed client.,"- Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- 21 C.F.R. §§ 10.20, 10.30(b)(3) (Citizen Petition requirements)
- 21 C.F.R. § 25.31 (Environmental Impact categorical exclusion)
- 21 C.F.R. § 25.40 (Environmental assessment provision)","FDA’s designation of Reference Standards (RS) in the Orange Book for Abbreviated New Drug Application (ANDA) bioequivalence testing, particularly the status of DermOtic Oil, 0.01% (NDA 019452) by Hill Dermaceuticals Inc. as the current RS","Designate ANDA No. A091306 / Fluocinolone Acetonide Oil, 0.01% Ear Drops, owned by Identi Pharmaceuticals Inc., as the new Reference Standard (RS) drug in the Orange Book for this product category, due to unavailability of the current RS (DermOtic Oil, 0.01%)
","- The current RS (DermOtic Oil, 0.01%) has been in long-term backorder with no anticipated availability.
- The Identi product is the market leader based on units sold.
- ANDA applicants cannot access sufficient quantities of the RLD to perform bioequivalence studies.
- Designating Identi’s product as RS would facilitate generic development",FALSE,"Missing in original spreadsheet, so completed in full here."
FDA-2018-P-0268-0001_Citizen_Petition_from_Arent_Fox_LLP.pdf,1/16/2018,,Arent Fox LLP,Representing an unnamed client.,"- Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- 21 C.F.R. §§ 10.20, 10.30(b)(3) (Citizen Petition requirements and economic impact)
- 21 C.F.R. § 25.31 (Categorical exclusion from environmental assessment)
- 21 C.F.R. § 25.40 (Environmental assessment provision)","The FDA’s designation of Reference Standards (RS) in the Orange Book, specifically for Fluocinolone Acetonide 0.01% Topical Oil (Body Oil). The current RS, Derma-Smoothe/FS (NDA 019452), is on long-term backorder and unavailable for bioequivalence testing","FDA should designate ANDA No. A201764, Fluocinolone Acetonide 0.01% Topical Oil (Body Oil), owned by Identi Pharmaceuticals Inc., as the new Reference Standard (RS) in place of Derma-Smoothe/FS
","- Derma-Smoothe/FS is unavailable (long-term backorder), preventing ANDA applicants from obtaining sufficient quantity for bioequivalence testing.
- Identi’s product is therapeutically equivalent and is the market leader by units sold.
- Replacing the RS would facilitate generic development by ensuring an accessible comparator",FALSE,"Missing in original spreadsheet, so completed in full here."
FDA-2018-P-0269-0001_Citizen_Petition_from_Arent_Fox_LLP.pdf,1/16/2018,,Arent Fox LLP,Representing an unnamed client.,"- Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- 21 C.F.R. §§ 10.20 and 10.30(b)(3) (Citizen Petition procedural and economic impact requirements)
- 21 C.F.R. § 25.31 (categorical exclusion from environmental assessment)
- 21 C.F.R. § 25.40 (environmental assessment provision)","FDA’s policy on designating Reference Standards (RSs) for ANDA submission, particularly when the currently designated RS (Derma-Smoothe/FS) is unavailable due to long-term backorder
","FDA should designate ANDA No. A201759 / Fluocinolone Acetonide 0.01% Topical Oil (Scalp Oil), owned by Identi Pharmaceuticals Inc., as the new Reference Standard (RS) in the Orange Book, replacing Derma-Smoothe/FS (NDA 019452)
","- Derma-Smoothe/FS is unavailable due to long-term backorder, with no anticipated return.
- The petitioner’s client cannot obtain enough product to perform required bioequivalence testing.
- The Identi product is therapeutically equivalent and is the market leader in units sold.
- Replacing the RS would enable generic ANDA filings
",FALSE,"Missing in original spreadsheet, so completed in full here."
FDA-2018-P-0322-0001_Petition_for_Stay_of_Action_from_Commonwealth_Bran.pdf,1/19/2018,"Letterhead and stamp dated January 19, but digital heading reflects January 23.","Commonwealth Brands, Inc. (CBI)
",Not mentioned.,"- 21 C.F.R. § 10.35 (Petition for stay of action)
- 21 C.F.R. § 10.75 (Supervisory review)
- 21 U.S.C. § 387j(a)(2)(B) (Substantial equivalence of tobacco products)
- 5 U.S.C. §§ 551, 558(c) (Administrative Procedure Act)","Issuance of Not Substantially Equivalent (NSE) orders dated January 4, 2018, by the FDA's Center for Tobacco Products (CTP) for seven Substantial Equivalence (SE) Reports submitted by CBI
","Immediate and indefinite stay of the seven NSE orders to allow CBI to pursue supervisory review under 21 C.F.R. § 10.75 without irreparable harm
","- Products have been marketed provisionally since 2011 under the FDCA.
- The SE Reports demonstrated substantial equivalence in all material respects.
- FDA issued NSE orders without proper notice and opportunity to respond, violating the Administrative Procedure Act and Due Process Clause.
- Irreparable harm from immediate withdrawal from the market.
- FDA failed to respond to earlier stay request (Jan 10, 2018).
- Sound public policy and administrative fairness support the stay, and no urgent public health interest outweighs it
",FALSE,"Missing in original spreadsheet, so completed in full here."
FDA-2018-P-0327-0001_Citizen_Petition_Fresenius_KabiUSA__LLC.pdf,1/22/2018,,"Fresenius Kabi USA, LLC",Not mentioned.,"- 21 C.F.R. § 10.30 (Citizen petition procedures)
- 21 C.F.R. § 314.161 (FDA determination on withdrawn drug products)
- 21 C.F.R. § 314.162 (Listing and delisting of approved drugs)
- 21 C.F.R. § 25.31 (Environmental Impact—categorical exclusion)","FDA’s listing of Mitomycin (NDA 050450) in the “Discontinued Section” of the Orange Book, which affects its eligibility for ANDA submissions
","FDA should determine whether Mitomycin (NDA 050450, 5 mg/vial and 20 mg/vial), held by Bristol Laboratories Inc., was withdrawn from sale for reasons of safety or efficacy
","- Mitomycin is listed in the Discontinued Section of the Orange Book.
- FDA must determine whether the drug was withdrawn for safety/efficacy reasons or for business reasons, as required before an ANDA can be approved.
- Fresenius Kabi seeks this determination to support ANDA referencing",FALSE,"Missing in original spreadsheet, so completed in full here."
FDA-2018-P-0339-0001_Citizen_Petition_from_Hahn_Loeser___Parks_LLP.pdf,1/19/2018,"Letterhead dated January 19, but stamp reflects January 23.",Hahn Loeser & Parks LLP,Not mentioned.,"- FDC Act § 505(j)(2)(C) (Suitability petition for ANDA submission)
- 21 C.F.R. §§ 10.20 and 10.30 (Citizen petition procedures)
- FDC Act § 505B (Pediatric Research Equity Act)
- 21 C.F.R. § 25.31 (Environmental impact categorical exclusion)
- 21 C.F.R. § 10.30(b) (Economic impact provision)","FDA’s regulation of suitability determinations for ANDA submissions that differ in strength from the listed drug product (i.e., change from 25 mg or 100 mg/vial to 200 mg/vial for Bendamustine Hydrochloride)","FDA should declare that Bendamustine Hydrochloride for Injection, 200 mg/vial is suitable for submission in an ANDA, based on reference to TREANDA (25 mg/vial and 100 mg/vial) approved under NDA 022249
","- Proposed product is quantitatively and qualitatively the same as the listed drug when reconstituted.
- 200 mg strength offers greater convenience for typical dosing needs and reduces need for multiple vials, minimizing risk of medication errors and cytotoxic exposure.
- No other changes in labeling, dosage form, or administration",FALSE,"Missing in original spreadsheet, so completed in full here."
FDA-2018-P-0343-0001_Citizen_Petition_from_Fish___Richardson_PC.pdf,1/23/2018,,"Fish & Richardson P.C.
","Representing Iroko Pharmaceuticals, LLC
","- 505(j)(4)(C)(i) of the FDCA
- 505(j)(4)(G) of the FDCA
- 505(q) of the FDCA
- 21 C.F.R. §§ 10.30, 10.31, 314.127, 314.92(a)(1), 314.94(a)(5), 314.94(a)(8), 314.127(a)(3), 314.127(a)(7), 314.95(3)(b), 320.1(c), 314.108","FDA’s potential approval of Abbreviated New Drug Application (ANDA) No. 210299 submitted by Apotex Inc. for a generic version of ZORVOLEX®
","Request for the FDA to refuse approval of ANDA No. 210299 by Apotex Inc. because:
- The active ingredient (diclofenac sodium) is not the same as that in the RLD (diclofenac free acid)
- The labeling is not the same as that approved for ZORVOLEX®","- Diclofenac sodium is a different active ingredient from diclofenac free acid due to differences in chemical structure and physical properties (solubility, bioavailability, GI permeability)

- Labeling differences create safety concerns and confusion, as the RLD label explicitly warns against interchangeability with salt forms like diclofenac sodium",FALSE,"Missing in original spreadsheet, so completed in full here."
FDA-2018-P-0345-0001_Citizen_Petition_from_Macleods_Pharmaceuticals_Lim.pdf,1/23/2018,,Macleods Pharmaceuticals Limited,Not mentioned.,"- Section 505(j) of the Federal Food, Drug, and Cosmetic Act
- 21 CFR §§ 10.25(a), 10.30, 314.93 (Citizen petition and ANDA standards)
- 21 CFR §§ 25.31(a), 25.15(d) (Environmental impact categorical exclusion)","FDA’s designation of Furadantin® (NDA# N009175) as the reference standard (RS) for Nitrofurantoin Oral Suspension in the Orange Book, despite limited commercial availability","Request FDA to designate approved ANDA #A201679 (Nitrofurantoin Oral Suspension, 25 mg/5 mL by Amneal Pharmaceuticals) as the new reference standard (RS) for ANDA submissions
","- Furadantin® (RLD) is not readily available for bioequivalence testing due to limited distribution.
- Amneal’s product is the market leader and therapeutically equivalent.
- FDA guidance allows selecting a new RS under such conditions",FALSE,"Missing in original spreadsheet, so completed in full here."
FDA-2018-P-0345-0007_Withdrawal_of_Citizen_Petition.pdf,11/12/2020,"Date was incorrectly identified by ChatGPT, but date has been manually adjusted. ",Macleods Pharmaceuticals Limited,Not mentioned.,Not applicable.,Not applicable.,"Withdrawal of the previously submitted citizen petition.

","The Reference Listed Drug (RLD) is now available in the Orange Book, making the petition to designate RS unnecessary. Bioequivalence testing and ANDA filing can now proceed using the RLD listed
",FALSE,
FDA-2018-P-0564-0001_Citizen_Petition_from_Panera_LLC.pdf,1/18/2018,,"Panera, LLC
",Not mentioned.,"- 21 U.S.C §§ 401, 403, 371 (FDCA Sections)
- 21 CFR 160.100, 160.105, 160.110, 160.115, 160.140, 160.145, 160.150, 160.180, 160.185, 160.190 (Egg-related standards)
- 21 CFR 101.4(b)(10)-(12) (Ingredient labeling)
- 21 CFR 130.5(b) (Standard of identity)
- 21 CFR 25.32 (Environmental Impact exclusion)","The absence of a formal definition for the term “egg” under 21 CFR 160.100 and the permissive labeling of processed egg products as “egg,” “egg whites,” or “egg yolks” under 21 CFR 101.4","- Amend 21 CFR 160.100 to define “egg” as a food made from a cracked shell egg without additives or further processing, except for pathogen control (e.g., pasteurization).
- Amend 21 CFR 101.4 to prohibit processed egg products containing additives from being labeled simply as “egg,” “egg whites,” or “egg yolks”","- Current regulations lack clarity and allow processed egg products with additives (e.g., preservatives, emulsifiers) to be labeled simply as “egg,” misleading consumers.
- Panera uses real shell eggs and wants transparency and fairness in product naming.
- A clear standard would support honest labeling and consistent use in retail and foodservice.
- Suggested definition aligned with 9 CFR 590.1 under the Egg Inspection Act",FALSE,"Missing in original spreadsheet, so completed in full here."
FDA-2018-P-0597-0001_Citizen_Petition_from_the_Alliance_for_Natural_Hea.pdf,2/7/2018,,"Alliance for Natural Health USA (ANH-USA)
",Not mentioned.,"- 21 C.F.R. §§ 10.20, 10.30 (Citizen Petition procedures)
- 21 C.F.R. § 25.30 (Environmental Impact categorical exclusion)
- 21 C.F.R. § 10.30(b) (Economic impact clause)
- Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (Compounding provisions)","FDA’s appointment of the Pew Charitable Trusts as a voting member of the Pharmacy Compounding Advisory Committee (PCAC)
","Remove the Pew Charitable Trusts from its voting position on the PCAC, due to conflict of interest
","- Pew has partnered with PhRMA and BIO, groups with vested pharmaceutical interests opposed to compounded drugs.
- Signed a joint letter with PhRMA (June 12, 2017) advocating positions financially benefiting drug companies.
- Co-sponsored Congressional briefings that pushed anti-compounding narratives.
- Other PCAC members with potential conflicts are non-voting, while Pew is a voting member, making its conflict more serious.
- Pew’s involvement undermines the impartiality and credibility of PCAC",FALSE,"Missing in original spreadsheet, so completed in full here."
FDA-2018-P-0598-0001_Citizen_Petition_from_Hyman__Phelps___McNamara__PC.pdf,2/7/2018,,"Hyman, Phelps & McNamara, P.C.
","Representing United Therapeutics Corporation (UTC)
","- 21 U.S.C. §§ 355(a), 355(j), 355(b)(2) (FDCA sections)
- 21 C.F.R. § 10.30 (Citizen petition procedure)
- 505(q) of the FDCA
- 21 C.F.R. § 25.31(c) (Environmental Impact categorical exclusion)","FDA's potential approval of NDA or ANDA referencing Sodium Bicarbonate Injection, USP products (particularly from manufacturer Cumberland Pharmaceuticals Inc.) without adequate data to support approval routes
","- FDA should refuse approval of any NDA or ANDA for Sodium Bicarbonate Injection, USP that does not meet applicable regulatory requirements.
- Require any applicant to submit a full NDA (not an ANDA or 505(b)(2)) unless the applicant demonstrates its product is pharmaceutically equivalent to an RLD","- Products currently on market are unapproved or lack data on equivalence, sterility, or stability.
- No ANDA or 505(b)(2) product should be approved unless it shows pharmaceutical equivalence and meets FDA’s own technical and regulatory standards.
- Improper approval undermines FDA’s authority and poses safety risks",FALSE,"Missing in original spreadsheet, so completed in full here. Representation status was incorrectly identified by ChatGPT."
FDA-2018-P-0599-0001_Citizen_Petition_from_National_Pediculosis_Associa.pdf,2/6/2018,,"National Pediculosis Association, Inc. (NPA)
",Not mentioned.,"510(k) medical device clearance (FDA K981250); general reference to FDA policy and website standards. No citation of 505(q) or 21 C.F.R. 10.30
","The petition comments on the FDA’s public education materials and website content regarding lice treatment options, specifically their emphasis on chemical remedies and lack of comparable attention to combing and the LiceMeister comb
","The NPA requests the FDA to:
• Update its website and educational materials to better emphasize combing as a treatment option.
• Acknowledge that not all lice combs are equivalent.
• Mention the LiceMeister® comb by name, similar to how chemical treatments are branded","- The LiceMeister comb was cleared as a 510(k) device for lice detection and removal.
- Research shows combing is more effective and safer than chemical treatments, especially for children.
- FDA materials currently downplay the effectiveness of combing and overlook the risks of chemical treatments (e.g., lindane).
- Environmental concerns about pesticide use and its effects on water systems and public health.
- Inclusion of combing aligns with FDA’s 2018 policy goal to empower consumers with informed health decisions",FALSE,"Missing in original spreadsheet, so completed in full here."
FDA-2018-P-0614-0001_Citizen_Petition_from_GeneYork_Pharmaceuticals_Gro.pdf,2/7/2018,,"GeneYork Pharmaceuticals, LLC
",Not mentioned.,"- 21 C.F.R. § 10.25(a) (General filing procedures)
- 21 C.F.R. § 10.30 (Citizen petition)
- 21 C.F.R. § 314.122 (Reference Listed Drug availability)
- 21 C.F.R. § 25.24(c)(1) (Environmental impact exclusion)
- 21 C.F.R. § 10.30(b) (Economic impact)","FDA’s current designation of HEXADROL (NDA 014694, Organon USA Inc.) as the Reference Listed Drug (RLD), and Luitpold’s product (ANDA 087440) as the Reference Standard (RS) for dexamethasone sodium phosphate injection
","FDA should designate ANDA 084916 (owned by Fresenius Kabi USA, Inc.) as an alternate Reference Standard (RS) for HEXADROL, to support generic drug development
","- Both the current RLD (HEXADROL) and RS (Luitpold) products are no longer commercially available, making it difficult to develop a generic product.
- Fresenius Kabi’s ANDA 084916 product is pharmaceutically equivalent (same ingredient, dosage form, strength) and holds over 80% of market share, making it the most accessible and practical RS.
- Ensuring access to an available RS aligns with the Hatch-Waxman Act’s goal of facilitating affordable generics",FALSE,"Missing in original spreadsheet, so completed in full here."
FDA-2018-P-0625-0001_Citizen_Petition_from_Made_in_the_USA_Foundation.pdf,2/1/2018,"Letterhead dated February 1, but stamp reflects February 8.","Made in the USA Foundation
",Not mentioned.,"- 19 U.S.C. § 1304
- 19 C.F.R. §§ 134.1(d), 134.25, 134.46
- 21 U.S.C. §§ 331, 352
- 21 C.F.R. § 201.1",The absence of a requirement for country-of-origin labeling on prescription drug packaging sold in pharmacies,"The petitioner requests that the FDA initiate a rulemaking proceeding to require that:
1) All prescription drugs dispensed by pharmacies state their country of origin in at least 12-point font.
2) Labels referring to the U.S. (e.g., “USA”) must disclose the actual country of origin in type at least as large.
3) Failure to comply may result in criminal prosecution","- To ensure transparency and protect consumers from misleading labeling.
- Federal law already requires country-of-origin labeling for imported goods, and this should extend to prescription drugs.
- FDA inspections of foreign manufacturing facilities are infrequent, particularly in India and China, from where 80% of U.S. prescription drugs are sourced.
- The change would reduce the carbon footprint and promote U.S. drug manufacturing.
",FALSE,"Missing in original spreadsheet, so completed in full here."
FDA-2018-P-0664-0001_Citizen_Petition_from_Prinston_Pharmaceutical_Inc_.pdf,2/9/2018,,"Prinston Pharmaceutical Inc.
",Not mentioned.,"- 21 C.F.R. §§ 10.25(a), 10.30 (Citizen petition submission procedures)
- 21 C.F.R. § 25.31 (Environmental impact exclusion)
- 21 C.F.R. § 10.30(b) (Economic impact)
- Reference to Section 505(j) of the FD&C Act","The FDA’s current designation of ANDA 079195 as the Reference Standard (RS) for Rocuronium Bromide Injection, which is allegedly not available in sufficient quantities for comparative analysis","Prinston requests that FDA designate ANDA 091115 (held by TAMARANG SA) as the new Reference Standard (RS) for Rocuronium Bromide Injection, 50 mg/5 mL and 100 mg/10 mL
","- The currently designated RS (ANDA 079195) is not sufficiently available for in vivo bioequivalence testing.
- FDA guidance allows RS designation changes when distribution is limited.
- ANDA 091115 is commercially available and has greater market share.
- This change would facilitate market competition and help avoid potential drug shortages",FALSE,"Missing in original spreadsheet, so completed in full here."
FDA-2018-P-0664-0004_Withdrawal_from_Prinston_Pharmaceutical_Inc.pdf,3/13/2019,,"Prinston Pharmaceutical Inc.
",Not mentioned.,Not applicable.,Not applicable.,"Withdrawal of the previously submitted citizen petition.

","Not provided in the withdrawal request; the letter simply states the intent to withdraw without explanation
",FALSE,
FDA-2018-P-0670-0010_Withdrawal_from_Sean_Griffin.pdf,7/19/2019,"Date was incorrectly identified by ChatGPT, but date has been manually adjusted. ",Sidley Austin LLP,"Representing Paragon Bioteck, Inc.",Not applicable.,Not applicable.,"Withdrawal of the previously submitted citizen petition.

","Not mentioned (no rationale or reason is provided for the withdrawal)
",FALSE,
FDA-2018-P-0673-0001_Citizen_Petition_from_Justice_for_Jake.pdf,11/13/2017,"Signature dated November 13, but stamp reflects February 8.","Justice for Jake (Board of Directors)
",Not mentioned.,"- Section 355(e) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. § 10.30
- §360bbb-2 of U.S.C. (Classification of products)
- §811 Part C (5)
- Controlled Substances Act of 1970","Classification of Alprazolam as a Schedule IV drug under the Controlled Substances Act
","Reschedule alprazolam from Schedule IV to Schedule II and conduct a study on its control in relation to the opioid crisis
","- Alprazolam is involved in a significant portion of opioid overdose deaths (e.g., ~25% of overdoses involving opioids like hydrocodone, oxycodone, methadone).
- 1 in 3 opioid overdose deaths involves an anti-anxiety drug; 90% of these involve alprazolam.
- Recreational use is rising, with 125,000 hospital visits per year.
- Liquid formulations linked to suicides and fatalities.
- Pharmacy controls are lax (e.g., imprecise counting, refills).
- Environmental data from a 2013 study shows overdose deaths involving benzodiazepines like alprazolam have increased 5x since 1996.
- Petition argues alprazolam's abuse and danger justify placement in Schedule II
",FALSE,"Missing in original spreadsheet, so completed in full here."
FDA-2018-P-0674-0001_Citizen_Petition_from_Medtech_Products_Inc.pdf,2/9/2018,"Letterhead dated February 9, but stamp reflects February 12.",Medtech Products Inc.,Not mentioned.,"- 505(j)(2)(C) of the FD&C Act
- 21 C.F.R. §§ 10.20, 10.30, 314.93 (ANDA suitability petition regulations)
- 21 C.F.R. § 25.31(a) (Environmental impact exemption)
- 21 U.S.C. § 355c(a)(4)(A)(ii) (Pediatric Research Equity Act waiver request)",Suitability petition for submission of an ANDA with a dosage form different from the Reference Listed Drug (RLD): Excedrin® Migraine (tablet),"FDA approval to submit an ANDA for acetaminophen 250 mg, aspirin 250 mg, and caffeine 65 mg in powder dosage form for OTC treatment of migraine
","- Powder dosage form does not require new safety/efficacy studies as the active ingredients and strengths are identical to the RLD.
- Bioequivalence studies will be conducted and included in the ANDA.
- The powder form is already a common OTC form in this category.
- No significant labeling changes required.
- Offers an alternative for patients with dysphagia (difficulty swallowing).
- The RLD (Excedrin® Migraine) remains marketed and has no unexpired exclusivity, per the Orange Book",FALSE,"Missing in original spreadsheet, so completed in full here."
FDA-2018-P-0829-0001_Citizen_Petition_from_Prinston_Pharmaceutical_Inc_.pdf,2/22/2018,,"Prinston Pharmaceutical Inc.
",Not mentioned.,"- 21 C.F.R. §§ 10.25(a), 10.30 (Citizen petition procedures)
- 21 C.F.R. § 25.31 (Environmental impact exemption)
- 21 C.F.R. § 10.30(b) (Economic impact disclosure)
- Section 505(j) of the FD&C Act (generic drug approval requirements)
- FDA Draft Guidance (Jan. 2017), Referencing Approved Drug Products in ANDA Submissions","FDA’s designation of NDA 050746 (BACTROBAN, held by GlaxoSmithKline) as the Reference Standard (RS) for Mupirocin Calcium Cream, EQ 2% Base
","Prinston requests that FDA designate ANDA 201587 (held by Glenmark Pharmaceuticals Inc. USA) as the new Reference Standard for Mupirocin Calcium Cream, EQ 2% Base
","- Current RS (NDA 050746) is unavailable in sufficient commercial quantities for in vivo bioequivalence testing.
- FDA has discretion to select a different RS when access to the current RS is limited.
- ANDA 201587 is the only commercially available formulation of the product.
- Redesignating the RS will facilitate market entry of generics and mitigate drug shortage risks",FALSE,"Missing in original spreadsheet, so completed in full here."
FDA-2018-P-0870-0001_Citizen_Petition_from_LACHMAN_CONSULTANT_SERVICES_.pdf,2/26/2018,,"Lachman Consultant Services, Inc.
",Representing an unnamed client.,"- Section 505(j)(2)(C) of the FD&C Act
- 21 C.F.R. § 10.30 (Citizen Petition procedures)
- 21 C.F.R. § 25.31 (Environmental impact categorical exclusion)
- 21 U.S.C. § 355B (505B) (Pediatric Research Equity Act – cited for inapplicability)","Suitability determination for submission of an ANDA for Potassium Chloride Extended Release Tablets, 8 mEq, based on a change in strength from the RLD (K-Dur, 20 mEq)
","That FDA declare Potassium Chloride Extended Release Tablets, 8 mEq to be suitable for submission as an ANDA referencing the RLD, Potassium Chloride ER Tablets 20 mEq (NDA 19439)
","- The proposed product differs only in strength (8 mEq vs 20 mEq) from the RLD.
- The change in strength aligns with approved labeling dosing guidelines (e.g., doses divided so no more than 20 mEq is given at once).
- There is no change in indications, warnings, or directions for use.
- Multiple 8 mEq ER potassium chloride tablets have already been approved by FDA, as shown in a table on page 2 listing other products by AbbVie, Upsher-Smith, Mylan, etc.
- No clinical investigations should be required because safety and efficacy are not impacted by the proposed strength change.
- The Pediatric Research Equity Act (PREA) does not apply to this request.",FALSE,"Missing in original spreadsheet, so completed in full here."
FDA-2018-P-0874-0001_Citizen_Petition_from_Bonumose_LLC.pdf,2/22/2018,"Date was incorrectly identified by ChatGPT, but date has been manually adjusted. ","Bonumose, LLC
",Not mentioned.,"- 21 C.F.R. § 10.30 (Citizen petition regulations)
- 21 U.S.C. § 321 (ff) (Definition of dietary supplement)
- 21 C.F.R. § 101.36 (Nutrition labeling of dietary supplements)
- 21 U.S.C. § 343(a)(1) (Misbranding provision)
- 21 C.F.R. §§ 101.3, 101.4, 101.9 (Labeling provisions for foods)","FDA's current labeling policy and enforcement practices that require ""Total Sugars"" and ""Added Sugars"" declarations on the Nutrition Facts Label for all monosaccharides and disaccharides, including rare sugars such as tagatose and allulose","Bonumose requests that FDA:
1. Reclassify tagatose and similar rare sugars to exclude them from ""Total Sugars"" and ""Added Sugars"" on Nutrition Facts Labels.
2. Amend regulations and guidance to reflect this exclusion.
3. Issue a guidance document or enforcement discretion policy pending formal rulemaking","- Tagatose is minimally absorbed and metabolized, does not raise blood glucose levels, and has low caloric value (1.5 kcal/g).
- Including tagatose in “Total Sugars” and “Added Sugars” is misleading to consumers and inconsistent with FDA's goal of informed dietary choices.
- Health benefits include prebiotic effects, dental health advantages, and lack of impact on insulin/glucose response.
- Tagatose is chemically a sugar, but functionally behaves more like fiber or polyols, which are not classified as “added sugars.”
- Current labeling rules may discourage manufacturers from using healthier sugar alternatives like tagatose",FALSE,"Missing in original spreadsheet, so completed in full here."
FDA-2018-P-0876-0001_Citizen_Petition_from_Hyman__Phelps___McNamara.pdf,2/23/2018,,"Hyman, Phelps & McNamara, P.C.
",Representing an unnamed client.,"- 21 C.F.R. § 10.30 (Citizen petitions)
- 21 C.F.R. § 10.20 (General filing regulations)
- 21 C.F.R. § 314.93 (Suitability petitions)
- Section 505(j)(2)(C) and 505(j)(2)(A)(iii) of the FD&C Act
- 21 C.F.R. § 25.31 (Environmental categorical exclusions)
- 21 C.F.R. § 10.30(b) (Economic impact information upon request)
- 505B(a)(1)(A) (Pediatric Research Equity Act)",FDA’s authority to determine suitability of an ANDA submission for a product that differs from a Reference Listed Drug (RLD) in strength only. The RLD is ALBENZA (albendazole) 200 mg tablets,"Request for FDA to determine that Albendazole Tablets, 400 mg are suitable for submission in an ANDA, referencing ALBENZA 200 mg as the RLD
","- The only difference from the RLD is tablet strength (400 mg vs 200 mg); all other elements—active ingredient, route of administration, dosage form, and regimen—remain the same.
- The proposed product would reduce tablet burden for patients needing 400 mg or 800 mg daily, aligning with approved RLD dosing (which currently requires 2 or 4 tablets).
- The petition asserts no safety or efficacy issues arise from the change.
- PREA does not apply since this is not a new active ingredient, dosage form, indication, route, or regimen",FALSE,"Missing in original spreadsheet, so completed in full here."
FDA-2018-P-0877-0001_Citizen_Petition_from_The_Food_Lawyers.pdf,2/24/2018,,"The Food Lawyers®
",Not mentioned.,"- 21 C.F.R. §101.9(c)(6)(i)
- 21 C.F.R. §10.30
- 21 C.F.R. §25.30(k)
- 21 C.F.R. §10.30(b)",The current exclusion of konjac flour from the FDA's list of recognized dietary fibers under 21 C.F.R. §101.9(c)(6)(i).,"The petitioner requests the FDA to engage in rulemaking to amend 21 C.F.R. §101.9(c)(6)(i) to include konjac flour (konjac glucomannan) in the list of dietary fibers.
","- Konjac flour is an isolated nondigestible carbohydrate that meets the FDA’s criteria for dietary fiber.
- It has documented physiological benefits recognized by FDA, including:
- Reduction in LDL cholesterol and total blood lipids
- Increased daily fecal weight and defecation frequency (laxative effect)
- The petition cites multiple peer-reviewed clinical studies supporting these benefits.
- The structure and chemistry of konjac glucomannan meet FDA requirements (β-1,4 linkages resistant to digestion, molecular weight, etc.).",FALSE,"Missing in original spreadsheet, so completed in full here."
FDA-2018-P-0878-0001_Citizen_Petition_from_Hyman__Phelps___McNamara__P_.pdf,2/26/2018,,"Hyman, Phelps & McNamara, P.C.
",Representing an unnamed client.,"- 505(j)(2)(C) of the FD&C Act
- 21 C.F.R. § 314.93
- 21 C.F.R. § 10.20
- 21 C.F.R. § 10.30
- 21 C.F.R. § 25.31 (Environmental impact exclusion)
- 21 C.F.R. § 10.30(b) (Economic impact)
- References to PREA (Pediatric Research Equity Act) and FDC Act § 505B(a)(1)(A)","The petitioner comments on FDA's regulatory procedures governing the submission of ANDAs (Abbreviated New Drug Applications) for drug products with different tablet strengths than the reference listed drug (RLD)
","FDA is requested to determine that Sorafenib Tosylate Tablets, 400 mg is suitable for submission as an ANDA referencing NEXAVAR (sorafenib tosylate) Tablets, 200 mg
","- The proposed product differs only in tablet strength (400 mg vs. 200 mg).
- The active ingredient, route of administration, dosage form, and dosing regimen remain the same as the RLD.
- Labeling and safety/efficacy profiles are consistent with the RLD.
- The 400 mg strength reduces tablet burden (1 tablet vs. 2 tablets).
- PREA does not apply as no new indication, dosage form, or route of administration is involved.
- Bioequivalence will be demonstrated to NEXAVAR 200 mg",FALSE,"Missing in original spreadsheet, so completed in full here."
FDA-2018-P-0884-0001_Citizen_Petition_from_Buchanan_Ingersoll___Rooney_.pdf,2/26/2018,,Buchanan Ingersoll & Rooney PC ,"Representing Synergy Pharmaceuticals Inc.
","- 21 C.F.R. § 10.30
- 21 U.S.C. § 352(f)
- 21 C.F.R. § 201.100(c)(1)
- 21 C.F.R. § 314.70
- 21 C.F.R. § 201.57(c)(7)(ii)(A)
- 21 C.F.R. § 25.31(a)",The FDA-approved package insert (PI) of Linzess (linaclotide) — specifically the labeling related to adverse event (AE) data and presentation for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C),"The petitioner requests that the FDA require revisions to the Linzess PI to:
1. Convert narrative AE data for 72 mcg dose into a table.
2. Add AE data for the 290 mcg dose with a footnote.
3. Disclose allowance for 3-day drug holidays in AE discontinuation data.
4. Note the AE threshold of “annoyance” in tables
","- AE data for the 72 mcg and 290 mcg doses is not clearly or fully disclosed.
- Narrative format makes AE data less accessible and misleading.
- Data omits temporary treatment discontinuations and patient subjectivity in reporting AEs (e.g., only “annoying” events are counted).
- The current PI fails to provide adequate, standardized information to support proper risk-benefit analysis and treatment decisions",FALSE,"Missing in original spreadsheet, so completed in full here."
FDA-2018-P-0945-0001_Citizen_Petition_from_Scott_Beach_Redacted.pdf,2/21/2018,,"Scott G. Beach
",Not mentioned.,"- 21 C.F.R. § 10.30
- 21 C.F.R. § 25.31
- 21 C.F.R. § 10.30(b)","Inclusion of aluminum hydroxide and other aluminum salts in injectable vaccines
","Issue an order prohibiting the inclusion of aluminum hydroxide and other aluminum salts in injectable vaccines. Explicit language requested: ""Aluminum hydroxide and other aluminum salts shall not be included in injectable vaccines.”","- Scientific research (e.g., by Dr. Christopher A. Shaw and Dr. Christopher Exley) allegedly links aluminum salts to motor neuron damage and autism spectrum disorder.
- Studies cited suggest potential adverse neurological effects from aluminum exposure in neonatal mice.
- Invokes the precautionary principle due to lack of safety studies in children.
- Asserts that aluminum salts should not be injected into children or anyone else",FALSE,"Missing in original spreadsheet, so completed in full here."
FDA-2018-P-0964-0001_Citizen_Petition_from_Fresenius_Kabi_USA__LLC___Co.pdf,3/2/2018,,"Fresenius Kabi USA, LLC (FK USA)
",Not mentioned.,"- 21 C.F.R. § 10.30
- 21 C.F.R. § 314.161
- 21 C.F.R. § 314.162
- 21 C.F.R. § 25.31
- 21 C.F.R. § 10.30(b)","Determination of whether the NDA holder (Baxter Healthcare Corp.) for Plasma-Lyte 148 and Dextrose 5% (NDA 017451) has withdrawn the product for reasons of safety or efficacy
","Request for FDA to determine whether the listed drug (Plasma-Lyte 148 and Dextrose 5%) has been withdrawn for reasons of safety or efficacy, which is required prior to approval of an Abbreviated New Drug Application (ANDA)
","- The product appears in the “Discontinued Section” of the FDA’s Orange Book.
- Regulatory framework requires FDA to confirm whether discontinuation was for safety/efficacy reasons before approving related ANDAs",FALSE,"Missing in original spreadsheet, so completed in full here."
FDA-2018-P-0967-0001_Citizen_Petition_from_Fresenius_Kabi_USA__LLC.pdf,3/2/2018,,"Fresenius Kabi USA, LLC (FK USA)
",Not mentioned.,"- 21 C.F.R. § 10.30
- 21 C.F.R. § 314.161
- 21 C.F.R. § 314.162
- 21 C.F.R. § 25.31
- 21 C.F.R. § 10.30(b)",Whether the NDA holder (Baxter Healthcare Corp.) for Plasma-Lyte M and Dextrose 5% (NDA 017390) has withdrawn or withheld the product from sale for reasons of safety or efficacy,"FDA should determine whether the product has been voluntarily withdrawn or withheld from sale for reasons related to safety or efficacy before approving any related ANDAs
","- Product appears in the “Discontinued Section” of the FDA Orange Book.
- Required determination by FDA under 21 C.F.R. § 314.161 before an ANDA referencing the product can be approved.
- FDA must clarify if the withdrawal was due to safety or effectiveness concerns, or for other business reasons",FALSE,"Missing in original spreadsheet, so completed in full here. Similar to FDA-2018-P-0964-0001_Citizen_Petition_from_Fresenius_Kabi_USA__LLC___Co.pdf, but slightly different."
FDA-2018-P-0998-0001_Citizen_Petition_from_Hyman_Phelps___McNamara_P_C_.pdf,3/5/2018,,"Hyman, Phelps & McNamara, P.C.
",Not mentioned.,"- 21 C.F.R. § 10.25
- 21 C.F.R. § 10.30
- 21 C.F.R. § 314.122
- 21 C.F.R. § 314.161
- 21 C.F.R. § 314.162
- 21 C.F.R. § 25.31
- FDCA §§ 505(j), 505(w)",Determination of whether PROLIXIN (fluphenazine HCl) Tablets—NDA 011751—was withdrawn for reasons of safety or effectiveness,"FDA should determine that PROLIXIN Tablets (1 mg, 2.5 mg, 5 mg, and 10 mg) were not withdrawn for reasons of safety or effectiveness, allowing it to be referenced in an ANDA
","- PROLIXIN is listed in the “Discontinued Drug Product List” in the Orange Book.
- Approval was voluntarily withdrawn by the NDA holder (Apothecon) in 2009 for commercial reasons, not for safety or effectiveness.
- No evidence indicates safety or effectiveness concerns prompted the withdrawal",FALSE,"Missing in original spreadsheet, so completed in full here."
FDA-2018-P-1008-0001_Suitability_Petition_from_VPCI__Inc_.pdf,3/5/2018,,"Veetech Pharmaceutical Consultants International, Inc. (VPCI, Inc.)
",Not mentioned.,"- Section 505(j)(2)(C) of the Food, Drug, and Cosmetic Act (FDCA)
- 21 CFR §314.93
- 21 CFR §10.30
- 21 CFR §25.31(a) (Environmental Impact waiver)
- 21 CFR §25.21",Approval process for an Abbreviated New Drug Application (ANDA) submission that differs in concentration from the Reference Listed Drug (RLD).,"FDA approval to submit an ANDA for phenylephrine hydrochloride injection, 0.1 mg/mL, a ready-to-use product that differs from the RLD (VAZCULEP 10 mg/mL) only in concentration.
","- Proposed product has same active ingredient and therapeutic effect as the diluted form of the RLD.
- Eliminates need for dilution, reducing contamination and dosing error risks.
- Same dosage and administration route as RLD’s diluted form.
- Offers convenience and improved safety",FALSE,"Missing in original spreadsheet, so completed in full here."
FDA-2018-P-1008-0006_Withdrawal_from_VPCI_Inc.pdf,11/8/2018,"Date was incorrectly identified by ChatGPT, but date has been manually adjusted. ","Veetech Pharmaceutical Consultants International, Inc. (VPCI, Inc.)
",Not mentioned.,Not applicable.,Not applicable.,"Withdrawal of the previously submitted citizen petition.

","Not mentioned. The letter simply requests withdrawal without offering a reason
",FALSE,
FDA-2018-P-1014-0001_Citizen_Petition_from_Haynes_and_Boone_LLP.pdf,3/6/2018,,"Haynes and Boone, LLP
","Representing Vertice Pharma LLC
","- 21 C.F.R. §§ 10.25(a) and 10.30
- 21 C.F.R. § 320.24(b)
- 21 C.F.R. § 25.31","FDA’s Draft Guidance for Mycophenolate Mofetil Oral Suspension (October 2017 revision), which permits use of metabolite-only data to establish bioequivalence","- Withdraw the current Draft Guidance
- Issue new guidance requiring use of both parent compound (MMF) and metabolite (MPA) data for bioequivalence
- Deny approval of any ANDA relying only on metabolite data
- Change AB therapeutic equivalence rating for previously-approved ANDAs that do not meet the revised criteria (including lacking nasogastric tube studies)","- Technological advancements now allow accurate MMF measurement in plasma
- MMF pharmacokinetics may significantly impact clinical outcomes due to variability in conversion to MPA
- Use of only MPA data ignores key differences that may affect drug safety and efficacy
- Precedents exist for requiring parent compound analysis for other prodrugs
- Nasogastric administration studies are critical to demonstrate equivalent delivery and safety",FALSE,"Missing in original spreadsheet, so completed in full here."
FDA-2018-P-1019-0001_Citizen_Petition_from_Lachman_Consultant_Services_.pdf,3/2/2018,,"Lachman Consultant Services, Inc.
",Representing an unnamed client.,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FDCA)
- 21 C.F.R. § 10.30
- 21 C.F.R. § 25.31
- 21 C.F.R. § 505B (PREA, referenced as not applicable)","Submission and acceptability of an ANDA for Glycopyrrolate Injection in strengths not currently marketed (0.6 mg/3 mL and 1.0 mg/5 mL), despite the RLD (Robinul®) being discontinued","The petitioner requests that the FDA declare that Glycopyrrolate Injection, 0.6 mg/3 mL and 1.0 mg/5 mL single dose prefilled syringes are suitable for submission as an ANDA
","- Proposed changes are in total drug content (not active ingredient or dosage form)
- Same route of administration and use as the RLD (Robinul®)
- Dosing aligns with typical Neostigmine co-administration practices
- No safety or effectiveness concerns identified
- Draft labeling provided, consistent with RLD except for strength and format",FALSE,"Missing in original spreadsheet, so completed in full here."
FDA-2018-P-1019-0009_Withdrawal_from_Lachman_Consultant_Services__Inc.pdf,8/25/2023,"Date was incorrectly identified by ChatGPT, but date has been manually adjusted. ","Lachman Consultant Services, Inc.
",Representing an unnamed client.,Not applicable.,Not applicable.,"Withdrawal of the previously submitted citizen petition.

","No specific justification provided. The withdrawal is stated to be ""without prejudice to future submission""

",FALSE,
FDA-2018-P-1040-0001_Citizen_Petition_From_Joshua_Brooks_Redacted.pdf,2/28/2018,,Joshua Brooks,Not mentioned.,"The petition refers to the Controlled Substances Act, specifically Schedule I and Schedule II of DEA Drug Scheduling. No specific CFR citations (e.g., 21 C.F.R. 10.30) are provided
","No specific FDA policy or guidance is referenced. The petitioner is proposing a new regulatory classification for added sugar.
","Classify added sugar as either a Schedule I or Schedule II drug, substance, or chemical under the Controlled Substances Act","- High potential for abuse and addictive nature of added sugar
- No currently accepted medicinal use for added sugar
- Examples of public concern and legislative efforts (e.g., banning sugary sodas from school vending machines)
- Comparison with other controlled substances such as alcohol, tobacco, and marijuana
- Describes sugar as “legal cocaine” due to its addictive properties and impact on children and consumers",FALSE,"Missing in original spreadsheet, so completed in full here."
FDA-2018-P-1068-0001_Citizen_Petition_from_Spear_Pharmaceuticals__Inc.pdf,3/8/2018,,"Spear Pharmaceuticals, Inc.
",Not mentioned.,"- 21 U.S.C. § 355 (section 505 of the FDCA)
- 21 C.F.R. §§ 10.20, 10.30, 320.1, 320.22-24, 320.24(b)(4), 25.31(a)
- 21 U.S.C. § 355(j)(8)(B)(i)
- 21 U.S.C. § 355(j)(8)(C)
- 21 C.F.R. § 320.31(a)(3)","The FDA’s initiative to apply in vitro bioequivalence methods (e.g., IVRT/IVPT) to topical drug products, specifically the potential change in requirements for approval of generic Efudex® (5% fluorouracil cream) without comparative clinical trials
","That the FDA reaffirm its earlier decision requiring comparative clinical efficacy trials (clinical trials in actinic keratosis patients) for ANDA applicants seeking approval of generic versions of Efudex® cream, rather than allowing approvals based solely on in vitro bioequivalence methods
","The petition provides multiple justifications:
- There are already three FDA-approved generic versions of Efudex® on the market, making alternative pathways unnecessary.
- Efudex® is a cytotoxic drug with serious side effects and requires clinical trials to ensure safety and efficacy.
- In vitro methods (IVRT/IVPT) are less accurate, sensitive, and reproducible than clinical trials and fail to reflect the variability in real patient skin conditions.
- FDA has historically required clinical trials for 5-FU generics and deviating from this standard would be arbitrary and capricious.
- Past successful trials by Spear and Taro prove such studies are feasible.
- FDA regulations rank clinical trials higher in reliability for bioequivalence when pharmacokinetic methods aren’t viable.
- Public health risks from under- or over-delivery of the drug are significant, especially for a potentially fatal disease like squamous cell carcinoma
",FALSE,"Missing in original spreadsheet, so completed in full here."
FDA-2018-P-1068-0019_Docket_No__FDA_2018_P_1068___Request_for_Withdrawa.pdf,4/9/2018,"Date was incorrectly identified by ChatGPT, but date has been manually adjusted. ","Spear Pharmaceuticals, Inc.
",Not mentioned.,Not applicable.,Not applicable.,"Withdrawal of the previously submitted citizen petition.

","Not explicitly stated in the letter. The withdrawal is submitted “without prejudice,” suggesting intent to preserve the option for future resubmission

",FALSE,
FDA-2018-P-1099-0001_Citizen_Petition_from_Lachman_Consultant_Services_.pdf,3/12/2018,,"Lachman Consultant Services, Inc.",Not mentioned.,"- Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. § 10.30
- 21 C.F.R. § 314.94(a)(3)
- 21 C.F.R. § 25.31","The lack of designation of Excela Pharma Sciences LLC’s product (Pantoprazole Sodium Powder for IV, NDA 209463) as a reference listed drug (RLD) despite being a pharmaceutical equivalent to an existing RLD (PROTONIX IV, N020988).
","Designate Pantoprazole Sodium Powder for IV (infusion) EQ 40 MG BASE/VIAL by Excela Pharma Sciences LLC (NDA 209463) as an additional reference listed drug (RLD).
","- The Excela product is a pharmaceutical equivalent to the currently designated RLD.
- The current lack of RLD designation may shield the Excela product from generic competition.
- The Excela product was approved via the 505(b)(2) pathway.
- Designation as an additional RLD would facilitate ANDA submissions and increase access to generics.",FALSE,"ChatGPT 4o noted that there was no indication that Lachman Consultant Services explicitly represented another entity but the petition related to a drug marketed by Excela Pharma Sciences LLC, so could be implicitly tied. "
FDA-2018-P-1099-0005_Withdrawal_Letter_from_Lachman_Consultant_Services.pdf,9/20/2018,"Date was incorrectly identified by ChatGPT, but date has been manually adjusted. ","Lachman Consultant Services, Inc.",Not mentioned.,Not applicable.,Not applicable.,"Withdrawal of the previously submitted citizen petition.

","Not mentioned. The document simply states that the petition is being withdrawn without further explanation

",FALSE,
FDA-2018-P-1173-0001_Citizen_Petition_from_the_Alliance_for_Natural_Hea.pdf,3/15/2018,,Alliance for Natural Health USA,Not mentioned.,"- 21 C.F.R. § 10.20
- 21 C.F.R. § 10.30
- 21 C.F.R. § 25.30(h)
- Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act
- Section 201(ff)(3)(B)(ii) of the FD&C Act (21 U.S.C. § 321(ff)(3)(B)(ii))
- 21 C.F.R. Part 312","The FDA’s Investigational New Drug Applications Guidance, specifically Section VI.D.1., which states that a clinical investigation of a dietary supplement intended to diagnose, cure, mitigate, treat, or prevent a disease requires an IND (Investigational New Drug application)","Revise Section VI.D.1. of the FDA’s IND Guidance to clarify that an IND is not required when:
- There is no intent to seek drug approval for the dietary supplement
- The clinical investigation is used to substantiate a legal dietary supplement claim (e.g., structure/function or health claim)

Additionally, the petitioner requests the removal of the final paragraph of Section VI.D.1. that imposes this IND requirement","- Requiring an IND could effectively turn a dietary supplement into a drug, threatening its status as a legally marketable supplement.
- IND requirements create published studies that trigger drug classification under current FDA interpretation.
- Supplements are not intended to diagnose, cure, or treat disease and should not fall under IND protocols.
- FDA’s interpretation contradicts the original purpose of Part 312, which was designed for drugs, not supplements.
- The regulation of intended use should be based on marketing and labeling, not on the intent behind clinical investigations.
- Signed affidavits could ensure no post-study marketing as a drug.
- Regulatory clarity is needed to protect the viability of legal dietary supplement research and claims.",FALSE,
FDA-2018-P-1174-0002_Citizen_Petition_from_Pharma_Regulatory_Consultant.pdf,3/10/2018,,Pharma Regulatory Consultants LLC,Pharma Regulatory Consultants LLC submitted the petition on behalf of a client. The client’s identity is not disclosed in the document.,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. § 10.30
- 21 C.F.R. § 25.31
- Pediatric Research Equity Act (PREA)","The FDA’s requirement for determining the suitability of a new dosage form under an ANDA, specifically for changing the dosage form of the reference-listed drug (Revatio) from powder for oral suspension to liquid oral suspension","That the Commissioner declare Sildenafil Citrate Oral Suspension, 10 mg/mL suitable for submission under an ANDA, with a dosage form change from powder to liquid oral suspension (same strength as the RLD)","- The only proposed change is the dosage form (from powder to ready-to-use liquid suspension); the strength and therapeutic intent remain unchanged.
- The product would be identical at the time of administration.
- The proposed change would improve convenience by eliminating the need for reconstitution.
- No new safety or efficacy concerns are introduced.
- A waiver from pediatric studies is requested based on prior safety concerns in pediatric use documented in the RLD labeling",FALSE,
FDA-2018-P-1185-0001_Suitability_Petition_from_Provetica_Animal_Health_.pdf,3/12/2018,,Provetica Animal Health LLC,Not mentioned.,"- Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act (FFDCA)
- 21 C.F.R. § 25.33(d)(5)
- 21 C.F.R. § 25.21
- Freedom of Information Act (FOIA), 21 C.F.R. § 20.61","Request to permit submission of an Abbreviated New Animal Drug Application (ANADA) for a product with a different dosage form than the approved pioneer drug (Heartgard® Plus chewable tablet).
","Approval of a Suitability Petition to allow filing of an ANADA for a generic ivermectin/pyrantel pamoate product in flavored soft tab form, differing in dosage form from the pioneer chewable tablet","- The proposed product is pharmacologically equivalent to the pioneer (same active ingredients, dosage strengths, and indications).
- The only difference is the dosage form: non-meat flavored soft tab versus meat-based chewable tablet.
- The soft tab eliminates the need for chewing, offering dosing flexibility for dogs with food allergies or swallowing preferences.
- Dissolution is expected to be complete without chewing.
- Labeling will parallel the pioneer product, with minor differences in administration instructions and storage depending on stability data",FALSE,
FDA-2018-P-1195-0001_Citizen_Petition_from_Hyman__Phelps___McNamara__PC.pdf,3/19/2018,,"Hyman, Phelps & McNamara, P.C.","Hyman, Phelps & McNamara, P.C. appears to be submitting the petition on behalf of a client, though the represented entity is not explicitly named in the document
","- Federal Food, Drug, and Cosmetic Act (FDC Act), § 505(j)
- 21 C.F.R. §§ 10.25(a), 10.30, 25.31, 314.3","FDA’s designation of a Reference Standard (RS) in the Orange Book. The current RS (and RLD) for Naproxen Oral Suspension, 25 mg/mL, is reportedly no longer marketed (NAPROSYN, NDA 018965). The petition requests replacing this RS to enable generic competition","Designate Naproxen Oral Suspension, 25 mg/mL, approved under ANDA 074190 as a new Reference Standard (RS) in the Orange Book
","- The current RS (NAPROSYN, NDA 018965) is reportedly no longer available in the U.S., blocking further generic competition.
- Designating ANDA 074190 as the new RS would allow ANDA applicants to rely on it for in vivo bioequivalence testing.
- The request aligns with FDA’s policy to consider marketing status and support competition by choosing a new RS when appropriate.
- The proposed RS is therapeutically equivalent and can help prevent shortages and improve development efficiency",FALSE,
FDA-2018-P-1195-0004_Citizen_Petition_Supplement__from_Hyman__Phelps___.pdf,8/13/2018,,"Hyman, Phelps & McNamara, P.C.","Not explicitly stated in the supplement, but consistent with the original petition (March 19, 2018) which suggests submission on behalf of a client; represented entity not named
","Not newly cited in the supplement, but reinforces the context of:
- 21 C.F.R. § 10.30 (original petition basis)
- No new statutory citations in this supplement","FDA's maintenance of the current Reference Standard (RS) in the Orange Book for Naproxen Oral Suspension, 25 mg/mL — specifically, NAPROSYN under NDA 018965, which the petitioner claims is unavailable in the market.","Reinforces the original request: Designate ANDA 074190 (Naproxen Oral Suspension, 25 mg/mL) as a new Reference Standard (RS) in the Orange Book, due to the unavailability of the current RS
","- The original RS, NAPROSYN (NDA 018965), is still not available through legitimate distribution channels.
- Letters from drug suppliers (confidential attachments) confirm the unavailability.
- One comment opposing the petition (submitted July 12, 2018) claimed a generic firm could procure the RLD, but the petitioner disputes this with evidence.
- Continued unavailability prevents ANDA filers from performing bioequivalence studies, thus blocking generic competition",FALSE,Amendment to original petition noted above. May be a candidate for a removal with that in mind.
FDA-2018-P-1197-0001_Citizen_Petition_from_Exela_Pharma_Sciences.pdf,3/19/2018,,Exela Pharma Sciences,Not mentioned.,"- Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. §§ 10.25(a), 10.30 (citizen petition regulations)
- 21 C.F.R. § 314.3(b) (definition of therapeutic equivalence)
- 21 C.F.R. § 314.94(a)(9)(iii) (excipients and ANDA limitations)
- 21 C.F.R. § 25.31 (categorical environmental exclusion)
- 21 C.F.R. § 10.30(b) (economic impact requirements)","FDA's practice of not assigning a Therapeutic Equivalence (TE) Code (specifically ""AP"") to Exela’s Palonosetron Hydrochloride Injection (0.25 mg/2 mL) despite its bioequivalence and pharmaceutical equivalence to Helsinn’s Aloxi® (Palonosetron HCl, 0.25 mg/5 mL)
","Exela requests that the FDA assign a Therapeutic Equivalence Evaluation Code “AP” to its Palonosetron Hydrochloride Injection, 0.125 mg/mL (2 mL vial), approved under NDA 207963, for listing in the Orange Book
","- Bioequivalence: Exela's drug product contains the same active ingredient, same route of administration, same dosage form, and same total strength (0.25 mg) as Aloxi®.
- Regulatory basis: Though Exela used a 505(b)(2) pathway (due to non-exception excipients), the therapeutic equivalence should still qualify under FDA's standards.
- Labeling comparison: Both Exela’s and Helsinn’s labels confirm identical dosing and strength
.
- TE Code impact: TE Code assignment would allow Exela to seek refund or exemption of user fees (PDUFA) and gain recognition as therapeutically equivalent for substitution and competition purposes.
- Policy consistency: Other precedents exist where FDA granted “AP” rating even when vial content differed but concentration was equivalent.",FALSE,
FDA-2018-P-1238-0001_Citizen_Petition_from_Lachman_Consultant_Services.pdf,3/22/2018,Letter received on March 22 but letterhead has March 23.,"Lachman Consultant Services, Inc.",Submitted on behalf of a client (client's name not disclosed). ,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. § 10.30 (citizen petition procedures)
- 21 C.F.R. § 25.31 (categorical environmental exclusion)
- FD&C Act § 505B (Pediatric Research Equity Act – discussed as inapplicable)","Suitability of a new drug strength and presentation (i.e., change from 200 mg/10 mL multi-dose vial to 100 mg/5 mL single-dose prefilled syringe) of Succinylcholine Chloride Injection for submission via an Abbreviated New Drug Application (ANDA)
","Declare Succinylcholine Chloride Injection 100 mg/5 mL (20 mg/mL) in a single-dose prefilled syringe as suitable for submission as an ANDA, referencing the RLD QUELICIN® (200 mg/10 mL)","- The proposed strength (100 mg/5 mL) has the same concentration (20 mg/mL) as the RLD, differing only in total drug content.
- The 5 mL single-dose syringe offers practical clinical advantages (closer to common patient dosing, reduces waste).
- No changes to indications, uses, or safety profile.
- PREA does not apply because the petition involves a new strength only.
- Labeling changes are limited to strength, container closure, and administrative details
",FALSE,
FDA-2018-P-1238-0007_Withdrawal_from_Lachman_Consultant_Services__Inc.pdf,8/25/2023,"Date was incorrectly identified by ChatGPT, but date has been manually adjusted. ","Lachman Consultant Services, Inc.",Submitted on behalf of a client (client's name not disclosed). ,Not applicable.,Not applicable.,"Withdrawal of the previously submitted citizen petition.

","Not explicitly stated. The petition is withdrawn “without prejudice,” indicating the petitioner may submit again in the future, but no specific rationale is provided

",FALSE,
FDA-2018-P-1310-0001_Citizen_Petition_from_Vertice_Pharma_Management_Co.pdf,3/28/2018,,Vertice Pharma Management Corp.,Not mentioned.,"- Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. §§ 10.25(a), 10.30 (Citizen petition provisions)
- 21 C.F.R. § 25.31 (Environmental impact exemption)
- 21 C.F.R. § 10.30(b) (Economic impact information requirements)","FDA’s Draft Guidance for Sucralfate Oral Suspension (October 2017) — specifically, its requirement that generic formulations be both qualitatively (Q1) and quantitatively (Q2) the same as the reference listed drug (RLD), Carafate®","Revise the Draft Guidance for Sucralfate Oral Suspension by:
1. Eliminating the requirement for quantitative sameness of excipients;
2. Replacing it with a requirement for a comprehensive, validated, orthogonal series of eight in vitro bioassays to demonstrate bioequivalence (BE), including pepsin inhibition, acid diffusion, bile salt interaction, and mucoadhesion assays","- Quantitative sameness is unnecessary because sucralfate acts locally with negligible systemic absorption.
- FDA has allowed non-Q2 sameness for other locally-acting drugs with similar mechanisms (e.g., colesevelam, cholestyramine, sucroferric oxyhydroxide).
- The excipients (e.g., glycerin, sorbitol, methylcellulose) are GRAS or inert and unlikely to affect local action or absorption.
- A set of eight in vitro tests more effectively assesses formulation performance, including early and late stage mechanisms of action.
- Existing guidance-recommended assays are insufficient to establish true bioequivalence based on sucralfate’s complex local mechanism",FALSE,
FDA-2018-P-1335-0001_Citizen_Petition_form_Hyman__Phelps___McNamara__P_.pdf,3/30/2018,,"Hyman, Phelps & McNamara, P.C.","The firm submitted the petition directly, but it is not explicitly stated whether they are representing another entity. The likely implication is submission on behalf of a client, but represented entity is not disclosed.
","- Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FDC Act)
- Section 505(w) of the FDC Act
- 21 C.F.R. §§ 10.25, 10.30 (general citizen petition provisions)
- 21 C.F.R. §§ 314.122, 314.161 (drug withdrawal determination)
- 21 C.F.R. § 25.31 (environmental impact exclusion)
- 21 C.F.R. § 10.30(b) (economic impact provision)","FDA’s classification of DITROPAN XL® (Oxybutynin Chloride Extended Release Tablets) under NDA 020897 as discontinued in the Discontinued Drug Product List of the Orange Book (February 2018). The petitioner requests an official determination regarding whether the withdrawal was for safety or effectiveness reasons
","The petitioner asks the FDA to determine that DITROPAN XL® (5 mg, 10 mg, and 15 mg tablets) was not withdrawn for reasons of safety or effectiveness, thereby allowing it to remain listed in the Orange Book as a reference listed drug (RLD)
","- The petitioner is not aware of any safety or effectiveness concerns behind the withdrawal.
- Believes the withdrawal was due solely to commercial considerations.
- NDA 020897 appears only in the “Discontinued Drug Product List,” and no official determination has been made yet.
- Keeping the product listed in the Orange Book would allow its continued citation in ANDAs
",FALSE,
FDA-2018-P-1349-0001_Citizen_Petition_from_Douglass_Oeller_Consulting__.pdf,3/19/2018,"Letter from US Agent for Felix Pvt. Ltd. (Douglass S. Oeller, DVM) stamped on March 18 and letterhead has March 19. Petitioner is Felix Pharamaceuticals Pvt. Ltd. (from Ireland) and the request is dated March 15, 2018. ","Felix Pharmaceuticals Pvt. Ltd.
","The petition was submitted by Douglass Oeller Consulting, Inc. as the U.S. Agent for Felix Pharmaceuticals Pvt. Ltd.
","- Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. § 25.30(h) (categorical exclusion for environmental impact)
- 21 C.F.R. § 25.21 (extraordinary circumstances)","FDA’s current reference approval for Vetmedin® (Pimobendan) Tablets, a hard compressed chewable tablet. The petitioner seeks approval to submit an ANADA for a soft chewable dosage form, differing in formulation but not in route of administration or strength","Request for permission to file an Abbreviated New Animal Drug Application (ANADA) for a generic compressed soft chewable tablet of Pimobendan that differs from the approved pioneer product (Vetmedin®) in dosage form only
","- The change is limited to oral dosage form: from a hard compressed tablet to a soft compressed chewable tablet.
- The generic formulation will be bioequivalent to the pioneer.
- The same dosage strength and route of administration as the RLD.
- All excipients in the soft chewable form are already approved for use in dogs.
- Minor differences in tablet size and labeling (e.g., palatability and manufacturer info).
- The modified dosage form does not adversely affect the safety or effectiveness of the product",FALSE,Seems to be a duplicate of FDA-2018-P-1351-0001_Citizen_Petition_from_Douglass_Oeller_Consulting__.pdf
FDA-2018-P-1351-0001_Citizen_Petition_from_Douglass_Oeller_Consulting__.pdf,3/19/2018,"Letter from US Agent for Felix Pvt. Ltd. (Douglass S. Oeller, DVM) stamped on March 18 and letterhead has March 19. Petitioner is Felix Pharamaceuticals Pvt. Ltd. (from Ireland) and the request is dated March 15, 2018. ","Felix Pharmaceuticals Pvt. Ltd.
","The petition was submitted by Douglass Oeller Consulting, Inc. as the U.S. Agent for Felix Pharmaceuticals Pvt. Ltd.
","- Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. § 25.30(h) (categorical exclusion from environmental assessment)
- 21 C.F.R. § 25.21 (extraordinary circumstances provision)","Request pertains to the FDA's approval pathway for animal drugs—specifically, submission of an Abbreviated New Animal Drug Application (ANADA) for a chewable tablet dosage form of Marbofloxacin, in contrast to the existing approved formulation Zeniquin® (a hard compressed tablet) sponsored by Zoetis LLC
","Permission to file an ANADA for a generic compressed chewable tablet of Marbofloxacin that differs in dosage form (chewable vs. hard tablet) but retains the same active ingredient, strength, and route of administration
","- The generic chewable tablet will be bioequivalent to the pioneer product (Zeniquin®).
- The route of administration, dosage strength, and use in cats and dogs remain the same.
- Tablet shape and formulation differ (soft chewable vs. hard tablet), but all excipients are approved for veterinary use.
- Tablet size differs slightly; score line included as in the pioneer.
- Label differences limited to product name, manufacturer, palatability, and supply details.
- No adverse impact on safety or effectiveness is expected from the dosage form change
",FALSE,Seems to be a duplicate of FDA-2018-P-1349-0001_Citizen_Petition_from_Douglass_Oeller_Consulting__.pdf.
FDA-2018-P-1361-0002_Citizen_Petition_from_Ajanta_Pharma_USA_Inc_.pdf,4/2/2018,,Ajanta Pharma Limited,Not mentioned.,"- 21 C.F.R. §§ 10.25, 10.30 (general petition regulations)
- 21 C.F.R. §§ 314.122, 314.161, 314.162 (drug withdrawal and ANDA-related provisions)
- FDC Act § 505(j)(2)
- 21 C.F.R. § 25.31 (categorical exclusion for environmental impact)
- 21 C.F.R. § 10.30(b) (economic impact disclosure)","FDA’s placement of DITROPAN XL® (Oxybutynin Chloride Extended Release Tablets, NDA 020897) in the Discontinued Drug Product List of the Orange Book, February 2018 edition.","Petitioner requests that FDA determine DITROPAN XL® (5 mg, 10 mg, and 15 mg tablets) was not withdrawn for reasons of safety or effectiveness, so it may remain eligible as a Reference Listed Drug (RLD) for ANDAs
","- Product appears to have been withdrawn from the market, triggering RLD review requirements.
- No publicly known evidence that discontinuation was due to safety or efficacy concerns.
- FDA’s determination is necessary under 21 C.F.R. 314.122 and 314.161 for continued citation in ANDAs.
- The product remains relevant for generic development if deemed not withdrawn for safety/effectiveness reasons",FALSE,
FDA-2018-P-1441-0001_Citizen_Petition_from_Patients_for_Access_to_Advan.pdf,4/8/2018,,Patients for Access to Advanced Hemophilia Therapy,Not mentioned.,"- Federal Food, Drug, and Cosmetic Act (referenced as the legal basis for FDA’s sole authority over drug approval and market access).
Note: No specific statute (e.g., 21 C.F.R. 10.30 or section 505(q)) is cited by name","Concern regarding the impact of commerce-driven, court-ordered restrictions on patient access to FDA-approved drugs, specifically citing the case of Baxalta/Shire vs. Genentech/Roche and access to Hemlibra®
","Request for the FDA to hold a public hearing to examine the impact of court-ordered drug access restrictions on:
- Medical care delivery
- Drug development
- Patient access to novel therapies

Also asks the FDA to consider whether legislation or rulemaking is needed to prevent such restrictions
","- Baxalta/Shire requested a preliminary injunction limiting access to Hemlibra based on a patent suit, potentially excluding many hemophilia patients.
- The petitioners argue that legal actions unrelated to clinical risk undermine FDA’s regulatory authority and could harm therapeutic progress.
- Some petitioners or their family members are directly affected by these legal filings and might be denied access to Hemlibra if court restrictions are enforced.
- Petitioners assert this sets a dangerous precedent and could affect future access to innovative treatments.
- The hearing would support FDA’s broader mission of protecting access and encouraging competition in the pharmaceutical market",FALSE,
FDA-2018-P-1448-0001_Citizen_Petition_from_Hyman__Phelps___McNamara__PC.pdf,4/9/2018,,"Hyman, Phelps & McNamara, P.C. for Collegium Pharmaceutical, Inc.","Submitted by Kurt R. Karst on behalf of a client. The name of the represented entity is not disclosed in the petition
","- Federal Food, Drug, and Cosmetic Act § 505(j)
- 21 C.F.R. §§ 10.25(a), 10.30 (citizen petition process)
- 21 C.F.R. §§ 314.122, 314.161 (drug withdrawal rules)
- 21 C.F.R. § 25.31 (environmental assessment exclusion)
- 21 C.F.R. § 10.30(b) (economic impact provision)","FDA’s listing of Cysteine Hydrochloride Injection USP, 50 mg/mL (NDA 017377) in the Discontinued Drug Product List of the Orange Book. The petitioner seeks an official determination of whether it was withdrawn for reasons of safety or effectiveness
","The petitioner requests that the FDA determine that Cysteine Hydrochloride Injection USP, 50 mg/mL was not withdrawn for safety or effectiveness reasons, allowing it to continue to be referenced as a Reference Listed Drug (RLD) for ANDA purposes
","- No evidence suggests the product was withdrawn for safety or efficacy concerns.
- Believed to have been withdrawn for commercial or business reasons only.
- Continued Orange Book listing is essential for generic competition via ANDA submissions.
- Removal without an official FDA determination could restrict access and hinder development
",FALSE,
FDA-2018-P-1453-0001_Citizen_Petition_from_Spear_Pharmaceuticals__Inc.pdf,4/9/2018,,"Spear Pharmaceuticals, Inc.",Not mentioned.,"- 21 C.F.R. §§ 10.25, 10.30 (citizen petition provisions)
- 21 C.F.R. § 25.31 (categorical exclusion from environmental impact requirements)
- 21 C.F.R. § 10.30(b) (economic impact clause)","FDA's Draft Product-Specific Guidance (PSG) for Tazarotene Topical Gel, 0.1%, issued in March 2018. Specifically, the petition challenges the proposed requirement for in vivo bioequivalence studies, which contradicts prior guidance allowing in vitro bioequivalence for this drug","Spear requests that FDA withdraw the March 2018 Draft PSG for Tazarotene Gel, 0.1%, and reinstate the prior September 2011 PSG, which permits in vitro bioequivalence testing instead of in vivo studies","- The March 2018 guidance reverses the FDA’s previous position, imposing in vivo clinical endpoint studies, which are costly and less scientifically justified.
- Tazarotene is a topical drug with minimal systemic absorption, making in vitro methods more appropriate.
- FDA has approved ANDA 090227 using in vitro methods under the prior guidance.
- Reversal of guidance undermines regulatory consistency and creates unfair burden on generics.
- The change harms public interest by potentially delaying or discouraging lower-cost generic availability",FALSE,
FDA-2018-P-1469-0001_Citizen_Petition_from_Epstein_Becker___Green_PC___.pdf,4/10/2018,,"Epstein Becker & Green, P.C.","Representing Innovative Health Solutions, Inc. (IHS)
","- 21 C.F.R. § 10.30 (citizen petition procedures)
- 21 C.F.R. § 882.5896 (classification regulation for percutaneous nerve field stimulators)
- 21 C.F.R. § 807.92(a)(3) (substantial equivalence in 510(k) submissions)
- Section 513(i) of the Federal Food, Drug, and Cosmetic Act (definition of substantial equivalence)
- 21 C.F.R. § 25.34 (categorical exclusion for environmental assessments)","The FDA’s classification of percutaneous nerve stimulators for substance use disorders under Class II, and associated special controls promulgated on February 5, 2018, allowing substantial equivalence claims to NSS-2 BRIDGE without requiring preclinical or clinical comparison testing","The petitioner requests that FDA require head-to-head preclinical (animal) and clinical studies demonstrating non-inferiority to the NSS-2 BRIDGE for any device seeking clearance under 21 C.F.R. § 882.5896 that differs from the NSS-2 BRIDGE in certain key attributes (e.g., nerve targeting, grounding, pin/array design, signal characteristics, and use of transillumination)
","- The NSS-2 BRIDGE is currently the only approved predicate under this classification.
- FDA's special controls are insufficient to assure performance for devices that differ even slightly in design, labeling, or indications for use.
- Patients undergoing opioid withdrawal are a highly vulnerable population and need safe, effective alternatives.
- IHS has generated extensive data validating its device through preclinical studies, randomized clinical trials, and use of novel technology.
- Differences in device characteristics (e.g., signal geometry, grounding method) significantly impact performance and cannot be assessed by benchtop or paper review alone.
- Without requiring rigorous comparative testing, inferior or unsafe devices may enter the market, undermining public health and the credibility of the 510(k) process",FALSE,
FDA-2018-P-1484-0001_Citizen_Petition_from_Macleods_Pharmaceuticals_Lim.pdf,4/12/2018,,Macleods Pharmaceuticals Limited,Not mentioned.,"- Section 505(j) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. §§ 10.25(a), 10.30, 314.93 (citizen petition and ANDA-related rules)
- 21 C.F.R. §§ 25.31(a), 25.15(d) (environmental impact exclusion)","FDA’s designation of the Reference Standard (RS) for Isoniazid Tablets, 100 mg and 300 mg listed under NDA 008678 (Sandoz Inc.) in the Orange Book. The petitioner argues that this RS is not practically available in the market, which affects the ability of ANDA applicants to conduct in vivo bioequivalence testing
","FDA should designate ANDA #A080937 (Isoniazid Tablets, 300 mg of Barr Laboratories Inc., marketed by Teva Pharmaceuticals USA, Inc.) as an alternative Reference Standard (RS) for in vivo bioequivalence studies","- The currently designated RS by Sandoz is not discontinued but is scarcely available in the market.
- Macleods and potentially other ANDA applicants cannot obtain sufficient quantity of the RS for testing.
- FDA's own guidance supports designating a new RS in such circumstances.
- The proposed alternative (ANDA #A080937) is therapeutically equivalent and the market leader as per IMS data.
- Consistency with FDA’s Draft Guidance for Industry: Referencing Approved Drug Products in ANDA Submissions supports this change",FALSE,
FDA-2018-P-1492-0001_Citizen_Petition_from_Lachman_Consultant_Services_.pdf,4/12/2018,,"Lachman Consultant Services, Inc.",Not mentioned.,"- 21 C.F.R. § 10.30 (citizen petition procedure)
- 21 C.F.R. § 314.161 (withdrawal determination)
- 21 C.F.R. § 314.162 (approval suspension/withdrawal criteria)
- 21 C.F.R. § 25.31 (environmental assessment exclusion)
- 21 C.F.R. § 10.30(b) (economic impact information)","The FDA's current listing of Roxicet (Acetaminophen and Oxycodone Hydrochloride) Oral Solution, 325 mg/5 mL, 5 mg/5 mL as “Discontinued” in the Orange Book, without an accompanying determination on whether the withdrawal was for safety or efficacy reasons
","The petitioner requests that the FDA:
1. Determine whether Roxicet (325 mg/5 mL, 5 mg/5 mL) was voluntarily withdrawn for safety or effectiveness reasons;
2. Designate the product as the Reference Listed Drug (RLD) in the absence of a current RLD for that formulation
","- The product is no longer available in the market and is listed as “Discontinued” in the Orange Book.
- Believed that the discontinuation was not due to safety or effectiveness concerns but likely for commercial reasons.
- No evidence has been found to indicate a safety/efficacy-based withdrawal.
- FDA regulations require a determination before approving ANDAs that refer to discontinued products.
- Petitioner offers to withdraw the petition should the innovator reintroduce the product.
",FALSE,
FDA-2018-P-1492-0005_Withdrawal_of_Citizen_Petition_FDA_2018_P_1492.pdf,9/17/2018,"Date was incorrectly identified by ChatGPT, but date has been manually adjusted. ","Lachman Consultant Services, Inc.",Not mentioned.,Not applicable.,Not applicable.,"Withdrawal of the previously submitted citizen petition.

","The FDA Commissioner already made and published the requested determination in the Federal Register, making the petition no longer necessary

",FALSE,
FDA-2018-P-1516-0001_Citizen_Petition_from_Encube_Ethicals_Private_Limi.pdf,4/13/2018,,Encube Ethicals Private Limited,Not mentioned.,"- 21 C.F.R. § 10.25(a) (citizen petition procedures)
- 21 C.F.R. § 10.30 (filing procedures)
- Section 505(j) of the Federal Food, Drug, and Cosmetic Act (ANDA pathway)
- 21 C.F.R. § 25.31 (environmental impact exclusion)
- 21 C.F.R. § 10.30(b) (economic impact information)","FDA's current designation of the Reference Standard (RS) for Mupirocin Calcium Cream, EQ 2% Base in the Orange Book, which currently lists NDA 050746 (Bactroban, GlaxoSmithKline) and ANDA 065123 (Perrigo New York Inc.), both of which are reportedly unavailable in sufficient commercial quantity
","Request that FDA designate ANDA 201587, held by Glenmark Pharmaceuticals Inc. USA, as the Reference Standard (RS) for Mupirocin Calcium Cream, EQ 2% Base, to facilitate submission of ANDAs by generic manufacturers","- Current RS products (NDA 050746 and ANDA 065123) are not commercially available in sufficient quantity for in vivo bioequivalence testing.
- FDA's own Draft Guidance (Jan. 2017) allows selection of a new RS when existing RS availability is limited.
- ANDA 201587 is the only commercially available formulation of the drug product.
- Selecting this new RS will enhance market competition and reduce risk of drug shortages by enabling approval of additional generics",FALSE,
FDA-2018-P-1531-0001_Petition_from_King___Spalding_LLP.pdf,4/2/2018,,King & Spalding LLP,"Submitted on behalf of a client (name of the represented entity is not disclosed)
","- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FDC Act)
- 21 C.F.R. § 10.20
- 21 C.F.R. § 10.30 (citizen petition procedures)
- 21 C.F.R. § 25.31(a) (environmental impact exclusion)
- 21 C.F.R. § 10.30(b) (economic impact submission)","Request for FDA determination that a change in drug strength (from the approved 50 mg/mL to a proposed 5 mg/mL) for Ephedrine Sulfate Injection, USP is suitable for submission in an ANDA. The action involves the substitution of a different strength and dosage presentation from the RLD Akovaz (NDA 208289) held by Flamel Ireland Limited
","FDA should determine that Ephedrine Sulfate Injection, USP, 25 mg/5 mL (5 mg/mL) is suitable for submission via an ANDA, despite the change in total strength compared to the RLD
","- The proposed strength matches the clinically administered dosage concentration recommended in the RLD labeling (5 mg/mL), but eliminates the need for dilution from 50 mg/mL, which reduces medication errors and contamination risk.
- The pre-filled syringe format reduces drug waste in clinical settings.
- There are no changes in active ingredients, dosage form, route of administration, or indications compared to the RLD.
- The change in total drug content is only due to volume, and does not affect safety or efficacy",FALSE,Seems to be a duplicate of FDA-2018-P-1532-0001_Petition_from_King___Spalding_LLP.pdf.
FDA-2018-P-1532-0001_Petition_from_King___Spalding_LLP.pdf,4/2/2018,,King & Spalding LLP,"Submitted on behalf of a client (name of the represented entity is not disclosed)
","- 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FDC Act)
- 21 C.F.R. § 10.20
- 21 C.F.R. § 10.30
- 21 C.F.R. § 25.31(a) (environmental impact exclusion)
- 21 C.F.R. § 10.30(b) (economic impact statement)","FDA’s approval pathway for a new drug strength differing from the RLD. Specifically, the petition comments on allowing Ephedrine Sulfate Injection, USP, 50 mg/10 mL (5 mg/mL) to be submitted as an ANDA despite differing in strength from the RLD (Akovaz 50 mg/mL)","That FDA determine Ephedrine Sulfate Injection, USP, 50 mg/10 mL (5 mg/mL) is suitable for submission in an ANDA as a different strength product than the reference listed drug (RLD), Akovaz (NDA 208289)
","- The proposed product has the same final dosage concentration (5 mg/mL) as the RLD post-dilution, but in a ready-to-use prefilled syringe, avoiding the dilution step required by the RLD.
- Eliminates risk of contamination and medication error.
- Provides greater convenience, dosing flexibility, and faster access in treating clinically important hypotension during anesthesia.
- The petition argues that the change in total drug content (by volume) does not impact safety or efficacy.
- No changes are proposed to the active ingredient, dosage form, route of administration, or intended use",FALSE,Seems to be a duplicate of FDA-2018-P-1531-0001_Petition_from_King___Spalding_LLP.pdf. Note that any differences are solely due to ChatGPT while processing the file. 
FDA-2018-P-1593-0001_Citizen_Petition_from_Pete_and_Gerry_s_Organics_LL.pdf,4/19/2018,,"Pete and Gerry's Organics LLC
",Not mentioned.,"- Federal Food, Drug, and Cosmetic Act (FDC Act)
- 21 C.F.R. § 10.30 (citizen petition regulation)
- 21 C.F.R. § 101.65(d) (regulation for “healthy” nutrient content claim)
- 21 C.F.R. § 25.30(k) (environmental impact exemption)
- 21 C.F.R. § 101.54(c) (nutrient content claim “good source”)","FDA’s definition and regulatory enforcement of the term “healthy” in nutrient content claims, specifically 21 C.F.R. § 101.65(d) and related 2016 FDA guidance titled “Use of the Term ‘Healthy’ in the Labeling of Human Food Products”
","1. Initiate rulemaking to amend 21 C.F.R. § 101.65(d) to allow eggs to be labeled “healthy”
2. In the interim, amend FDA guidance to allow eggs to be labeled “healthy” under enforcement discretion","- Current regulation is based on outdated views of fat and cholesterol.
- 2015–2020 Dietary Guidelines for Americans (DGA) identify eggs as nutrient-dense and recommend their inclusion in healthy diets.
- FDA has already shown willingness to update “healthy” criteria in 2016 guidance, but still excludes eggs due to cholesterol limits.
- Scientific consensus has shifted; dietary cholesterol is no longer considered a nutrient of concern.
- Eggs are rich in protein, choline, vitamin D, and other essential nutrients.
- FDA should update rules to reflect modern science and public health goals.",FALSE,
FDA-2018-P-1678-0001_Citizen_Petition_from__Mapi_USA__Inc.pdf,4/27/2018,,"Mapi USA, Inc.",Not mentioned.,"- FD&C Act § 505(j)(2)(C)
- 21 C.F.R. § 10.20
- 21 C.F.R. § 10.30
- 21 C.F.R. § 314.93
- 21 C.F.R. § 314.94(a)(8)(iv)
- 21 C.F.R. § 25.30
- 21 C.F.R. § 25.31
- 21 C.F.R. § 10.30(b)",The suitability of submitting an ANDA for a formulation of Midazolam Injection that differs in fill volume and container type (100 mL flexible plastic container) from the current reference standard products,"FDA is requested to determine that Midazolam Injection 1 mg/mL in a new total fill volume of 100 mL in a flexible plastic container is suitable for submission as an ANDA
","- The proposed product has the same strength, active ingredient, dosage form, and route of administration as the reference standard (Hospira).
- The only difference is the total fill volume (100 mL vs. 2–5 mL).
- Intended for ICU use where continuous infusion is required, aligning with dosage and administration standards.
- The petition includes a detailed comparison of labeling and justifications (Appendices 1–3).
- The product format better supports prolonged sedation in critical care settings.
- The proposed change is consistent with regulatory provisions requiring FDA approval for deviations from listed drug attributes.",FALSE,
FDA-2018-P-1698-0001_Suitability_Petition_from_Haynes_and_Boone__LLP.pdf,5/1/2018,,Haynes and Boone LLP,It does not indicate representation of another company. ,"- 21 U.S.C. § 355 (FDC Act § 505)
- 505(j)(2)(C) (Suitability Petitions)
- 505(j)(2)(A)(iii)
- 21 C.F.R. §§ 10.20, 10.30 (citizen petition regulations)
- 21 C.F.R. § 314.93 (suitability petitions)
- 21 C.F.R. § 25.31 (environmental impact exemption)
- 21 C.F.R. § 10.30(b) (economic impact)
- 21 U.S.C. § 355c(a)(4)(A) (PREA waiver for pediatric studies)",FDA’s requirement for prior approval of changes in dosage form under suitability petition regulations—specifically requesting approval to switch from tablet to oral solution dosage form for Midodrine Hydrochloride.,"That the FDA determine Midodrine Hydrochloride Oral Solution, 2.5 mg/5 mL is suitable for submission via an ANDA, despite a change in dosage form (from tablet to oral solution) from the RLD (Mylan’s Midodrine Hydrochloride Oral Tablets, 5 mg)
","- The proposed oral solution is an immediate-release form, just like the RLD.
- The change improves administration for patients with swallowing difficulties, while maintaining identical dosage strengths (2.5 mg, 5 mg, 10 mg).
- No new safety or efficacy concerns arise from the change in form.
- Pediatric study waiver requested due to low usage in pediatric population and no evidence of meaningful benefit for pediatric patients.
- No change in active ingredient, route of administration, indication, or labeling apart from those necessary for the new dosage form",FALSE,
FDA-2018-P-1719-0001_Citizen_petition_from_Sciarra_Laboratories__Inc.pdf,5/1/2018,,"Sciarra Laboratories, Inc.","Representing TBD Pharma, LLC
","- 21 U.S.C. § 355(j) (FD&C Act § 505(j))
- 21 C.F.R. § 10.25(a)
- 21 C.F.R. § 10.30
- 21 C.F.R. § 314.3
- 21 C.F.R. § 25.31 (environmental impact exclusion)
- 21 C.F.R. § 10.30(b) (economic impact analysis)","The petition comments on the FDA’s designation of Reference Listed Drugs (RLDs) in the Orange Book—specifically requesting that Aeroseb-Dex (Dexamethasone Topical Aerosol, 0.01%) ANDA 083296 be designated as an RLD.","The petitioner requests that the FDA designate Aeroseb-Dex (Dexamethasone Topical Aerosol, 0.01%) ANDA 083296 as a Reference Listed Drug (RLD) to allow the submission of ANDAs referencing this product","- Aeroseb-Dex is listed in the discontinued section of the Orange Book but was determined by the FDA (in a 2011 response to a prior petition) not to be withdrawn for safety or efficacy reasons.
- No generic version of Aeroseb-Dex exists, and designating it as an RLD would facilitate generic competition.
- Designation would expedite generic drug access for U.S. patients.
- Supports FDA’s mission to increase availability of generic drugs
",FALSE,
FDA-2018-P-1719-0007_Withdrawal_from_Sciarra_Laboratories_Inc.pdf,12/4/2020,"Date was incorrectly identified by ChatGPT, but date has been manually adjusted. ","Sciarra Laboratories, Inc.","Representing TBD Pharma, LLC
",Not applicable.,Not applicable.,"Withdrawal of the previously submitted citizen petition.

","The withdrawal follows the publication of FDA’s final guidance in October 2020, titled “Referencing Approved Drug Products in ANDA Submissions”, which allows ANDA applicants to submit controlled correspondence to request RLD designation—rendering the petition unnecessary

",FALSE,
FDA-2018-P-1720-0001_Citizen_Petition_from_Gland_Pharma_Limited.pdf,5/2/2018,,Gland Pharma Limited,Not mentioned.,"- Section 505(j)(2)(C) of the FD&C Act
- 21 C.F.R. § 314.93
- 21 C.F.R. § 10.20
- 21 C.F.R. § 10.30
- 21 C.F.R. § 25.31 (Environmental Impact)
- 21 C.F.R. § 10.30(b) (Economic Impact)","FDA’s lack of designation of a Reference Standard (RS) in the Orange Book for LASIX (Furosemide) Injection, 10 mg/mL (NDA #016363).","That the FDA designate Furosemide Injection, 10 mg/mL, NDA #018667 held by Hospira as a Reference Standard (RS) to facilitate ANDA submissions for generic development","- The original RLD (LASIX by Sanofi Aventis, NDA #016363) is listed as discontinued in the Orange Book.
- FDA has confirmed the delisting was not due to safety or efficacy concerns.
- Hospira’s product (NDA #018667) is approved, “AP” rated, and therapeutically equivalent to the discontinued LASIX product.
- Assigning RS designation to Hospira's product will enable comparative studies for ANDA submission and facilitate generic drug development",FALSE,
FDA-2018-P-1734-0001_Citizen_Petition_from_Foley___Lardner_LLP.pdf,5/3/2018,,Foley & Lardner LLP,"The firm appears to be submitting on behalf of an unidentified client, but no specific represented entity is named in the petition.","- 21 C.F.R. § 10.30 (Citizen Petition)
- 21 C.F.R. § 314.161 (Determination if drug was withdrawn for safety/efficacy)
- 21 C.F.R. § 314.122, 314.162 (Drug listing and removal procedures)
- 21 C.F.R. § 25.31 (Environmental impact exclusion)
- 21 C.F.R. § 10.30(b) (Economic impact submission provision)","The FDA’s listing of IC-GREEN (Indocyanine Green) Injection in the Orange Book, specifically requesting a determination on whether the 10 mg/vial, 40 mg/vial, and 50 mg/vial strengths have been withdrawn for reasons of safety or effectiveness.","That the FDA determine whether IC-GREEN (Indocyanine Green) Injection (10 mg/vial, 40 mg/vial, and 50 mg/vial), NDA 011525, held by Akorn Inc., has been voluntarily withdrawn for safety or efficacy reasons
","- The Orange Book lists only the 25 mg/vial strength of IC-GREEN as active.
- The 10 mg, 40 mg, and 50 mg strengths are listed as discontinued.
- Petitioner seeks confirmation that these discontinuations were not for safety or effectiveness reasons, which is a regulatory prerequisite for others to submit ANDAs or 505(b)(2) NDAs referencing them",FALSE,
FDA-2018-P-1740-0001_Citizen_Petition_from_Provetica_Animal_Health_LLC.pdf,5/2/2018,"Letterhead dated May 2, but stamp reflects May 3.",Provetica Animal Health LLC,Not mentioned.,"- Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act (FFDCA)
- 21 C.F.R. § 25.33(d)(5) (Environmental Impact exclusion)
- 21 C.F.R. § 25.21 (Extraordinary Circumstances)
- 21 C.F.R. § 20.61 (FOIA confidentiality claims)","The petition comments on the dosage form of the approved pioneer animal drug Deramaxx™ (deracoxib) Chewable Tablets (NADA 141-203), specifically requesting allowance for a change in tablet scoring for a proposed generic equivalent.
","Permission to file an Abbreviated New Animal Drug Application (ANADA) for a generic version of deracoxib chewable tablets that differs from the pioneer product only in tablet scoring (i.e., only the smallest and largest strengths will be scored in the generic)","- The proposed generic is pharmaceutically comparable, containing the same active ingredient and manufactured by the same method (compression).
- Scoring differences do not affect the dosing strategy or therapeutic equivalence.
- Analysis demonstrated that scoring intermediate tablet strengths (25 mg, 50 mg, 75 mg) does not significantly enhance dosing accuracy.
- The label for the generic will mirror the pioneer label with minor revisions to reflect the scoring differences.
- The petition includes detailed dosage tables illustrating that effective dosing can still be achieved with the proposed scoring scheme",FALSE,
FDA-2018-P-1751-0001_Citizen_Petition_from_RegCon_Solutions__LLC_.pdf,5/4/2018,,"RegCon Solutions, LLC",Not mentioned.,"- Section 505(j) of the FD&C Act
- 21 C.F.R. §§ 10.20 and 10.30 (citizen petition procedures)
- 21 C.F.R. § 25.31 (Environmental Impact exclusion)
- 21 C.F.R. § 10.30(b) (Economic Impact submission provision)","The lack of designation of Nephron’s Albuterol Sulfate Inhalation Solution, 2.5 mg/0.5 mL (0.5% base), ANDA 075664 as a Reference Standard (RS) in the Orange Book.","Designate Nephron’s Albuterol Sulfate Inhalation Solution, 2.5 mg/0.5 mL (0.5% base), ANDA 075664 as a Reference Standard (RS) in the FDA’s Orange Book","- The FDA’s Orange Book currently lists Bausch and Lomb’s ANDA 075050 (100 mg/20 mL) as the RS, but it is not a unit-dose, preservative-free product.
- Nephron’s product (ANDA 075664) is the only approved preservative-free, unit-dose (0.5 mL) Albuterol Sulfate Inhalation Solution.
- Without RS designation, Nephron’s product is effectively shielded from generic competition, defeating the purpose of the generic approval pathway.
- The petitioner argues that there is a sound regulatory basis and precedent for this designation",FALSE,
FDA-2018-P-1760-0001_Citizen_Petition_from_Serenity_Pharmaceuticals__LL.pdf,5/4/2018,,"Serenity Pharmaceuticals, LLC",Not mentioned.,"- 505(q) of the FD&C Act
- 21 C.F.R. § 10.30 (citizen petition procedure)
- 21 C.F.R. § 25.31 (categorical exclusions from environmental assessment)
- 21 C.F.R. § 10.20 (submission of data and information)
- 21 C.F.R. § 10.30(b) (economic impact statement provision)","The anticipated approval of any ANDA referencing Serenity’s approved Nocdurna (desmopressin acetate) sublingual tablets, particularly those omitting essential clinical information required for safe use in certain populations (e.g., age limitations, gender-based dosage distinctions).","Serenity requests that the FDA not approve any ANDA referencing Nocdurna unless it includes the same labeling restrictions and warnings required to ensure safe use, especially for women and the elderly (including boxed warnings and dosage instructions).
","- Nocdurna has significant gender-based dosage limitations due to higher risks of hyponatremia in women.
- Clinical data demonstrated that different doses are required to ensure safety and efficacy between males and females.
- The FDA-approved labeling includes a boxed warning and specific dosage based on gender to prevent life-threatening hyponatremia.
- Petitioner argues that omitting such labeling in generic versions could compromise patient safety.
- Cites prior FDA precedent requiring labeling conformity to ensure safe use when there are significant clinical differences from reference drugs.",FALSE,
FDA-2018-P-1780-0001_Citizen_Petition_from_Pacira_Pharmaceuticals__Inc.pdf,5/7/2018,,"Pacira Pharmaceuticals, Inc.",Not mentioned.,"- 21 C.F.R. §§ 10.20, 10.30, and 10.31
- Section 505(q) of the FDCA, 21 U.S.C. § 355(q)
- 21 C.F.R. § 300.50(a)
- 21 C.F.R. § 25.31(a) (Environmental Impact)
- 21 C.F.R. § 10.30(b) (Economic Impact)
- 21 C.F.R. § 10.31(c) (Certification) ","Potential approval of a New Drug Application (NDA) for HTX-011, a fixed-dose combination of bupivacaine and meloxicam developed by Heron Therapeutics, Inc., especially if submitted without factorial design clinical data comparing both active ingredients individually and together. 
","- FDA should refrain from approving any NDA for a fixed-dose combination of bupivacaine and meloxicam unless:
    • Adequate and well-controlled studies (including factorial studies) are provided
    • Safety concerns (particularly from the novel extended-release vehicle) are addressed
- Require a Black Box warning for the NSAID (meloxicam) component of such combinations ","- The HTX-011 Phase 3 trials did not compare the combination product against meloxicam alone, violating FDA’s combination product approval standards.
- Factorial studies are critical to demonstrate the individual contribution of each drug to safety and efficacy.
- Heron’s Biochronomer® delivery system may cause localized inflammation and adverse events (e.g., edema, bradycardia, impaired wound healing).
- NSAIDs (including meloxicam) are associated with impaired wound healing and cardiovascular risks; hence, they warrant a Black Box warning.
- FDA must ensure robust data to safeguard against safety risks posed by novel drug combinations used for post-surgical pain management.",FALSE,
FDA-2018-P-1808-0001_Citizen_Petition_from_Lachman_Consultant_Services_.pdf,5/8/2018,,"Lachman Consultant Services, Inc.",Lachman submitted the petition on behalf of a client (name not disclosed).,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. § 10.30
- 21 C.F.R. § 314.93
- 21 C.F.R. § 25.31 (Environmental Impact)",Request for approval of a suitability petition to allow submission of an Abbreviated New Drug Application (ANDA) for a different strength of an existing Reference Listed Drug (RLD). ,"The petitioner asks the FDA to declare that Cysteine Hydrochloride Injection 5% (containing 34.6 mg/mL of cysteine base) is suitable for submission as an ANDA, despite it being a different strength from the RLD (Cysteine Hydrochloride Injection 7.25%). 
","- The proposed change is a decrease in drug strength (0.346 g vs. 0.5 g).
- No changes are proposed to indications, usage, or directions for use aside from necessary strength-related modifications.
- Clinical administration adjustments are straightforward and quantified.
- The RLD was not withdrawn for safety or effectiveness reasons.
- The petitioner's formulation may reduce drug waste in neonatal and adult settings.
- Pediatric Research Equity Act (PREA) does not apply to this type of change. ",FALSE,
FDA-2018-P-1846-0002_Acknowledgment_Letter_from_FDA_DDM_to_Data_Based_M.pdf,5/10/2018,,Data Based Medicine Americas Ltd.,Not mentioned.,"- 21 C.F.R § 25.31(a) (Environmental impact exemption)
- 21 C.F.R. § 10.30 (Citizen petition regulation)","Existing drug labeling and post-marketing risk communication concerning SSRIs and SNRIs. Specifically, inadequate warnings about persistent sexual side effects.","- Immediate revision of all SSRI and SNRI product labels (branded and generic) to include:
• Warnings, precautions, highlights of prescribing info for risks like genital anesthesia, pleasureless orgasm, etc.
• Inclusion of persistent genital arousal disorder (PGAD) in warnings.
• A boxed warning for persistent sexual side effects.
- Require manufacturers to:
• Send “Dear Health Care Provider” letters to inform about the risks.
• Develop a Medication Guide and Communication Plan as part of a Risk Evaluation and Mitigation Strategy (REMS).","- Extensive literature, case reports, and studies over 30+ years confirm sexual dysfunctions, including genital anesthesia, loss of libido, erectile dysfunction, and PGAD, that persist long after discontinuation of SSRIs/SNRIs.
- Inadequate product labeling denies patients informed consent and misrepresents risks.
- Studies and pharmacovigilance data from multiple countries (Netherlands, UK, etc.) substantiate the claims.
- Calls attention to parallels with finasteride and isotretinoin, which have received label updates for similar risks.
- Petition stresses the life-altering impact of conditions like PSSD and PGAD on patients' ability to engage in relationships and normal functioning",FALSE,
FDA-2018-P-1853-0001_Citizen_Petition_from_Aurobindo_Pharma_USA__Inc_.pdf,5/10/2018,,"Aurobindo Pharma USA, Inc.",Not mentioned.,"- Section 505(j) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. §§ 10.25(a), 10.30, 314.93
- 21 C.F.R. §§ 25.31(a), 25.15(d) (environmental impact exclusion)
- Draft Guidance: Referencing Approved Drug Products in ANDA Submissions, III. C.2 and 3 ","The designation of the reference standard (RS) in the Orange Book for Fluoxetine Delayed-Release Capsules USP, 90 mg, specifically the unavailability of PROZAC Weekly™ (NDA #021235) by Eli Lilly & Co. as the current RS ","FDA is requested to designate the approved generic product Fluoxetine Delayed-Release Capsules USP, 90 mg (ANDA #078572 by Dr. Reddy’s Laboratories Ltd.) as the new reference standard (RS) for the purposes of conducting in vivo bioequivalence studies in support of ANDA submissions ","- PROZAC Weekly™ (NDA #021235), the currently listed RS, is unavailable in the market and not found in the NDC directory despite not being marked discontinued in the Orange Book
- Aurobindo could not obtain sufficient quantities of the current RS for required in vivo testing
- Dr. Reddy’s version (ANDA #078572) is the most marketed product and meets the criteria under FDA’s draft guidance for designation as RS
- Petition supported with data: Orange Book listings, NDC search, Drugs@FDA records, IMS MAT data showing Dr. Reddy’s product as the U.S. market leader, and a pharmacy’s non-availability statement for PROZAC Weekly™",FALSE,Note: similar to FDA-2018-P-1869-0001_Citizen_Petition_from_Aurobindo_Pharma_USA_Inc.pdf but are distinct petitions. 
FDA-2018-P-1869-0001_Citizen_Petition_from_Aurobindo_Pharma_USA_Inc.pdf,5/11/2018,,"Aurobindo Pharma USA, Inc.",Not mentioned.,"- Section 505(j) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. §§ 10.25(a), 10.30, 314.93
- 21 C.F.R. §§ 25.31(a), 25.15(d)
- 21 C.F.R. § 10.30(b) (for economic impact, if requested)","Designation of a reference standard (RS) for in vivo bioequivalence studies under the ANDA process; specifically the non-availability of the currently designated RS for Dicyclomine Hydrochloride Capsules 10 mg (BENTYL® by Allergan Sales LLC) 
","FDA is requested to:
• Designate the approved generic product Dicyclomine Hydrochloride Capsules USP, 10 mg (ANDA #085082) by Watson Laboratories Inc. as the new reference standard (RS), or
• Designate a suitable alternative RS for in vivo bioequivalence testing","- The current RS (BENTYL®) is not discontinued per the Orange Book but is functionally unavailable in the market for bioequivalence testing.
- IMS (MAT) and NDC data indicate limited or no distribution of BENTYL®.
- Watson Laboratories’ product (ANDA #085082) is the most widely marketed and thus meets FDA's criteria for selecting a new RS.
- In line with FDA Draft Guidance on selecting RS when existing RS is unavailable, Aurobindo believes their request meets FDA expectations ",FALSE,Note: similar to FDA-2018-P-1853-0001_Citizen_Petition_from_Aurobindo_Pharma_USA__Inc_.pdf but are distinct petitions. 
FDA-2018-P-1876-0001_Citizen_Petition_from_UIC_College_of_Pharmacy.pdf,5/11/2018,,UIC College of Pharmacy (Sarfaraz Niazi),Not mentioned.,"- Biologics Price Competition and Innovation Act (BPCIA), specifically Section 7002 of H.R. 3590
- 42 USC 262(k)(2)(A)(ii)
- 21 CFR 10.30 (petition certification)
- 21 CFR 25.42 (Environmental Impact)","FDA guidance and regulatory approach to the approval process for biosimilar biological products under BPCIA, particularly concerning:
- Bridging studies
- Immunogenicity testing
- Analytical similarity criteria
- Pharmacokinetic/Pharmacodynamic (PK/PD) study protocols","The petitioner requests the FDA to:
• Waive bridging studies under specific conditions
• Declare biosimilars substitutable for naïve patients
• Accept in vitro immunogenicity tests in place of human studies
• Modify PK/PD study designs for clinical relevance
• Revise Tier 1 testing requirements in analytical similarity guidance","The petitioner argues that:
• The high cost and long timelines for biosimilar development hinder market access
• FDA already has legal discretion to vary biosimilarity evidence requirements under 42 USC 262(k)(2)(A)(ii)
• Ethical concerns exist over unnecessary human testing (e.g., immunogenicity studies)
• Clinical relevance should guide testing protocols rather than rigid statistical methods
• Expedited biosimilar approvals could save U.S. healthcare over $50 billion annually",FALSE,
FDA-2018-P-1877-0001_Citizen_Petition_from_Laurus_Labs.pdf,5/14/2018,,Laurus Labs Limited,Not mentioned.,"- 21 C.F.R. § 10.30 (Citizen Petition)
- 21 C.F.R. § 25.31 (Environmental Impact exclusion)
- 21 C.F.R. § 10.30(b) (Economic Impact)","Discontinuation status of 534 mg strength of ESBRIET (pirfenidone) Tablets by Genentech, Inc., listed as “Discontinued” in the Orange Book","The petitioner requests that the FDA:
- Determine whether the 534 mg strength of ESBRIET was discontinued for safety or efficacy reasons.
- If not, accept ANDAs (Abbreviated New Drug Applications) for all three strengths (267 mg, 534 mg, 801 mg) of pirfenidone tablets as generics referencing ESBRIET (NDA #208780)","- The 534 mg strength of ESBRIET is currently listed as “Discontinued” in the Orange Book.
- The petition argues that the discontinuation may not be due to safety or efficacy concerns.
- Requests confirmation so that ANDAs can be filed using this strength as a reference listed drug.
- Cites labeling and listing status on FDA platforms to support the claim",FALSE,
FDA-2018-P-1880-0001_Citizens_Petition_from_Louis_Morris_Aledort_MD_Red.pdf,5/14/2018,,"Louis Morris Aledort, MD",Not mentioned.,"21 C.F.R. §§ 25.30, 25.31, 25.32, 25.33, or § 25.34; Environmental assessment under § 25.40 is also referenced. No mention of 505(q) or 21 C.F.R. § 10.30 specifically","Licensing and black box warning of Hemlibra (emicizumab)
","Reverse the licensing of Hemlibra; reassess the black box warning; reevaluate whether the drug should remain on the market
","- Safety concerns due to cases of thrombotic microangiopathy (TMA), some of which involved rFVIIa rather than Feiba, suggesting Hemlibra might be responsible.
- Five reported deaths with no publicly available data.
- Insufficient bleeding control in certain patients.
- Occurrence of neutralizing antibodies in a patient.
- Belief that Hemlibra may not be appropriate for all inhibitor patients.
- Data cited includes a NEJM paper, licensing documents, and company memos
",FALSE,
FDA-2018-P-1891-0001_Citizen_Petition_from_PuraCap_Pharmaceutical__LLC_.pdf,5/11/2018,"Letterhead dated May 11, but stamp reflects May 14.","PuraCap Pharmaceutical, LLC","PuraCap Pharmaceutical, LLC is acting as the regulatory agent on behalf of Epic Pharma, LLC. ","Not Mentioned
","The existing Reference Standard listed in the Orange Book (Mikart ANDA #040658) for Hydrocodone Bitartrate and Acetaminophen Tablets USP (5 mg/300 mg, 7.5 mg/300 mg, and 10 mg/300 mg), which was discontinued as of December 2, 2017
","The petitioner requests that the FDA assign a new Reference Standard for Hydrocodone Bitartrate and Acetaminophen Tablets USP (5 mg/300 mg, 7.5 mg/300 mg, and 10 mg/300 mg)",The previously designated Reference Standard (Mikart ANDA #040658) was discontinued and is no longer available for purchase. Epic Pharma intends to file an ANDA for the stated drug formulations and requires an available Reference Standard to perform the necessary comparative testing,FALSE,
FDA-2018-P-1892-0001_Citizen_Petiton_from_Aurobindo_Pharma_USA__Inc.pdf,5/15/2018,,"Aurobindo Pharma USA, Inc.",Not mentioned.,"- Section 505(j) of the Federal Food, Drug, and Cosmetic Act
- 21 CFR 10.25(a), 10.30, and 314.93
- 21 C.F.R. 25.31(a), 25.15(d)
- 21 C.F.R. 10.30(b)","The petition addresses the FDA’s designation of a Reference Standard (RS) for Dicyclomine Hydrochloride Tablets USP, 20 mg, currently listed as BENTYL® by Allergan Sales LLC.","The petitioner requests the FDA to: Designate Dicyclomine Hydrochloride Tablets USP, 20 mg (ANDA #085223) of Watson Laboratories Inc. as a suitable alternative reference standard for in vivo bioequivalence testing for ANDA submissions","- The currently listed reference standard (BENTYL®) is not readily available in the market despite being listed as active in the Orange Book.
- IMS data and pharmacy statements confirm limited supply/unavailability of the current RS.
- FDA guidance (Referencing Approved Drug Products in ANDA Submissions, III. C.2 and C.3) allows designation of a new RS if the current one is unavailable.
- The Watson Laboratories product (ANDA #085223) is widely marketed and therapeutically equivalent, making it an appropriate alternative RS",FALSE,
FDA-2018-P-1949-0001_Citizen_Petition_from_Avadel_Specialty_Pharmaceuti.pdf,5/18/2018,,"Avadel Specialty Pharmaceuticals, LLC",Not mentioned.,"- 505(q) of the FDCA
- 21 C.F.R. § 10.30
- FDCA § 505(b)(2)
- 21 C.F.R. § 314.50(i)
- 21 C.F.R. § 314.52(a)
- 21 C.F.R. § 25.31
- 21 C.F.R. § 10.30(b)",Potential FDA approval of Ferring Pharmaceuticals' NDA 022517 for Nocdurna (desmopressin acetate) for nocturia,"- Do not approve NDA 022517 without:
• ≥2 representative clinical trials
• Standard efficacy endpoints using validated PRO tools
• Acceptable bioavailability/absorption data
• Risk mitigation studies
• Proper patent certifications and Paragraph IV notices
- Establish new FDA standards for:
• Effectiveness measures
• Trial design reflecting real-world use
• Bioavailability/absorption standards","- Clinical trials lacked real-world conditions and at-risk populations
- Efficacy thresholds and outcome measures were inadequate
- Unreliable and variable bioavailability of sublingual dosage form
- Non-compliance with patent certification/notice requirements under 505(b)(2)
- History of FDA concerns, including previous rejections and advisory committee objections",FALSE,
FDA-2018-P-1966-0001_Suitability_Petition_from_McNeely__Hare___War__LLP.pdf,5/17/2018,,"McNeely, Hare & War LLP","The firm submitted the petition on behalf of a client (the specific client is not named)
","- Section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act (FDC Act)
- 21 C.F.R. §§ 10.20 and 10.30",Suitability of 150 mg and 300 mg strengths of Celecoxib Oral Capsules for submission in an Abbreviated New Drug Application (ANDA) based on the reference listed drug Celebrex®,"The petitioner requests that FDA determine that 150 mg and 300 mg Celecoxib oral capsules are suitable for submission in an ANDA
","- Proposed strengths are intermediate (between approved 50, 100, 200, and 400 mg) and match route/formulation of the RLD.
- Intended to reduce pill burden and increase convenience, especially for conditions like rheumatoid arthritis and ankylosing spondylitis.
- Prescription data supports need for intermediate strengths due to frequent co-prescribing of existing strengths to achieve desired doses.
- The new strengths offer physicians more options to prescribe the lowest effective dosage consistent with treatment goals",FALSE,
FDA-2018-P-1980-0001_Citizen_Petition__from_Foley___Lardner_LLP.pdf,5/22/2018,,Foley & Lardner LLP,"Foley & Lardner LLP submitted the petition on behalf of an unnamed petitioner; the individual signatory is David L. Rosen, B.S. Pharm., JD. No specific company client is identified, but the petition supports designation of Hospira, Inc.'s product","21 C.F.R. § 10.30; 21 C.F.R. § 25.1(g)
","The current designation in the FDA’s Orange Book for Furosemide Injection 10 mg/mL, specifically that the designated Reference Listed Drug (RLD), NDA 18579 by Luitpold Pharmaceutical Inc., is listed as discontinued","The petitioner requests that the FDA designate ANDA 075241 (Furosemide Injection 10 mg/mL by Hospira, Inc.) as a reference standard in the FDA’s Orange Book for purposes of comparison in support of ANDA filings
","The current RLD is discontinued, and the petitioner seeks designation of an available product (Hospira’s ANDA 075241) as the reference standard to facilitate comparison testing and ANDA submissions",FALSE,
FDA-2018-P-2025-0001_Citizen_Petition_from_Center_for_Biological_Divers.pdf,5/24/2018,,Center for Biological Diversity,Not mentioned.,"- 21 C.F.R. § 10.30 (citizen petition regulation)
- Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. § 25.1 (environmental policy)
- National Environmental Policy Act (NEPA)
- Endangered Species Act (ESA)","FDA’s failure to require an environmental impact analysis before approving animal drugs that are medically important antimicrobials and are excreted into the environment.
","The petitioner requests that the FDA:
- Begin conducting environmental reviews for new and existing approvals of animal drugs that are medically important antimicrobials, under NEPA.
- Disclose environmental assessments and findings.
- Reevaluate existing approvals where drugs may be contributing to antimicrobial resistance or harming wildlife and ecosystems.","The petitioner argues that:
- FDA has unlawfully failed to consider the environmental impacts of its approvals of animal drugs.
- The excretion of medically important antimicrobials from food animals into the environment contributes to antimicrobial resistance.
- This resistance poses a significant public health threat and harms wildlife.
- Environmental analysis is required under NEPA and consistent with FDA’s environmental regulations.",FALSE,
FDA-2018-P-2040-0001_Citizen_Petition_from_Jerry_Taylor_Reed_Redacted.pdf,5/28/2018,,Jerry Taylor Reed,Not mentioned.,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FDCA)
- 21 C.F.R. §§ 10.20, 10.30, 314.93
- 21 C.F.R. § 314.94(a)(9)(iii)
- 21 C.F.R. § 25.31
- 21 C.F.R. § 10.30(b)","Approval of an Abbreviated New Drug Application (ANDA) for Atropine Sulfate Injection, USP in strengths that differ from the Reference Listed Drug (RLD) (i.e., 1.0 mg/mL and 0.4 mg/mL in 1 mL single-dose vials)
","Request for FDA to declare that the proposed formulations of Atropine Sulfate Injection, USP (1.0 mg/mL and 0.4 mg/mL in 1 mL single-dose vials) are suitable for submission in an ANDA","- The proposed strengths align with recommended product doses in the RLD’s prescribing information.
- The dosage form, route of administration, and use are the same as the RLD.
- The products are true solutions and, if bioequivalence is shown, should have the same therapeutic effect.
- The petitioner’s formulation omits benzyl alcohol (a preservative) to differentiate from the RLD.
- This supports FDA’s goal of increasing generic drug competition and access",FALSE,
FDA-2018-P-2040-0006_Withdrawal_from_Jerry_Reed.pdf,5/9/2019,"Date was incorrectly identified by ChatGPT, but date has been manually adjusted. ",Jerry Taylor Reed,Not mentioned.,Not applicable.,Not applicable.,"Withdrawal of the previously submitted citizen petition.

","Not mentioned. The document contains no explanation for the withdrawal

",FALSE,
FDA-2018-P-2050-0001_Citizen_Petition_from_SS_Formulations__LLC_.pdf,,No date recognized by ChatGPT nor apparent through a quick skim.,"SS Formulations, LLC",Not mentioned.,"- 21 C.F.R. § 10.30 (Citizen Petition provision)
- 21 C.F.R. Part 330.10 (OTC drug monograph requirements)
- 21 C.F.R. Part 358 (Wart remover & corn/callus remover products)
- 21 C.F.R. Part 25 (Environmental assessments and exclusions)","FDA’s regulation concerning over-the-counter (OTC) drug monographs, particularly regarding the use of sodium salicylate in topical applications for hyperpigmentation removal.","Petitioner requests FDA to issue a clearance in the form of an effective Monograph Change Notification to permit the use of 2-hydroxy, monosodium salt (sodium salicylate) in aqueous mixtures applied to human skin for removal of hyperpigmented spots.","- Sodium salicylate (related to salicylic acid) is already FDA-approved for other topical uses (e.g., wart, corn, callus removal).
- Petitioner conducted an IRB-approved study showing effective use in treating hyperpigmented spots.
- Scientific literature supports its use.
- Environmental impact deemed minimal due to rapid biodegradation and non-toxic exposure levels to aquatic/terrestrial organisms.",FALSE,
FDA-2018-P-2073-0001_Citizen_Petition_from_LMS_Direct_Research_Foundati.pdf,5/16/2018,"Letterhead dated May 16, but stamp reflects May 30.","Sarah Salem-Robinson, PA-C (Physician Assistant in OB/GYN)
",Not mentioned.,"- 21 C.F.R. § 10.30 (citizen petition procedures)
- 21 C.F.R. § 803.1(a) and § 803.10 (medical device reporting requirements)
- Section 895.21 (Procedures for banning a device)",The 2014 FDA advisory and labeling update regarding laparoscopic and hysteroscopic power morcellators; the petitioner argues this was insufficient and seeks a complete ban,A total ban on the use of power morcellators in all gynecological (GYN) surgeries,"- New studies (e.g., Green Journal, April 2018) report 1.0–8.6% risk of hidden cancer in women undergoing hysterectomy thought to be for benign conditions.
- Morcellators may spread undiagnosed sarcomas, upstaging cancer.
- Violation of surgical principles and ethics (“do no harm”).
- Manufacturers and medical institutions failed to report adverse events as required by law.
- 510(k) clearance pathway for morcellators was flawed and failed to ensure safety.
- Morcellator use increased post-warning due to inadequate professional transparency.
- The FDA should lead with a strong ban to protect future patients",FALSE,
FDA-2018-P-2104-0001_Citizen_Petition_from_Nostrum_Pharmaceuticals__LLC.pdf,5/31/2018,,"Nostrum Pharmaceuticals, LLC",Not mentioned.,"- 21 CFR 10.25(a)
- 21 CFR 10.30
- 21 CFR 314.122","Lack of designation of a Reference Standard (RS) for Theophylline Extended Release Tablets, 300 mg, in the FDA Orange Book.","To designate Alembic Pharmaceutical Ltd.'s Theophylline ER Tablets, 300 mg (ANDA 090430), as an alternate Reference Standard for in vivo bioequivalence and in vitro dissolution studies.","- The original RLDs (Schering’s Theo-Dur) are discontinued.
- No RS is currently listed for the 300 mg strength.
- Pliva’s designated RS products are unavailable or on long-term backorder.
- Alembic’s 300 mg and 450 mg strengths are currently available on the market.
- Designation would facilitate a site transfer of Nostrum's approved ANDA and support market entry, benefiting public healthcare costs and preventing drug shortages.",FALSE,
FDA-2018-P-2104-0005_Citizen_Petition_Withdrawal_from_Nostrum_Pharmaceu.pdf,1/24/2020,"Date was incorrectly identified by ChatGPT, but date has been manually adjusted. ","Nostrum Pharmaceuticals, LLC",Not mentioned.,Not applicable.,Not applicable.,"Withdrawal of the previously submitted citizen petition.

","The FDA previously issued an interim response on November 27, 2018, stating it could not reach a decision because the petition “raises complex issues requiring extensive review and analysis by Agency officials.” The petitioner opted to withdraw afterward

",FALSE,
FDA-2018-P-2175-0001_Citizen_Petition_from_Pharmalucence_Inc.pdf,6/5/2018,,"Pharmalucence, Inc.",Not mentioned.,"- 21 C.F.R. § 10.30
- Section 505(j)(2)(A)(i) of the FDCA
- 21 C.F.R. § 314.94(a)(9)
- 21 C.F.R. § 314.127(a)(8)","The petition comments on the FDA’s policy of evaluating ANDA (Abbreviated New Drug Application) submissions, particularly regarding whether labeling for a proposed generic omits critical information in the RLD.","The petitioner requests the FDA to:
- Refuse to approve any ANDA that omits the requirement for a thyroid blocking agent pretreatment for [I-131] iobenguane use unless FDA determines such omission is scientifically justified.","Pharmalucence asserts that omitting this required labeling element poses safety risks and would render a proposed generic drug less safe and effective than the RLD. They argue that the thyroid blocking agent is essential for patient safety during radiopharmaceutical administration.
",FALSE,
FDA-2018-P-2175-0003_Withdrawal_from_Sun_Pharmaceutical_Industries__Inc.pdf,10/7/2021,"Date was incorrectly identified by ChatGPT, but date has been manually adjusted. ","Pharmalucence, Inc. (later acquired and renamed Sun Pharmaceutical Industries, Inc.)
",Not mentioned.,Not applicable.,Not applicable.,"Withdrawal of the previously submitted citizen petition.

","The FDA granted a refund of program fees after determining that Sun’s CIS-MDP product is pharmaceutically equivalent to Jubilant Draximage’s product. As a result, the issue raised in the petition was effectively resolved, prompting withdrawal to help free Agency resources

",FALSE,Note: this is a request for a withdrawal due to recent FDA action so may be a candidate for removal.
FDA-2018-P-2344-0001_Suitability_Petition_from_Noble_Pharma_LLC.pdf,6/15/2018,,"Noble Pharma, LLC",Not mentioned.,"Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act (FFDCA); 21 CFR 25.33(d)(5); 21 CFR 25.21; 21 CFR 20.61
",Filing of an Abbreviated New Animal Drug Application (ANADA) for a different dosage form of an approved pioneer product (praziquantel tablet),Permission to file an ANADA for a scored soft chewable tablet of praziquantel (generic) as an alternative dosage form to the pioneer product—a compressed scored tablet,"- Proposed generic product will have same active ingredient, dosage, administration method, therapeutic effect, cautions, and warnings as the pioneer.
- Soft chewables are more palatable and improve compliance.
- All excipients used are approved for dogs and pose no safety/effectiveness concerns.
- Labeling will closely parallel pioneer product labeling with differences noted in formulation and format.",FALSE,
FDA-2018-P-2361-0001_Citizen_Petition_from_BF_Innovation_Inc____on_beha.pdf,6/12/2018,,BF Innovation Inc.,"Acting on behalf of Bright Future Pharmaceutical Laboratories Limited
","- Federal Food, Drug and Cosmetic Act (FDC Act)
- 21 C.F.R. § 10.30
- Section 505(j) of the FDC Act
- 21 C.F.R. § 25.31 (environmental impact)","The designation of TRIAMCINOLONE ACETONIDE CREAM 0.1% (Application No: A085692 by Fougera Pharmaceuticals Inc.) as an additional Reference Listed Drug (RLD)
",Designate the Reference Standard (RS) TRIAMCINOLONE ACETONIDE CREAM 0.1% (by Fougera) as an additional RLD for ANDA submissions,"- The current RLD (Application No: N011601 by Mylan) is unavailable in the market.
- The RS by Fougera is therapeutically equivalent.
- Designating RS as an RLD would enhance generic market competition and facilitate additional ANDA submissions.",FALSE,
FDA-2018-P-2361-0006_Withdrawal_from_Bright_Future_Pharmaceutical_Labor.pdf,11/24/2020,"Date was incorrectly identified by ChatGPT, but date has been manually adjusted. ",BF Innovation Inc.,"Acting on behalf of Bright Future Pharmaceutical Laboratories Limited
",Not applicable.,Not applicable.,"Withdrawal of the previously submitted citizen petition.

","Withdrawal was made “at the suggestion of a representative of the Office of Regulatory Policy”. No further reasoning is provided

",FALSE,
FDA-2018-P-2362-0001_Citizen_Petition_from_Lachman_Consultant_Services_.pdf,6/18/2018,"Letterhead dated June 18, but stamp reflects June 20.","Lachman Consultant Services, Inc.",Not mentioned.,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. § 10.30
- 21 C.F.R. § 25.31 (Environmental Impact)
- FDC Act § 505B (Pediatric Research Equity Act)","The petition addresses a request for suitability for filing an ANDA referencing a different strength (800 mg) of VOTRIENT (pazopanib) Tablets, currently approved in 200 mg and 400 mg doses.","Request for FDA to declare that Pazopanib Tablets 800 mg is suitable for submission as an ANDA, based on the reference listed drug VOTRIENT (pazopanib) Tablets (200 mg and 400 mg) by Novartis Pharmaceuticals Corp.","- The proposed 800 mg strength is within the approved dosage (800 mg daily) of the RLD.
- A single 800 mg tablet would improve patient convenience and reduce pill burden.
- No changes in labeling or indication except for strength.
- The change is quantitative only (in strength) and should not affect safety or efficacy.
- PREA does not apply to the new strength per 505B(a)(1)(A).",FALSE,
FDA-2018-P-2362-0006_Withdrawal_from_Lachman_Consultant_Services__Inc.pdf,8/29/2023,"Date was incorrectly identified by ChatGPT, but date has been manually adjusted. ","Lachman Consultant Services, Inc.",Not mentioned.,Not applicable.,Not applicable.,"Withdrawal of the previously submitted citizen petition.

","Not explicitly stated. The letter only mentions that the request is made “without prejudice to future submission”

",FALSE,
FDA-2018-P-2407-0001_Citizen_Petition_from_Ray_Law_Firm__PLLC.pdf,6/14/2018,,"Ray Law Firm, PLLC (Harry B. Ray)","Ray Law Firm, PLLC is submitting on behalf of an unnamed client pursuing approval for a generic drug
","- Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. 25.15
- 21 C.F.R. 25.33(e)
- 21 C.F.R. 25.21
- 21 C.F.R. 10.30(b)","Approval process and requirements for new animal drug applications, specifically Abbreviated New Animal Drug Applications (ANADA)",Approval of new strengths (37.5mg and 50mg) of generic Carprofen Chewable Tablets for dogs,"- Existing approved strengths (25mg, 75mg, 100mg) do not allow convenient dosing for 16–30 lb dogs
- New 37.5mg and 50mg strengths would simplify dosing and eliminate need for splitting tablets
- No change in indications, safety, or effectiveness is implied for the new strengths",FALSE,
FDA-2018-P-2408-0001_Citizen_Petition_from_Public_Citizen.pdf,6/21/2018,,Public Citizen,Not mentioned.,"- 21 U.S.C. § 355(o)(4)
- 21 C.F.R. § 10.30",The ongoing marketing of oral benzocaine products despite serious safety concerns.,"- Immediately remove all oral benzocaine products from the market.
- Initiate withdrawal procedures under 21 CFR 314.150.","- Oral benzocaine products are associated with serious and potentially fatal adverse effects, including methemoglobinemia.
- FDA itself has issued safety communications about these risks.
- There is a lack of evidence supporting any meaningful therapeutic benefit.
- Alternatives exist that are safer and more effective.",FALSE,
FDA-2018-P-2506-0001_Citizen_Petition_from_K_L_Gates_LLP.pdf,6/27/2018,,K&L Gates LLP,"Representing no other named entity; however, the subject drug (AXIRON®) was held by Eli Lilly and Company
","- 21 C.F.R. §§ 10.25 and 10.30
- 21 C.F.R. §§ 314.122 and 314.161
- Sections 505(j) and 505(w) of the Federal Food, Drug, and Cosmetic Act (FDCA)",FDA's listing of AXIRON® as a discontinued Reference Listed Drug (RLD) and withdrawal of approval for NDA N022504,"Request for FDA to determine that AXIRON® (testosterone) transdermal metered solution, NDA N022504, was not withdrawn for reasons of safety or effectiveness",The petitioner asserts there is no known information suggesting AXIRON® was withdrawn for safety or effectiveness reasons and requests a determination confirming that it was not,FALSE,
FDA-2018-P-2658-0001_Citizen_Petiton_from_Hyman__Phelps___McNamara__PC.pdf,7/10/2018,,"Hyman, Phelps & McNamara, P.C.","Petition appears to be submitted on behalf of an unspecified client; no other entity explicitly mentioned as being represented.
","- Federal Food, Drug, and Cosmetic Act (FDC Act) § 505(j)
- 21 C.F.R. § 10.25(a)
- 21 C.F.R. § 10.30
- 21 C.F.R. § 314.3
- 21 C.F.R. § 25.31","Selection of Reference Standards (RS) for generic drug applications, specifically related to the designation in the Orange Book for Methylphenidate Hydrochloride Extended Release 60 mg capsules.",That FDA designate ANDA 078873 as an additional Reference Standard (RS) for Methylphenidate Hydrochloride Capsules Extended Release 60 mg in the Orange Book.,"- The current RS (Metadate CD 60 mg, NDA 021259) appears to be discontinued and is unavailable for sampling.
- ANDA 078873 is a therapeutically equivalent version of the RLD and the current market leader.
- Designating it as an RS would facilitate further generic competition.
- FDA’s own guidance allows designation of a new RS when current RS is not available for in vivo bioequivalence testing. ",FALSE,
FDA-2018-P-2659-0001_Citizen_Petiton_from_Hyman__Phelps___McNamara__PC_.pdf,7/10/2018,,"Hyman, Phelps & McNamara, P.C. (for United Therapeutics)","Representing Taro Pharmaceuticals U.S.A., Inc.
","- 21 C.F.R. § 10.30
- Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FDCA)
- 21 C.F.R. § 314.127(a)(3)
- 21 C.F.R. § 314.94(a)(9)
- 21 C.F.R. § 320.24
- 21 C.F.R. § 320.25
- FDA Draft Guidance “Chlorthalidone Tablets” (2017)",Review and potential approval of any abbreviated new drug applications (ANDAs) referencing Hygroton® (chlorthalidone) that rely solely on bioequivalence (BE) studies conducted on the 50 mg strength.,"FDA should not approve any ANDA referencing Hygroton® (chlorthalidone) unless it includes comparative BE studies on each strength for which approval is sought, or provides other scientifically valid evidence justifying a waiver (biowaiver) for lower strengths.
","- The petitioner argues that chlorthalidone does not exhibit dose-proportional pharmacokinetics.
- Citing FDA guidance and scientific studies, they contend that strength-specific BE studies are necessary.
- They emphasize the potential for therapeutic inequivalence or safety/efficacy concerns if approval is based solely on higher strength BE data.
- The request aligns with FDA’s past precedent and guidance documents requiring strength-specific evaluation when pharmacokinetics are non-linear.",FALSE,
FDA-2018-P-2659-0014_Withdrawal_from_Hyman_Phelps_and_McNamara_PC.pdf,8/16/2018,"Date was incorrectly identified by ChatGPT, but date has been manually adjusted. ","Hyman, Phelps & McNamara, P.C. (for United Therapeutics)","Representing Taro Pharmaceuticals U.S.A., Inc.
",Not applicable.,Not applicable.,"Withdrawal of the previously submitted citizen petition.

","No justification provided. The letter states that a formal response is no longer necessary but does not explain why

",FALSE,
FDA-2018-P-2720-0001_Citizen_Petition_from_Hyman__Phelps___McNamara__P_.pdf,7/13/2018,,"Hyman, Phelps & McNamara, P.C.","Not Mentioned (The petition is submitted directly by the law firm; no separate client or represented entity is identified)
","- Federal Food, Drug and Cosmetic Act (FDC Act) § 505(j)
- 21 C.F.R. §§ 10.25(a) and 10.30
- 21 C.F.R. § 314.3
- 21 C.F.R. § 25.31
- 21 C.F.R. § 10.30(b)","The FDA's designation of a Reference Standard (RS) in the Orange Book for Benztropine Mesylate Tablets. Specifically, the petitioner addresses the fact that the current RS (ANDA 040103) is not marketed and unavailable for sampling, potentially hindering generic competition ","FDA is requested to designate ANDA 204713 (or another suitable ANDA) as a new or additional Reference Standard for Benztropine Mesylate Tablets (0.5 mg, 1 mg, and 2 mg) in the Orange Book, replacing the discontinued ANDA 040103. This change would facilitate the submission of new generic ANDAs by enabling bioequivalence testing ","- The current RS (ANDA 040103) appears to be inactive and not available for sampling.
- Lack of an available RS impedes new generic drug applications and competition.
- FDA’s own guidance supports changing the RS if the current one is unavailable.
- ANDA 204713 is a therapeutically equivalent and recently approved drug product suitable for this purpose ",FALSE,
FDA-2018-P-2749-0001_Citizen_Petition_from_Anne_A__Shirinian_Orlando_Re.pdf,7/13/2018,"Letterhead dated July 13, but stamp reflects July 17.","Anne A. Shirinian-Orlando, Ph.D.",Not mentioned.,"- Section 355(e) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. § 25.31(a)","Lack of strict dosage, administration, and procurement monitoring guidelines for prostate cancer chemotherapy medications","- Issue strict FDA-approved dosage and administration guidelines for prostate chemotherapy medications
- Monitor procurement of chemotherapy medications to ensure sourcing from safe manufacturers","- Overdosing of patients, especially stage 4 prostate cancer patients, has led to liver and other organ damage
- Examples include drugs such as ZYTIGA, JEVTANA, and XTANDI, which have harmful side effects including organ failure and death
- Chemotherapy drugs are highly toxic, lack clear detoxification protocols, and are administered without individualized assessments (e.g., based on tumor growth rate)
- Efficacy claims rely on median survival statistics rather than precise disease progression measures",FALSE,
FDA-2018-P-2754-0001_Citizen_Petition_from_Ascend_Laboratories_LLC.pdf,7/18/2018,,"Ascend Laboratories, LLC",Not mentioned.,"- 21 CFR §§ 10.25, 10.30
- Sections 505(j) and 505(w) of the FDCA
- 21 CFR §§ 314.122, 314.161, 314.162
- 21 CFR § 25.31
- 21 CFR § 10.30(b)","The inclusion of ONFI (clobazam) 5 mg tablets in the ""Discontinued Section"" of the Orange Book, and whether it was withdrawn for safety or efficacy reasons",Ascend Laboratories requests the FDA to determine whether ONFI (clobazam) 5 mg tablets (NDA 202067) has been withdrawn or withheld from sale for reasons of safety or efficacy,"The petition notes that ONFI (clobazam) 5 mg tablets, approved on October 21, 2011, is now listed in the ""Discontinued Section"" of the Orange Book. FDA is required to determine if a product has been withdrawn for reasons of safety or efficacy before approving an ANDA referencing that drug
",FALSE,
FDA-2018-P-2755-0001_Citizen_Petition_from_Ascend_Laboratories__LLC.pdf,7/17/2018,,"Ascend Laboratories, LLC",Not mentioned.,"21 C.F.R. § 10.25(a), 10.20, 10.30, 314.93; FDC Act § 505(j); 21 C.F.R. § 314.3; 21 C.F.R. § 25.31","Reference Listed Drug (RLD) designation in the Orange Book and absence of a Reference Standard (RS) for Methylphenidate Hydrochloride Extended-Release Capsules 10–60 mg
","FDA should designate any other approved generic version of METADATE CD (Methylphenidate Hydrochloride Extended-Release Capsules, NDA No. 021259) as an alternate Reference Standard (RS) for ANDA submission purposes","The original RLD, METADATE CD by Lannett Co. Inc., has been discontinued and neither it nor the authorized generic is available in the market. There is no currently assigned RS for this product in the Orange Book, preventing ANDA submissions. Market data and distributor letters support the lack of availability of the reference product",FALSE,
FDA-2018-P-2838-0001_Citizen_Petition_from_Public_Citizen_s_Health_Rese.pdf,7/23/2018,,"Public Citizen’s Health Research Group
",Not mentioned.,"- Sections 331(a) and 342(f) of the Federal Food, Drug, and Cosmetic Act (FDCA)
- 21 C.F.R. § 10.30",FDA's inaction regarding the continued marketing of dietary supplements containing cesium chloride (CsCl) or other cesium salts,"1. Require immediate removal from the market of all dietary supplements containing cesium chloride or other cesium salts.
2. Issue a safety communication to advise consumers and healthcare professionals about associated harms ","- CsCl poses a significant or unreasonable risk of serious illness or injury, particularly life-threatening cardiac arrhythmias.
- It is promoted for unproven and unsafe cancer treatments.
- FDA and its Pharmacy Compounding Advisory Committee have recognized CsCl's serious safety concerns including cardiac toxicity and central nervous system effects.
- Documented adverse events include seizures, syncope, QT prolongation, torsades de pointes, and deaths.
- Animal and in vitro studies corroborate cardiotoxicity.
- Vulnerable cancer patients are being misled by unverified health claims.
- There is no scientific evidence supporting CsCl’s efficacy in treating any health condition ",FALSE,
FDA-2018-P-2851-0001_Citizen_Petition_from_Pharmaceutical_Manufacturing.pdf,7/23/2018,,"Hyman, Phelps & McNamara, P.C. ","Representing Pharmaceutical Manufacturing Research Services, Inc.","- Section 505(j) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. § 10.30",The FDA’s potential approval of any ANDA referencing Colestid® (colestipol hydrochloride) Tablets unless specific bioequivalence requirements are met.,"The petitioner requests the FDA not to approve any ANDA referencing Colestid® Tablets unless the applicant demonstrates bioequivalence through:
• A comparative clinical endpoint bioequivalence study in patients with hypercholesterolemia; or
• A comparative efficacy study measuring serum LDL-cholesterol as a surrogate endpoint.","The justification provided includes:
• Colestipol tablets are not absorbed, and their action is local in the GI tract, making traditional PK studies inappropriate.
• The FDA’s own bioequivalence guidance for colestipol granules calls for clinical endpoint studies.
• There is no published evidence showing that PK-based studies are sufficient to establish therapeutic equivalence for colestipol tablets.
• Substituting without proper equivalence could undermine treatment and public health.",FALSE,
FDA-2018-P-2862-0001_Citizen_Petition_from_Lupin_Pharmaceuticals__Inc.pdf,7/23/2018,,"Lupin Pharmaceuticals, Inc.",Not mentioned.,"- Section 505(j) of the Federal Food, Drug, and Cosmetic Act
- 21 CFR § 10.25(a)
- 21 CFR § 10.30
- 21 CFR § 25.31 (Environmental Impact)","Discontinuation of the Reference Listed Drug (RLD) and Reference Standard (RS) for Azithromycin Tablet, 600 mg – specifically, ZITHROMAX® 600 mg (NDA # N050730) by Pfizer Central Research ","FDA is requested to designate a suitable alternate Reference Standard (RS) for Azithromycin Tablet, 600 mg, for use in in vitro bioequivalence studies, due to the unavailability of the current RLD/RS and the authorized generic in the market ","- ZITHROMAX® 600 mg (current RLD/RS) is no longer available in the market, although not officially listed as discontinued in the Orange Book.
- Pfizer confirmed discontinuation (Attachment-1).
- The authorized generic by Greenstone LLC is also unavailable as of July 2017 (Attachment-4).
- Lupin cannot perform required bioequivalence studies without an RS.
- Per FDA’s Draft Guidance (Jan 2017), a citizen petition can be submitted to request a different RS under such circumstances",FALSE,
FDA-2018-P-2901-0001_Citizen_Petition_from_Yiling_Pharmaceutical_Ltd.pdf,7/26/2018,,Yiling Pharmaceutical Ltd,Not mentioned.,"- 21 C.F.R. 10.25(a)
- 21 C.F.R. 10.30","The selection of the reference standard (RS) for VOLTAREN (diclofenac sodium delayed-release tablets, 75mg, 50mg, and 25mg)","That the FDA select a different listed drug (from the current CASI-assigned reference standard) to be used as the RS for conducting in vivo bioequivalence studies in ANDA applications.

","- The currently assigned RS product (CASI’s ANDA products) is not available on the market: 50mg tablets have been discontinued and 75mg are expected to be unavailable soon.
- As per FDA’s 2017 Draft Guidance, a petition is appropriate when “there are limited or no quantities of the reference standard in distribution.”
- Only three holders of approved ANDAs for all strengths exist; petitioner requests FDA select RS from other available suppliers like Carlsbad Technology Inc. or Unique Pharmaceutical Laboratories.",FALSE,
FDA-2018-P-2962-0001_Citizen_Petition_from_Americans_for_Homeopathy_Cho.pdf,7/25/2018,,Americans for Homeopathy Choice,Not mentioned.,"- 21 C.F.R. § 10.30
- Federal Food, Drug, and Cosmetic Act (implicitly referenced)",Draft Guidance titled “Drug Products Labeled as Homeopathic Guidance for FDA Staff and Industry” (Docket No. FDA-2017-D-6580),"- Withdraw the draft guidance.
- Replace it with a new guidance developed with public and stakeholder input.
- Establish an advisory committee of homeopathy stakeholders.
- Declare a formal enforcement policy that reflects this new guidance.","- The current draft guidance was issued without adequate public input or stakeholder consultation.
- It departs from the historical FDA regulatory approach to homeopathy established in the 1988 Compliance Policy Guide (CPG 400.400).
- The draft guidance imposes potentially overbroad regulatory standards on all homeopathic products regardless of safety history.
- Lack of clarity could cause confusion and fear among consumers and manufacturers.
- Petitioners argue that homeopathic products are generally recognized as safe and have a long history of consumer use.",FALSE,
FDA-2018-P-2985-0001_Citizen_Petition_from_Norbrook_Inc_.pdf,7/26/2018,"Letterhead dated July 26, but stamp reflects July 30.",Norbrook Laboratories Limited,Not mentioned.,"- Section 512(n)(3)(A) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. §314.93
- 21 CFR 25.15
- 21 CFR 25.21
- 21 CFR 33(a)(1)",Filing of an Abbreviated New Animal Drug Application (ANADA) for a generic drug differing in dosage form from the listed product FELIMAZOLE® (methimazole) Coated Tablets,"Granting permission to file an ANADA for a Methimazole 5 mg/mL Oral Solution as a generic version of FELIMAZOLE® tablets, based on a change in dosage form","- The generic product contains the same active ingredient (methimazole) and is intended for the same species (cats) with identical indications.
- The dosage strength and route of administration remain consistent with the pioneer drug, although the generic uses an oral solution instead of tablets.
- All excipients used are approved in other companion animal drugs in the U.S.
- Prior similar suitability petition (FDA-2014-P-1802) was approved in 2015.
- Petition asserts environmental exclusion under FDA rules and affirms compliance with bioequivalence and other regulatory standards",FALSE,
FDA-2018-P-2997-0003_Citizen_Petition_from_New_Civil_Liberties_Alliance.pdf,7/31/2018,,New Civil Liberties Alliance,Not mentioned.,"- 21 U.S.C. § 371(a) (FD&C Act § 701)
- 5 U.S.C. § 553(e) (APA rulemaking provision)
- 21 C.F.R. § 10.30 (FDA petition regulations)
- Multiple legal precedents cited (e.g., Perez v. Mortgage Bankers Ass’n, Chrysler Corp. v. Brown)","FDA’s use of guidance documents that purportedly create legally binding obligations without going through notice-and-comment rulemaking; also refers to internal practices of issuing, relying on, or defending “improper agency guidance”","The petitioner requests the FDA to promulgate a formal, binding regulation that prohibits the issuance, reliance on, or defense of guidance documents that function as de facto legislative rules without meeting APA requirements (i.e., without notice-and-comment rulemaking)","- Agencies, including FDA, often bypass notice-and-comment procedures by issuing guidance documents with de facto binding legal effects.
- This practice violates the Constitution and the APA.
- Courts often cannot review such guidance due to procedural barriers like non-finality.
- Past reform efforts (e.g., OMB Bulletin, DOJ Sessions and Brand Memos) are insufficient because they are not binding or enforceable.
- The proposed rule would close these gaps, enhance accountability, protect constitutional rights, and ensure FDA actions comply with lawful procedures",FALSE,
FDA-2018-P-3076-0001_Citizen_Petition_from_Dr__Joseph_Purita_Redacted.pdf,7/23/2018,,Dr. Joseph Purita,Not mentioned.,"- 21 CFR Part 347
- 21 CFR 330.11
- 21 CFR 314.50
- 21 CFR 10.30
- 21 CFR 330.10(a)(12)
- Section 505 of the FD&C Act
- 21 CFR Section 25.30",Amendment of the OTC monograph for Skin Protectant Drug Products (21 CFR Part 347),"To amend the OTC monograph for Skin Protectant Drug Products (21 CFR Part 347) to include Avenanthramides as an alternative active ingredient to Colloidal Oatmeal, with a minimum concentration of 0.007% (or 0.003% when combined with mineral oil)","- Avenanthramides are natural compounds found in oats with proven antioxidant activity, similar to Colloidal Oatmeal.
- Scientific literature supports the inclusion of Avenanthramides due to their efficacy and safety profile.
- Synthetic derivatives like Dihydroavenanthramide D also demonstrate similar effects.
- Aligns with FDA’s goals to foster innovation and improve outdated monographs.
- Legal framework allows for such monograph amendments via citizen petition",FALSE,
FDA-2018-P-3102-0001_Citizen_Petition_From_Richard_M__Fleming_Redacted.pdf,7/31/2018,,Richard M. Fleming,Not mentioned.,"- 21 C.F.R. § 25.30
- 21 C.F.R. § 25.31
- 21 C.F.R. § 25.32
- 21 C.F.R. § 25.33
- 21 C.F.R. § 25.34
- 21 C.F.R. § 25.40","- Approval and reimbursement practices related to Technetium-99m isotopes Sestamibi and Tetrofosmin
- Claims of “quantification” by nuclear camera companies (SPECT and PET)
- Approval and radiation safety claims of 3D tomosynthesis mammography equipment
- Use of CPT coding for reimbursement, especially for faux “quantification”","The petitioner requests that FDA:
1. Address false claims and excessive use of Technetium-99m isotopes
2. Address misleading claims of disease quantification by SPECT/PET camera producers
3. Address misleading radiation safety claims of 3D tomosynthesis
4. Eliminate CPT coding as a reimbursement method
5. Accept the petitioner’s patented method (FMTVDM) for testing cardiac and oncologic drugs","- Technetium-99m isotopes redistribute, negating the need for two doses, thus current practices increase costs, errors (35% error rate), and radiation exposure
- Nuclear imaging “quantification” is scientifically invalid without calibration, leading to a 33.95% error rate
- 3D tomosynthesis claims are misleading; it actually delivers more radiation per breast image than conventional methods
- CPT coding increases costs without improving healthcare
- The patented FMTVDM method allows true quantification and can reduce healthcare costs while improving diagnostic accuracy",FALSE,
FDA-2018-P-3139-0001_Citizen_Petition_from_Hyman__Phelps___McNamara__P_.pdf,8/10/2018,,"Hyman, Phelps & McNamara, P.C.","Representing an unnamed client (identity not disclosed)
","- 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FDC Act)
- 21 C.F.R. § 314.93
- 21 C.F.R. § 10.20
- 21 C.F.R. § 10.30
- 21 C.F.R. § 25.31 (environmental exclusion)
- 21 C.F.R. § 10.30(b) (economic impact)
- FDC Act § 505B(a)(1)(A) (PREA exemption justification)","Determination of suitability for submission of a different tablet strength (750 mg) of Ranolazine Extended-Release Tablets as an Abbreviated New Drug Application (ANDA), relative to the Reference Listed Drug (RLD) Ranexa®","Request that FDA determine Ranolazine Extended-Release Tablets, 750 mg, is suitable for submission as an ANDA under the approved NDA for Ranexa® (currently 500 mg and 1000 mg only)
","- The 750 mg strength provides dosing flexibility (e.g., 1500 mg/day titration option).
- Demonstrated bioequivalence to 1000 mg strength expected through in-vitro dissolution testing and proportional similarity.
- 750 mg strength was used in Ranexa clinical trials.
- The product is not subject to PREA since only the strength is changing, not active ingredient, indication, or route of administration.
- Draft labeling and Orange Book references are included as attachments.
- No safety or effectiveness concerns raised",FALSE,
FDA-2018-P-3139-0006_Withdrawal_from_Hyman__Phelps_and_McNamara__PC.pdf,8/25/2023,"Date was incorrectly identified by ChatGPT, but date has been manually adjusted. ","Hyman, Phelps & McNamara, P.C.","Representing an unnamed client (identity not disclosed)
",Not applicable.,Not applicable.,"Withdrawal of the previously submitted citizen petition.

","Not provided. The letter simply states the petition is withdrawn without giving a reason

",FALSE,
FDA-2018-P-3176-0001_Citizen_Petition_from_Medefil_Inc_1.pdf,8/15/2018,,"Medefil, Inc.",Not mentioned.,"- 21 CFR § 10.25(a)
- 21 CFR § 10.30
- Section 505(b)(2) of the FD&C Act
- 21 CFR § 25.31(a) (for environmental impact)
- 21 CFR § 10.30(b) (for economic impact)","Assignment of a Therapeutic Equivalence Evaluation Code (""TE Code"") in the Orange Book for Medefil’s NDA 202832
","FDA to assign a TE Code of “AP” for Medefil's NDA 202832 (Sodium Chloride Injection, USP, 0.9%) in the Orange Book for the purpose of the prescription drug fee exception","- Medefil's product is pharmaceutically equivalent to Hospira’s NDA 018803.
- Same dosage form, route of administration, and active ingredient amount.
- Intended for the same use: dilution/dissolution of drugs for IV, IM, or subcutaneous injection.
- Both listed as RLD (Reference Listed Drugs) in the Orange Book.
- Meets FDA criteria for therapeutic equivalence: pharmaceutical equivalence and demonstrated bioequivalence",FALSE,
FDA-2018-P-3211-0001_Citizen_Petition_from_Aurora_Pharmaceutical_LLC.pdf,8/17/2018,,Aurora Pharmaceutical LLC,Not mentioned.,Section 512(n)(3) of the Federal Food Drug and Cosmetic Act; 21 CFR 25.15; 21 CFR 25.30(h); 21 CFR 25.21,Approval requirements for an Abbreviated New Animal Drug Application (ANADA) for a product that differs in dosage form and strength from the Reference Listed New Animal Drug (RLNAD),Permission to file an Abbreviated New Animal Drug Application (ANADA) for Firocoxib Solution 1.14% w/v that differs from the RLNAD (EQUIOXX® Oral Paste) in dosage form and strength,"The change in dosage form (paste to solution) and strength (8.2 mg/g to 11.4 mg/mL) is proposed for convenience, allowing multi-dose packaging. The active ingredient and dosage regimen remain the same. The goal is to offer a more convenient and potentially cost-effective alternative with equivalent therapeutic effect
",FALSE,
FDA-2018-P-3222-0001 Citizen Petition from Foley & Lardner LLP.pdf,8/17/2018,,Foley & Lardner LLP,Not mentioned.,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. §§ 10.30, 314.93, and 314.161",Determination of whether Mobic (meloxicam) Suspension 7.5mg/5mL by Boehringer Ingelheim was withdrawn for reasons of safety or effectiveness ,Request that the FDA determine Mobic (meloxicam) Suspension 7.5mg/5mL was not withdrawn for reasons related to safety or effectiveness ,"The product was discontinued for business reasons, not safety or efficacy. The petitioner includes a press release from Boehringer Ingelheim as evidence. Approving ANDAs for the discontinued product would provide public access to a needed drug that is currently unavailable. 
",FALSE,
FDA-2018-P-3222-0003_Citizen_Petition_Withdrawal_Letter_from_Foley___La.pdf,12/18/2018,"Letterhead dated December 18, but stamp reflects December 19. Date was incorrectly identified by ChatGPT, but date has been manually adjusted. ",Foley & Lardner LLP,Not mentioned.,Not applicable.,Not applicable.,"Withdrawal of the previously submitted citizen petition.

","The FDA determined that the product was not withdrawn for reasons related to safety or effectiveness, making a formal response to the petition no longer necessary

",FALSE,
FDA-2018-P-3266-0001_Citizen_Petition_from_Haynes_and_Boone__LLP___Reda.pdf,8/22/2018,,Haynes and Boone LLP,"Representing VistaPharm Inc. 
","- 21 C.F.R. §§ 10.25(a), 10.30
- 21 C.F.R. § 25.31
- 21 C.F.R. § 10.30(b)
- 21 C.F.R. § 320.24(a)
- 21 U.S.C. § 355",Draft Guidance for Mycophenolate Mofetil Oral Suspension (revised October 2017) allowing use of only metabolite data to establish bioequivalence to CellCept® Oral Suspension ,"- Withdraw the current Draft Guidance for Mycophenolate Mofetil Oral Suspension.
- Issue new guidance requiring use of both parent compound (MMF) and metabolite data to establish bioequivalence for ANDAs referencing CellCept® Oral Suspension.","- MMF (parent compound) can be accurately and reliably measured in human plasma using validated methods, as shown in Exhibit C and ANDA data.
- Measuring both MMF and its metabolite provides more accurate bioequivalence determination.
- Current guidance is outdated and inconsistent with FDA’s treatment of similar prodrugs like midodrine and temozolomide.
- FDA’s own guidance encourages use of parent compound data if feasible.
- Revising the guidance would promote safety, efficacy, and consistency in regulatory approach.",FALSE,
FDA-2018-P-3281-0001_Citizen_Petition_from_Pfizer_Inc.pdf,8/22/2018,,Pfizer Inc.,Not mentioned.,"- 21 C.F.R. § 10.30
- 42 U.S.C. § 262(a), § 262(k), § 262(i)(2)-(4)
- 21 C.F.R. § 601.2(d)
- 21 U.S.C. § 352(a), § 352(n), § 331(a)
- 21 C.F.R. § 201.6(a), § 202.1(e)(6)(ii), § 202.1
- 21 C.F.R. § 25.31","FDA’s oversight of communications regarding biosimilars, especially related to misleading or false claims by reference product sponsors. Pfizer comments on the lack of FDA guidance addressing sponsor communications about the safety and effectiveness of biosimilars, including interchangeable biologics, versus reference biologics.","Pfizer requests that the FDA issue guidance that:
• Defines inappropriate communications that are false or misleading about biosimilars.
• Provides examples of lawful, truthful, and non-misleading communications.
• Clarifies that biosimilar sponsors may share clinical data consistent with FDA-approved labeling.","Pfizer argues that:
• Misleading statements by reference product sponsors sow doubt about biosimilar safety and efficacy.
• Such communications hinder market adoption of biosimilars.
• Clear guidance is needed to ensure accurate, balanced information is available to physicians, patients, and payers, supporting competition and patient access.",FALSE,
FDA-2018-P-3284-0001_Citizen_Petition_from_Keryx_Biopharmaceuticals__In.pdf,8/23/2018,,"Keryx Biopharmaceuticals, Inc.","Submitted via Arnold & Porter Kaye Scholer LLP
","- 21 C.F.R. § 10.30
- Section 505(q) of the FDCA",Potential approval of any ANDA referencing Auryxia® (ferric citrate) Tablets that omits certain conditions of use,"Request that FDA not approve any ANDA for ferric citrate that seeks to omit the ""hyperphosphatemia in chronic kidney disease on dialysis"" indication unless the applicant submits sufficient data to show the product is safe and effective for the remaining indication (iron deficiency anemia in CKD not on dialysis) without risk.","The IDA indication is protected by a 3-year exclusivity period due to a new clinical investigation essential to approval. Approving a generic product without carving out this indication would violate statutory and regulatory provisions protecting the exclusivity. The petitioner asserts that approving an ANDA without the required carve-out would allow generic labeling that is false and misleading and violate 21 C.F.R. § 314.127(a)(3).
",FALSE,
FDA-2018-P-3325-0001_Citizen_Petition_from_Pfizer_Inc.pdf,8/29/2018,,Pfizer Inc.,Not mentioned.,"- 21 C.F.R. § 314.127(a)(7)
- 21 U.S.C. § 355(j)(2)(A)(v)
- 21 C.F.R. § 314.94(a)(9)(iii)
- 21 U.S.C. § 355(j)(4)
- 505(j) of the FDCA
- 21 C.F.R. § 10.30",FDA’s review and potential approval of any Abbreviated New Drug Application (ANDA) for bivalirudin in 5 mg/mL dosage strength that omits labeling information Pfizer believes is essential for safe use,"Pfizer requests that the FDA withhold approval of any ANDA referencing Toviaz® unless the ANDA includes adequate data demonstrating bioequivalence for both 4 mg and 8 mg dosage strengths, and especially for the 8 mg strength under both fasting and fed conditions.","Pfizer argues that failing to require bioequivalence data for the 8 mg strength would pose a safety and efficacy risk. Since the 8 mg strength shows dose-proportional pharmacokinetics and higher systemic exposure, it is critical that generic applicants demonstrate bioequivalence at this dose.
",FALSE,ChatGPT incorrectly identified a law firm as the representative when there is no mention of it apart from in a footnote for a source in the petition.
FDA-2018-P-3327-0001_Citizen_Petition_from_Hyman__Phelps___McNamara__PC.pdf,8/30/2018,,"Hyman, Phelps & McNamara, P.C. (on behalf of client)","The law firm submitted the petition on behalf of a client. The name of the client is not disclosed.
","- 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FDC Act)
- 21 C.F.R. § 314.93
- 21 C.F.R. § 10.20
- 21 C.F.R. § 10.30
- 21 C.F.R. § 25.31
- 21 C.F.R. § 10.30(b)
- Pediatric Research Equity Act (PREA) – FDC Act § 505B(a)(1)(A) and § 505B(a)(5)(A)",Establishment of suitability for submitting an ANDA for a modified dosage form and strength of a previously approved drug (Metformin Hydrochloride Oral Solution).,"That the FDA determine Metformin Hydrochloride Granules for Oral Solution (500 mg, 850 mg, and 1 g) is suitable for submission as an Abbreviated New Drug Application (ANDA). The petitioner also requests a waiver under PREA for pediatric studies. 
","- The proposed product uses the same active ingredient and indications as the Reference Listed Drug (Riomet).
- Differences in dosage form and strength do not raise new safety or efficacy concerns.
- Provides alternate formulation offering benefits in handling, administration, and flexible dosing.
- Labeling will be consistent with the RLD except for necessary differences.
- Past similar petitions have been approved.
- A full waiver from pediatric studies is justified since type 2 diabetes is not an indication in children under 10 years of age and the drug does not offer new therapeutic benefit over existing treatments. ",FALSE,
FDA-2018-P-3354-0001_Citizen_Petition_from_International_Contrast_Ultra.pdf,9/3/2018,,International Contrast Ultrasound Society (ICUS),Not mentioned.,"- 21 U.S.C. §§ 352 and 355 (FDCA §§ 502 and 505)
- 21 C.F.R. §§ 10.30 and 201.57(c)(1)
- 40 C.F.R. § 1508.4
- 21 C.F.R. § 25.30(h)","Boxed warnings required by FDA on ultrasound contrast agent (UCA) labels since 2007, specifically for products such as Optison, Definity, and Lumason",Remove the boxed warnings from all ultrasound contrast agent (UCA) product labels. Retain relevant information in the “warnings and precautions” section instead,"- Boxed warnings deter appropriate and beneficial clinical use of UCAs.
- Extensive new scientific data (including 18 large studies of 260,000+ patients) show UCAs are among the safest imaging products available.
- Boxed warnings are inconsistent with FDA’s own criteria and guidance for black box warnings.
- CEUS improves diagnosis, reduces radiation exposure, avoids more invasive and expensive procedures, and is especially beneficial for children, obese patients, and those with LVADs.
- Removing the black box promotes innovation and cost-effective care in line with FDA’s strategic goals",FALSE,
FDA-2018-P-3355-0003_Citizen_Petition_from_Oregon_Pain_Guidance.pdf,9/4/2018,,Oregon Pain Guidance,Not mentioned.,"Not explicitly cited by section. General mention of submitting under authority delegated to the Commissioner of Food and Drugs. Guidance mentioned: Innovative Approaches for Nonprescription Drug Products – Draft Guidance July 2018.
",Regulation of naloxone 4mg nasal spray as a prescription-only (legend) drug.,Re-categorize naloxone 4mg nasal spray from prescription-only (legend) status to over-the-counter (OTC) status.,"- The U.S. is facing an opioid overdose epidemic (64,000 deaths in 2016).
- Naloxone is effective, safe, and has minimal abuse potential.
- It meets all FDA criteria for OTC status: safe, effective, easy to use, low misuse risk.
- Current access is limited due to stigma and logistical barriers despite local initiatives.
- OTC reclassification would improve access, particularly in rural and underserved areas.
- Canada has already made similar regulatory changes.
- Supporting evidence includes CDC and other public health studies on naloxone access and usage effectiveness",FALSE,
FDA-2018-P-3372-0001_Citizen_Petition_from_Ohio_State_University.pdf,8/13/2018,,"Ohio State University (Lynne Gauthier, PhD)",Not mentioned.,"- Section 513(e) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. § 882.5050 (Biofeedback devices)
- 21 C.F.R. Part 807 Subpart E
- 21 C.F.R. §§ 25.30, 25.31, 25.32, 25.33, or 25.34 (Environmental impact)","Current FDA policy regarding 510(k) exemption status for battery-powered vs. non-battery-powered biofeedback devices, particularly video-based (optical) sensor devices used for muscular reeducation and relaxation.","Expand FDA 510(k) exemption status to all small and portable non-invasive devices used for relaxation and muscular reeducation, including optical sensor-based biofeedback devices.","- Current exemption criteria are outdated given the evolution of biofeedback technologies.
- Optical sensors (e.g., Microsoft Kinect) offer equal or greater safety and efficacy compared to battery-powered devices.
- Studies demonstrate similar clinical outcomes and safety profiles across sensor types.
- Exempting these devices will reduce commercialization barriers and promote broader adoption of innovative, research-based tools.
- Rapid technological changes make repeated 510(k) submissions burdensome and impractical for developers, especially academic institutions",FALSE,
FDA-2018-P-3382-0001_Citizen_Petition_from_Fresenius_Kabi_USA__LLC.pdf,9/6/2018,,"Fresenius Kabi USA, LLC",Not mentioned.,"- 21 CFR 10.25(a)
- 21 CFR 10.30
- 21 CFR 314.161
- 21 CFR 314.94(a)(3)
- 21 CFR 25.31
- 21 CFR 10.30(b)",Designation of reference listed drugs (RLDs) in the FDA's Orange Book,Designate Sodium Chloride 0.45% in Plastic Container (NDA 018016 by Baxter Healthcare Corp.) as an additional reference listed drug (RLD),"The petitioner (FK USA) intends to submit an Abbreviated New Drug Application (ANDA) based on Baxter’s mini bag product (NDA 018016), which is a pharmaceutical equivalent to currently listed RLDs. Therefore, they request FDA to designate this additional product as an RLD to support ANDA submission ",FALSE,
FDA-2018-P-3401-0001_Citizen_Petition_from_Novo_Nordisk_Inc_.pdf,9/5/2018,,Novo Nordisk Inc.,Not mentioned.,"- 21 C.F.R. § 10.30
- Section 505(j)(2)(A)(iv) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. § 314.94(a)(9)(iii)",The acceptance and approval of any Abbreviated New Drug Application (ANDA) referencing Novo Nordisk’s product Victoza® (liraglutide) that omits certain labeling information related to cardiovascular outcomes.,The petitioner requests that the FDA refuse to approve any ANDA for a generic version of Victoza® that omits the cardiovascular risk reduction labeling or that includes less than the full indication.,"Novo Nordisk argues that the omitted cardiovascular indication is protected by patent and/or exclusivity, and that allowing such ANDAs would be inappropriate under the carve-out regulations. They assert that the cardiovascular outcome labeling is not severable from the product’s overall indication, and any omission would result in a product that is not safe or effective for use.
",FALSE,ChatGPT incorrectly identified a law firm as the representative when there is no mention of it in the petition.
FDA-2018-P-3412-0001_Citizen_Petition_from_Aurolife_Pharma_LLC.pdf,9/6/2018,,"Aurolife Pharma LLC (subsidiary of Aurobindo Pharma USA, Inc.)",Not mentioned.,"- Section 505(j) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. §§ 10.25(a), 10.30, 314.122, 314.161, 314.162
- 21 C.F.R. §§ 25.31(a), 25.15(d), 10.30(b) (environmental and economic impact clauses)","The petitioner comments on the removal of QVAR 40 & QVAR 80 (Beclomethasone dipropionate HFA inhalation aerosol, NDA 020911) from the active section of the Orange Book and its inclusion in the discontinued section.",The petitioner requests the FDA to determine whether QVAR 40 & QVAR 80 (NDA 020911) were voluntarily withdrawn or withheld from sale for reasons of safety or effectiveness.,"- The drug appears in the discontinued section of the FDA’s Orange Book.
- The FDA’s database indicates that the manufacturer, Teva Branded Pharmaceutical Products R&D Inc, made a business decision to discontinue the product.
- Under FDA regulation (21 C.F.R. 314.161), the FDA must determine if a listed drug was withdrawn for safety or efficacy reasons before approving an ANDA referencing that drug. The petitioner seeks clarification to support potential ANDA submission.",FALSE,
FDA-2018-P-3413-0001_Citizen_Petition_from_Pharmaceutical_R_D_and_QA_Co.pdf,9/7/2018,,"Dilip R. Sanvordeker, Pharmaceutical R&D and QA Consulting Services
","Representing Centaur Pharmaceuticals Private Limited (Client)
","- Section 505(j) of the Federal Food, Drug, and Cosmetic Act
- 21 CFR 10.25(a)
- 21 CFR 10.30
- 21 CFR 314.93
- 21 CFR 25.31(a)
- 21 CFR 25.15(d)","The petition comments on the continued listing of Librium Capsules (ANDA 085475 of Valeant Pharmaceuticals International) as the reference standard in the Orange Book, despite unavailability in the market.","FDA is requested to designate an alternative reference standard for Chlordiazepoxide HCl Capsules (5 mg, 10 mg, and 25 mg), specifically those approved under ANDA #A084768, #A083116, and #A084769 (Barr Laboratories Inc. / Teva Pharmaceutical USA Inc.)","- The current reference standard (Librium, Valeant) is not discontinued per the Orange Book but is not available in the market for in vivo bioequivalence testing.
- Dailymed indicates Librium’s marketing stopped in December 2014.
- Teva’s generic products are discontinued, leaving Barr Laboratories/Teva as the only non-discontinued ANDA holders.
- FDA guidance allows for a new reference standard when availability of the current one is too limited for bioequivalence testing.
- Barr’s approved ANDAs remain active and are marketed under Teva’s name.
- Supporting data includes Orange Book results, Drugs@FDA searches, Newport Generics market data, and DailyMed inserts.",FALSE,
FDA-2018-P-3413-0004_Withdrawal_letter_from_Pharmaceutical_R___D_and_QA.pdf,10/6/2021,"Date was incorrectly identified by ChatGPT, but date has been manually adjusted. ","Dilip R. Sanvordeker, Pharmaceutical R&D and QA Consulting Services
","Representing Centaur Pharmaceuticals Private Limited (Client)
",Not applicable.,Not applicable.,"Withdrawal of the previously submitted citizen petition.

","An FDA interim response dated March 4, 2019, stated that a decision on the petition had not been reached due to the need to address other priorities, leading the petitioner to withdraw

",FALSE,
FDA-2018-P-3422-0001_Citizen_Petition_from_Novitium_Pharma_LLC_.pdf,9/6/2018,,Novitium Pharma LLC,Not mentioned.,"- 21 C.F.R. § 10.30
- 21 C.F.R. § 10.25(a)
- 21 C.F.R. § 314.94(a)(3)
- Drug Price Competition and Patent Term Restoration Act (Public Law 98-417)",FDA designation of a Reference Standard (RS) for Oxandrin (Oxandrolone) Tablets 2.5 mg and 10 mg (NDA 013718),Designate the generic product made by PAR Pharmaceutical Inc (ANDA A077827) as the RS for Oxandrin Tablets 2.5 mg & 10 mg (NDA 013718),"- The original brand manufacturer (Gemini Laboratories LLC) has discontinued marketing Oxandrin Tablets.
- No RLD/RS is available on the market.
- PAR Pharmaceutical Inc. is the current market leader among generic manufacturers.
- The RS designation will support generic drug development and reduce public healthcare costs.",FALSE,
FDA-2018-P-3426-0001_Citizen_Petition_from_Pharmax_Group__Inc.pdf,9/7/2018,,"Pharmax Group, Inc.","Submitted on behalf of a client (client not named explicitly)
","- 21 C.F.R. § 10.25
- 21 C.F.R. § 10.30
- Section 505(j)(2) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
","The unavailability of the current Reference Standard (RS) product (Cyproheptadine Hydrochloride Tablets, USP 4 mg, ANDA# A087056, IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS) in the market, and the selection of an alternative RS.","Request the FDA to designate SANTOS BIOTECH INDUSTRIES INC (ANDA# A040644) as the Reference Standard (RS) for Cyproheptadine Hydrochloride Tablets, USP 4 mg to allow ANDA submissions","- The currently designated RS (IVAX PHARMACEUTICALS/TEVA) is not available in the market.
- The Orange Book lists SANTOS BIOTECH INDUSTRIES INC as an approved ANDA holder.
- Breckenridge (distributor for Santos Biotech) is the generic market leader based on IMS sales data.
- FDA guidance allows substitution if RS is unavailable and the alternative is therapeutically equivalent and a market leader",FALSE,
FDA-2018-P-3535-0001_Petition_from_Norbrook_Laboratories_Limited.pdf,9/17/2018,"Letterhead dated September 17, but stamp reflects September 18.",Norbrook Laboratories Limited,Not mentioned.,"- Section 512(n)(3)(A) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. § 314.93
- 21 C.F.R. § 25.15 and § 25.30(h) (Environmental Impact)",The petitioner is commenting on the approval of a generic new animal drug product that differs in dosage form from the referenced listed new animal drug (RLNAD) — a change from chewable tablet to oral solution. ,"Approval of an Abbreviated New Animal Drug Application (ANADA) for Pimobendan 4 mg/mL Oral Solution, which differs from the RLNAD (Vetmedin® Chewable Tablets) in dosage form. ","- The generic product contains the same active ingredient (pimobendan) and is intended for the same species (canine).
- It has the same route of administration and dosage per treatment.
- The only difference is in dosage form (oral solution instead of chewable tablet), and all excipients are used in other approved animal drugs.
- The petitioner also intends to meet all bioequivalence requirements, and no changes are made to labeling except those necessary due to the form difference. ",FALSE,
FDA-2018-P-3545-0001_Citizen_Petition_from_Arnall_Golden_Gregory__LLP.pdf,9/12/2018,"Letterhead dated September 12, but stamp reflects September 19.",Arnall Golden Gregory LLP,"Not explicitly stated, but the petition is made against Emcure Pharmaceuticals Limited regarding its BiCNU (carmustine) drug product.","- 21 U.S.C. §§ 331(a), 381(a)
- 21 C.F.R. §§ 10.20, 10.30, 25.31","- Enforcement of Import Alert #66-40
- FDA’s prior Warning Letter (March 3, 2016) concerning Emcure's facility in Maharashtra, India",- FDA should not permit Emcure to import its BiCNU chemotherapy drug product until the company resolves the identified quality-related deficiencies.,"- FDA issued a Warning Letter for violations of Good Manufacturing Practices (GMP).
- Previous FDA Form 483s were issued.
- An alternative carmustine product has been approved (as of Sept 11, 2018), so there is no unmet need.
- The deficiencies remain unresolved, and the importation of adulterated drugs poses a public health risk.",FALSE,
FDA-2018-P-3545-0008_Withdrawal_from_Arnall_Golden_Gregory_LLP.pdf,12/17/2019,"Date was incorrectly identified by ChatGPT, but date has been manually adjusted. ",Arnall Golden Gregory LLP,"Not explicitly stated, but the petition is made against Emcure Pharmaceuticals Limited regarding its BiCNU (carmustine) drug product.",Not applicable.,Not applicable.,"Withdrawal of the previously submitted citizen petition.

","Withdrawal was made based on a telephone conversation with FDA officials. No further justification is provided

",FALSE,
FDA-2018-P-3597-0001_Citizen_Petition_from_Arent_Fox_LLP.pdf,9/21/2018,,Arent Fox LLP,"Submitted on behalf of a client (unnamed)
","- Federal Food, Drug, and Cosmetic Act (FD&C Act)
- 21 C.F.R. §§ 10.25(a), 10.30(b), 314.161, 314.122, 314.162","Determination of whether Lotrimin® (Clotrimazole 1% topical solution), NDA No. N017613, was withdrawn from the market for reasons of safety or effectiveness",The petitioner requests that the FDA determine whether NDA No. N017613 was voluntarily withdrawn for reasons of safety or effectiveness,"- NDA No. N017613 appears in the “Discontinued” section of the Orange Book
- ANDA No. A074580, referencing NDA No. N017613, continues to be marketed and used for bioequivalence
- Petitioner is unaware of any safety or efficacy reasons for its withdrawal
- FDA has previously ruled similar products (e.g., Mycelex® NDA No. N018181) were not withdrawn for safety or efficacy concerns
- Seeks clarity to facilitate ANDA submissions based on RLD Lotrimin®",FALSE,
FDA-2018-P-3599-0001_Citizen_Petition_from_AuroMedics_Pharma_LLC.pdf,9/21/2018,,AuroMedics Pharma LLC ,"Petition submitted on behalf of Aurobindo Pharma Limited
","21 CFR §§ 10.30, 10.20, 10.25(a), 314.122, 314.161, 314.94(a)(9)(iii), 314.99; 21 CFR § 25.31(a) (Environmental impact exclusion)",Determination whether original formulation of Kenalog®-10 (NDA 012041) was discontinued for safety or efficacy reasons,"- FDA should determine that the original formulation of NDA 012041 was not discontinued for safety or efficacy reasons.
- FDA should determine that this original formulation may be cited as the Reference Listed Drug (RLD) for an ANDA submission.","- The petition argues that the proposed generic contains the same active and inactive ingredients in the same concentration and dosage form as the original formulation.
- Precedents are cited, such as Kenalog®-40, Zosyn®, and Sandostatin®, where FDA accepted previously discontinued formulations as reference products for ANDAs, provided the discontinuation was not due to safety or efficacy concerns.
- The CMC Supplement S-043 for NDA 012041, approved on Oct. 26, 2015, was for global harmonization and had no impact on safety or efficacy.",FALSE,
FDA-2018-P-3616-0001_Citizen_Petition_from_Suven_Life_Sciences_Limited.pdf,9/21/2018,,Suven Life Sciences Limited,Not mentioned.,"- Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. § 10.30
- 21 C.F.R. § 10.25(a)
- 21 C.F.R. § 314.94(a)(3)
- FDC Act § 505(j)","The petitioner is commenting on the current designation of the reference standard (RS) for Chloroquine Phosphate Tablets 250 mg (EQ 150 mg base), specifically the reference standard status of the drug listed under ANDA 083082 (held by HIKMA Pharmaceuticals).","The petitioner requests that the FDA designate the approved generic product CHLOROQUINE PHOSPHATE TABLETS 250 MG (EQ 150 mg base) held by NATCO PHARMA LIMITED (ANDA 091621) as the new Reference Standard (RS) due to limited availability of the current RS.
","- Current RS (ANDA 083082) held by Hikma Pharmaceuticals has very limited availability, making it hard for ANDA applicants to obtain sufficient quantities for developmental studies.
- ARALEN (the RLD) has been discontinued.
- NATCO’s product (ANDA 091621) is the most marketed generic equivalent and is therapeutically equivalent to the discontinued RLD.
- FDA guidance allows designation of a new RS in cases of unavailability or limited supply.
- Supporting data includes Orange Book listings, MAT (Moving Annual Total) market data, NDC directory, and a statement on sample unavailability.",FALSE,
FDA-2018-P-3640-0001_Citizen_Petition_from_Information_Technology_and_I.pdf,9/24/2018,,"Information Technology and Innovation Foundation (ITIF)
",Not mentioned.,"- Section 403 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 343)
- 21 C.F.R. § 10.30 (regarding rulemaking petitions)","Use of the term ""Non-GMO"" and the Non-GMO Project’s butterfly logo on consumer food labeling, implying health/safety risks, which ITIF claims are scientifically unfounded and misleading
","- Prohibit the use of the term ""Non-GMO"" on consumer foods and goods
- Require distributors to revise labeling to remove ""Non-GMO"" claims and the Non-GMO Project butterfly logo","- The ""Non-GMO"" label is misleading, lacks scientific basis, and falsely implies health/safety risks.
- Labels convey a false distinction between GMO and non-GMO products.
- The butterfly logo misbrands food by suggesting GMO foods are unsafe, despite scientific consensus on their safety.
- The Non-GMO Project's classification system is arbitrary and deceptive.
- Labeling even appears on items that could never be genetically modified (e.g., salt), further misleading consumers.
- The practice violates the prohibition on false or misleading labeling under the Food, Drug, and Cosmetic Act
",FALSE,
FDA-2018-P-3666-0001_Citizen_Petition_from_Fresenius_Kabi_USA__LLC.pdf,9/25/2018,,"Fresenius Kabi USA, LLC",Not mentioned.,"- 21 CFR 10.30
- 21 CFR 320.22(b)
- Federal Food, Drug, and Cosmetic Act","Designation of therapeutic equivalence (with an ""AP"" rating) of Fresenius Kabi’s Indomethacin Injection (NDA 022536) to the RLD Indocin® Indomethacin Sodium Injection (NDA 018878) by Recordati Rare Diseases, Inc.","FDA is requested to designate Fresenius Kabi USA's Indomethacin Injection, 1 mg/5 mL (NDA 022536), as a therapeutic equivalent with an “AP” rating to the RLD Indocin® (NDA 018878).","- FK USA’s product is pharmaceutically and therapeutically equivalent to the RLD.
- Side-by-side comparison shows identical strength, route, dosage form, active ingredient, and labeling indications.
- Differences in excipients are minor and do not affect pH or stability.
- Waiver granted for in-vivo bioequivalence based on 21 CFR 320.22(b), applicable to sterile IV solutions.
- Literature and data support that excipient differences do not impact pharmacokinetics.
- NDA 022536 relied on RLD and literature for safety and efficacy data.",FALSE,
FDA-2018-P-3672-0001_Citizen_Petition_from_Zoetis_Inc_.pdf,9/25/2018,"Letterhead dated September 25, but stamp reflects September 27.",Zoetis Inc.,Not mentioned.,"Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act (FFDCA); 21 CFR 25.30(h); 21 CFR 25.21",Suitability Petition submission for an Abbreviated New Animal Drug Application (ANADA) for a different dosage form of an already approved product,"FDA approval to file an ANADA for a granular formulation of Generic “Nicarbazin 25% Type A Medicated Article” instead of the existing powdered dosage form
","The proposed formulation improves product handling by reducing dust, minimizing explosion risk, and enhancing flowability. It is more compatible with current manufacturing technologies and provides safety benefits for users and handlers compared to the powder blend. Both products contain the same active ingredient, with changes limited to dosage form and excipients
",FALSE,
FDA-2018-P-3691-0001_Citizen_Petition_from_Avanthi__LLC_.pdf,9/27/2018,,"Avanthi, LLC",Not mentioned.,"- 21 CFR §§ 10.25(a) and 10.30
- 21 CFR § 314.161
- Also references 21 CFR §§ 314.122, 314.162","Discontinuation of Chlor-Trimeton® (Chlorpheniramine Maleate) Extended-Release Tablets 8 mg, NDA #007638 held by Bayer Healthcare LLC from the market and whether it was for safety or effectiveness.",FDA is requested to make a determination on whether Chlor-Trimeton® has been voluntarily withdrawn from the market for reasons of safety or effectiveness.,"The petitioner noted that the drug appears to have been discontinued from marketing, as indicated in the electronic Orange Book (accessed September 25, 2018). Therefore, FDA determination is needed.
",FALSE,
FDA-2018-P-3709-0001_Citizen_Petition_from_Jennifer_Nelson_Redacted.pdf,9/28/2018,,Jennifer Nelson,Not mentioned.,"- 21 C.F.R. § 10.30 (Citizen Petition regulation)
- 21 C.F.R. § 895.21 (Procedures for banning a device)",The ongoing marketing and usage of Permanent Cautery Instruments (Spatula and Hook) for all Da Vinci robotic surgeries manufactured by Intuitive Surgical. The petitioner references prior FDA recalls and enforcement actions related to these devices.,The petitioner requests the FDA to ban the use of Permanent Cautery Instruments for the Da Vinci robotic surgical system in all surgeries across the United States.,"- Cites ongoing malfunctions, injuries, and deaths associated with the devices, as recorded in the FDA MAUDE database.
- Refers to known design defects acknowledged by the manufacturer.
- Cites historical FDA warning letters indicating violations by the manufacturer.
- Highlights potential for severe thermal injury due to arcing and electric current leakage.
- Expresses concern over lack of Active Electrode Monitoring (AEM) in the device design.
- Personal experience as a victim of device failure underscores the urgency for FDA intervention.",FALSE,
FDA-2018-P-3730-0001_Citizen_Petition_from_Aizant_Drug_Research_Solutio.pdf,10/1/2018,,"Aizant Drug Research Solutions Pvt. Ltd.
",Not mentioned.,"- Section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act
- 21 C.F.R. § 314.93
- 21 C.F.R. § 10.30
- 21 C.F.R. § 25.31 (environmental impact)
- 21 C.F.R. § 10.30(b) (economic impact)",Discontinuation status of ESBRIET (pirfenidone) Tablets 534 mg under NDA #208780,"Requesting FDA to determine that ESBRIET (pirfenidone) Tablets 534 mg was not discontinued for reasons of safety or efficacy, and therefore is eligible for submission of an ANDA for the same strength.
","- ESBRIET 534 mg tablets are currently marked as ""Discontinued"" in the Orange Book and drugs@fda.gov.
- Other strengths (267 mg and 801 mg) are still marketed.
- No evidence provided that the 534 mg strength was withdrawn for safety or efficacy reasons.
- Seeks FDA confirmation to allow ANDA submissions for all three strengths, including the 534 mg version.",FALSE,
FDA-2018-P-3742-0001_Citizen_Petition_from_Pharmacmechanics.pdf,10/1/2018,,"Saeed Qureshi, Ph.D., Principal at Pharmacmechanics
",Not mentioned.,"- 21 CFR 111.320
- 21 CFR 820.72
- 21 CFR 211.194(a)(2)
- USP General Chapter <711>
- References to several FDA guidance documents from 1997, 2017, and 2018","Guidance documents and regulatory recommendations concerning dissolution testing of immediate-release solid oral dosage forms, specifically those involving basket and paddle apparatuses","Withdrawal of the following guidance documents and regulatory references:
1. 2018 FDA Guidance on Dissolution Testing
2. 2017 Guidance on Waiver of In Vivo Bioavailability Studies
3. 1997 Guidance on Dissolution Testing
4. FDA’s Dissolution Methods Database","The petitioner argues that the drug dissolution testers used (paddle and basket apparatuses) have not been validated as required under cGMP regulations. As a result, dissolution data from these unvalidated testers are unreliable and may provide a false sense of product quality to consumers. The FDA’s reliance on these tools, according to the petitioner, leads to non-GMP-compliant practices and potentially inaccurate quality assessments of drug products
",FALSE,
FDA-2018-P-3746-0001_Citizen_Petition_from_BF_Innovation_Inc_on_behalf_.pdf,10/1/2018,,BF Innovation Inc. ,"Representing Bright Future Pharmaceutical Laboratories Limited 
","- Federal Food, Drug, and Cosmetics Act (""FDC Act"")
- 21 C.F.R. § 10.30","FDA’s designation of Reference Standards (RS) in the Orange Book, specifically the unavailability of the current RS (N019957 by Fougera Pharmaceuticals Inc.) for Fluticasone Propionate Ointment 0.005%
","Request FDA to designate Fluticasone Propionate Ointment 0.005% (Application No: A076668) by Perrigo New York Inc. as an additional Reference Standard (RS) to support ANDA submissions 
","- The current RS (Fougera’s product) is not available for sale.
- IMS data shows Perrigo’s version is the market leader in unit sales in 2017.
- Availability of an alternative RS would facilitate bioequivalence studies necessary for ANDA submissions and help avoid delay in generic drug development. ",FALSE,
FDA-2018-P-3770-0001_Citizen_Petition_from_Luitpold_Pharmaceuticals_Inc.pdf,9/4/2018,"Letterhead dated September 4, but stamp reflects September 5.",Luitpold Pharmaceuticals Inc.,Not mentioned.,"- Section 505(j)(2)(C) of the FDCA
- 21 C.F.R. §§ 10.20, 10.30, and 314.93","Suitability for submission of an ANDA for Levocarnitine Injection, 200 mg/mL, 20 mL Single Dose Vial","FDA approval of a Suitability Petition declaring that Levocarnitine Injection, 200 mg/mL (20 mL Single Dose Vial) is suitable for submission in an ANDA
","- Existing RLD (Carnitor®) is in 5 mL vials; proposed 20 mL vial would improve convenience.
- Supports FDA’s goal of increasing generic competition.
- Reduces sterility risk and vial usage for heavier patients (e.g., those over 60 kg often need >3,000 mg).
- The proposed change does not affect drug concentration, dosage form, or route of administration.
- Same active/inactive ingredients and therapeutic effect as RLD.",FALSE,
FDA-2018-P-3786-0001_Citizen_Petition_from_Hyman__Phelps___McNamara_PC.pdf,10/3/2018,,"Hyman, Phelps & McNamara, P.C.","Hyman, Phelps & McNamara, P.C. submitted the petition on behalf of a client (unnamed)
","- 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FDC Act)
- 21 C.F.R. § 314.93
- 21 C.F.R. § 10.20
- 21 C.F.R. § 10.30
- 21 C.F.R. § 25.31 (Environmental Impact)
- FDC Act § 505B(a)(1)(A) (PREA compliance reference)","Determination of suitability for submission of an Abbreviated New Drug Application (ANDA) for a new strength of an existing Reference Listed Drug (RLD): Janumet XR
","FDA is requested to determine that Metformin/Sitagliptin 750 mg/50 mg is suitable for submission as an ANDA based on Janumet XR as the RLD. The new product introduces an intermediate strength not currently marketed
","- The new strength (750 mg Metformin/50 mg Sitagliptin) offers dosing flexibility.
- Current Janumet XR strengths are limited to 500/50 mg, 1000/50 mg, and 1000/100 mg.
- Introducing a 750 mg strength allows finer dose titration, improved adherence, and reduces risk of dosing errors.
- Addresses patient needs who are already on 750 mg of metformin (e.g., Glucophage XR users).
- Does not raise new safety or efficacy questions; other conditions remain the same as the RLD.
- Petition claims exemption from Pediatric Research Equity Act (PREA) because this is only a strength change",FALSE,
FDA-2018-P-3806-0001_Citizen_Petition_from_Greg_Grillo_Redacted.pdf,,No date recognized by ChatGPT nor apparent through a quick skim.,"Dr. Greg Grillo, DDS, and more than 375 dental professionals and other citizens
",Not mentioned.,"- 21 C.F.R. §§ 10.25(a) and 10.30
- Federal Food, Drug and Cosmetic Act (FDC Act)
- 21 C.F.R. § 25.31 (Environmental impact exemption)","The current FDA classification and regulatory status of oral moisturizer products marketed for dry mouth that linger in the mouth, especially regarding their formulation safety
","The FDA should regulate oral moisturizer products marketed for mitigation, treatment, or prevention of dry mouth as drugs or devices under the FDC Act and ensure their formulations are safe—specifically, requiring a pH level that does not risk demineralization or erosion of teeth
","- Many currently marketed dry mouth products have dangerously low pH (as low as 2.9), which can lead to tooth demineralization, erosion, and cavities.
- Scientific studies (Delgado & Olafsson, 2017 & 2018) show products with pH below 5.5 are erosive, and safe pH should be around 6.7 or higher.
- These products are often marketed for frequent or prolonged oral use, increasing the risk to consumers—particularly those already vulnerable due to dry mouth (xerostomia).
- The regulatory status of these products is unclear, and most do not meet legal requirements for classification as drugs or devices",FALSE,
FDA-2018-P-3825-0001_Citizen_Petition_from_Pei_Wei_Asian_Diner__LLC_.pdf,10/8/2018,,"Pei Wei Asian Diner, LLC",Not mentioned.,"- 21 C.F.R. § 10.30
- 21 U.S.C. § 371(a) and § 371(h)
- 21 U.S.C. § 393(b)(2)(A)
- 21 C.F.R. § 101.11(a), (b)(2)(i)-(ii), (c)(3)
- 21 C.F.R. § 101.13(b)(1)
- 21 C.F.R. § 101.10
- 21 C.F.R. § 10.115(g)(1)
- 21 C.F.R. § 25.32(p)
- 21 C.F.R. § 10.30(b)(3)","The petition comments on current FDA regulations that exempt restaurants (covered establishments) from publicly disclosing ingredient details and substantiation of nutrient content claims unless requested by the FDA.
","1. Amend 21 C.F.R. § 101.11(c)(3) to require covered establishments to provide nutrient substantiation proactively—not only upon request.
2. Issue a Level 1 guidance document recommending that restaurants voluntarily provide ingredient lists for menu items upon request","- Consumers increasingly eat meals away from home and want access to ingredient and nutrient content information.
- Packaged food is subject to more rigorous transparency standards than restaurant food, which is inconsistent.
- Pei Wei's own commissioned study found a majority of consumers strongly desire ingredient transparency.
- Pei Wei argues for equity in labeling standards between packaged food manufacturers and restaurants and commits to voluntarily posting ingredient statements by the end of 2019",FALSE,
FDA-2018-P-3843-0001_Citizen_Petition_from_Hooman_Noorchashm_Readacted.pdf,10/9/2018,,"Hooman Noorchashm, MD, PhD",Not mentioned.,"21 C.F.R. § 10.30 (under which the petition was submitted)
","FDA's clearance of “contained” laparoscopic power morcellators (e.g., Olympus PneumoLiner) and the continued market availability and use of “uncontained” laparoscopic power morcellators (e.g., by Karl Storz), despite black-box warnings and epidemiological risk data","The petitioner requests that the FDA Commissioner ban all “uncontained” laparoscopic power morcellator devices from use in gynecological operations involving resection of the uterus or associated tumors
","- Recent epidemiological data from Yale University (Desai et al.) shows a 2–10% incidence of occult or missed cancers in symptomatic women undergoing gynecological procedures.
- FDA analysis in 2014 identified a 1 in 350 incidence of occult leiomyosarcomas, leading to a black-box warning on power morcellators.
- Despite this, some surgeons still use uncontained devices, and companies like Karl Storz continue marketing them.
- The availability of a contained device (Olympus PneumoLiner) removes justification for continued use of uncontained techniques.
- Ethical, scientific, and clinical rationale favors a ban due to the severe risk of iatrogenic cancer upstaging.
- Petitioner urges collaboration with CDC officials informed of the data (Drs. Redfield and Briss)",FALSE,
FDA-2018-P-3861-0001_Citizen_Petition_from_Innogenix_LLC.pdf,10/11/2018,,"Innogenix, LLC",Not mentioned.,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FDC Act)
- 21 C.F.R. §§ 10.20, 10.30, and 314.93
- 21 C.F.R. § 25.31 (Environmental Impact)","Request for a determination that a new 125 mg strength of Metronidazole Tablets is suitable for submission via an Abbreviated New Drug Application (ANDA), different from the currently approved 250 mg and 500 mg strengths of the Reference Listed Drug (RLD), Flagyl (Metronidazole Tablets, USP).
","FDA is requested to determine that the proposed 125 mg strength of Metronidazole Tablets is suitable for submission in an ANDA, under the Suitability Petition process.
","- The proposed 125 mg strength allows for more precise dosing, especially for pediatric patients and patients requiring dose adjustment (e.g., hepatic impairment).
- Flagyl tablets are unscored, which makes splitting difficult; a scored 125 mg tablet will improve dosing flexibility.
- The proposed strength remains within approved dosage ranges and is consistent with the RLD labeling.
- The change does not raise questions of safety or effectiveness.
- Pediatric assessments are not required as the active ingredient, dosage form, indication, and route remain unchanged from the RLD.
- Bioequivalence is expected through proportional similarity and dissolution testing across strengths.",FALSE,
FDA-2018-P-3883-0001_Citizen_Petition_from_Foley___Lardner_LLP.pdf,10/11/2018,,Foley & Lardner LLP,"Foley & Lardner LLP is acting on behalf of an unnamed petitioner; the exact represented entity is not explicitly mentioned in the petition.
","- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- 21 C.F.R. §§ 10.30, 314.93, and 314.161","Discontinuation of the Reference Listed Drug (RLD) product Cortisporin® Otic Solution, NDA #050479, from the Orange Book listing
","The petitioner requests that the FDA determine whether Cortisporin® Otic Solution (NDA #050479) was discontinued for safety or effectiveness reasons.
","- The drug is listed under Discontinued Products in the Orange Book without a noted reason for discontinuation.
- Active pharmaceutical ingredients and drug product have current USP monographs.
- Reference Standard and generic equivalents are still available in the market, suggesting it may not have been withdrawn for safety or efficacy concerns.",FALSE,
FDA-2018-P-3896-0001_Citizen_Petition_from_Chul_Hi_Park_Ph_D___Redacted.pdf,10/14/2018,,"Chul-Hi Park, Ph.D.",Not mentioned.,"- Sections 510 and 513 of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. §10.30","FDA’s current clearance practice for marketing surgical staplers and staple line reinforcement materials (buttresses) for use in surgeries involving the lung and digestive tract organs, which lacks requirements for specific performance data related to staple line safety under physiological load.","The petitioner requests the FDA to:
• Require risk analysis and additional performance tests for surgical staplers and buttress materials intended for use in lung and digestive tract surgeries.
• Ensure performance testing under realistic physiological conditions involving staple line geometry and anatomical disposition.
• Revise labeling and Instructions for Use (IFU) accordingly.","- Current stapler devices are being cleared without evaluating their performance under dynamic physiological stress conditions (e.g., breathing, digestion).
- Staple line leaks in the lung and GI tract are critical complications with significant health risks.
- Existing burst pressure tests are insufficient as they do not simulate real-world dynamic conditions or anatomical variations.
- Certain staple line geometries and locations (e.g., near GE junction or in circular anastomosis) pose greater risk of failure due to stress concentration.
- A new baseline of performance testing (including FEA-based stress analysis) would improve safety, better guide design, and support realistic labeling claims.",FALSE,
FDA-2018-P-3933-0001_Citizen_Petition_from_Fresenius_Kabi_USA_LLC.pdf,10/16/2018,,"Fresenius Kabi USA, LLC",Not mentioned.,"- Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. § 10.30
- 505(b)(1)
- 21 C.F.R. § 25.31 (for Environmental Impact categorical exclusion)","Requesting therapeutic equivalence designation and ‘AP’ rating for Magnesium Sulfate Injection, USP, 10 gm/10 mL (ANDA 202411 by Hospira, Inc.) relative to Fresenius Kabi’s own NDA 019316 formulation.
","Designate Hospira, Inc.’s Magnesium Sulfate Injection, USP, 10 gm/10 mL (ANDA 202411) as therapeutically equivalent (with an ‘AP’ rating) to FK USA’s NDA 019316.
","The petitioner provided a side-by-side pharmaceutical equivalence comparison showing that the two products are identical in strength, route of administration, dosage form, active ingredients, and labeling. They also meet FDA's requirements for therapeutic equivalence as outlined in the Orange Book, including bioequivalence, safety, efficacy, labeling, and cGMP compliance. 

",FALSE,
FDA-2018-P-3949-0001_Citizens_Petition_from_Lachman_Consultant_Services.pdf,10/17/2018,,"Lachman Consultant Services, Inc.","Submitted on behalf of an unnamed client
","21 C.F.R. § 10.30, 21 C.F.R. § 25.31","Determination of whether TRISENOX (Arsenic Trioxide) Injection, 1 mg/mL, has been discontinued for reasons of safety or effectiveness.","The petitioner requests that the FDA determine whether TRISENOX (Arsenic Trioxide) 1 mg/mL Injection has been discontinued for reasons related to safety or effectiveness. If it has not, the petitioner asks FDA to allow submission of ANDAs referencing both the 1 mg/mL and 2 mg/mL strengths of TRISENOX as the Reference Listed Drug (RLD).","The 1 mg/mL strength of TRISENOX is listed as ""Discontinued"" in the FDA’s Orange Book. It appeared in labeling as late as February 2015 but was excluded in the January 2018 update. Lachman contends that a formal determination is needed to allow ANDAs to reference TRISENOX as the RLD if the discontinuation was not for safety or effectiveness reasons",FALSE,
FDA-2018-P-3951-0001_Citizen_Petition_from_Chul_Hi_Park_Redacted.pdf,10/18/2018,,"Chul-Hi Park, Ph.D.",Not mentioned.,"- Sections 510 and 513 of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. §10.30
- 21 C.F.R. §25.34 (Environmental Impact exemption)",510(k) clearance process for surgical stapler devices,"The petitioner requests that FDA:
1. Develop standardized performance tests for retroactive assessment of sealing performance of stapler devices.
2. Require manufacturers to conduct these tests on marketed devices, publish the results, and revise labeling and instructions accordingly.","- Staple line leaks in surgeries can cause morbidity and mortality
- Lack of proper testing or consideration of real-world mechanical stresses in current stapler device evaluations
- Previous 510(k) clearances do not reflect performance under physiological loads
- Need for a scientifically sound baseline for device evaluation
- Improved labeling, adverse event tracing, and surgical practices expected as outcome of retroactive tests",FALSE,
FDA-2018-P-4088-0001_Citizen_Petition_from_Data_Based_Medicine_Americas.pdf,10/26/2018,,Data Based Medicine Americas Ltd.,Not mentioned.,"- 21 C.F.R. § 10.30 (implied by format, standard for citizen petitions)
- 21 C.F.R. § 25.31(a) (categorical exclusion from environmental assessment)","The petition comments on the lack of sufficient safety labeling on isotretinoin products, particularly the absence of warnings about sexual side effects including those that persist after discontinuation.
","The petitioners request the FDA to:
- Immediately revise all isotretinoin product labels (both branded and generic)
- Add warnings, precautions, highlights of prescribing information, and a boxed warning to inform of sexual side effects such as erectile dysfunction, decreased libido, genital anesthesia, etc., which may persist indefinitely after discontinuation","The petition cites:
- Clinical case reports and studies indicating sexual dysfunction from isotretinoin
- Data from regulatory databases (FDA, MHRA, RxISK, Lareb) showing numerous reports of adverse sexual effects
- Evidence that such effects can emerge during or after treatment and may be permanent
- Similarities to other syndromes such as Post-SSRI Sexual Dysfunction (PSSD) and Post-Finasteride Syndrome (PFS)
- The lack of sufficient warnings deprives patients of informed consent and the ability to make risk-benefit decisions",FALSE,
FDA-2018-P-4143-0001_Citizen_Petition_from_University_of_Toledo.pdf,10/31/2018,,"Aakash Agarwal, Adjunct Professor, Engineering Center for Orthopaedic Research Excellence (E-CORE), Departments of Bioengineering and Orthopaedic Surgery, University of Toledo",Not mentioned.,"- 510(k) (Premarket Notification)
- PMA (Premarket Approval)
- 21 C.F.R. §§ 25.30–25.34, 25.40 (Environmental impact)","The petitioner objects to the FDA’s continued clearance (510(k)) and approval (PMA) of reusable/reprocessed implantable orthopedic devices, particularly pedicle screws and interbody cages","- Cease clearing or approving the reuse/reprocessing (repeated sterilization) of implantable orthopedic devices
- Require all pedicle screws and other orthopedic implants to be provided pre-sterilized and untouched before implantation, to avoid contamination","- Reprocessed implants risk preoperative and intraoperative contamination, leading to possible infection and implant failure
- Scientific evidence and multicenter trials show high contamination levels (up to 10⁷ bacterial CFUs) during surgery 

- Use of sterile guards around implants showed zero contamination, supporting safer practices
- Supporting data from multiple peer-reviewed studies and clinical trials",FALSE,
FDA-2018-P-4281-0001_Citizen_Petition_from_Fresenius_Kabi_USA__LLC.pdf,11/7/2018,,"Fresenius Kabi USA, LLC",Not mentioned.,"- 21 C.F.R. §§ 10.20, 10.30, 314.93 (citizen petition and ANDA suitability petition procedures)
- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (ANDA requirements for drug content variation)
- 21 C.F.R. § 25.31(a) (environmental impact categorical exclusion)",The petitioner comments on FDA’s prior approval of a discontinued NDA (NDA 019329) for Sodium Chloride 23.4% Injection and seeks permission to file an ANDA for a new Pharmacy Bulk Package (PBP) format with larger fill volumes (100 mL and 200 mL vials),"The petitioner requests FDA to:
- Approve an ANDA Suitability Petition for Sodium Chloride 23.4% Injection, USP
- Allow the product to be marketed in 100 mL and 200 mL plastic pharmacy bulk package vials (in addition to the previous 30 mL single-dose vial)","- The only change from the reference listed drug is total drug content (volume per vial); concentration, active ingredients, and indications remain unchanged
- FDA has previously treated volume changes as a strength change requiring petition approval
- The larger volume options would reduce waste and stocking burden for hospitals and infusion centers
- The containers meet USP definitions for Pharmacy Bulk Packages, with appropriate labeling and aseptic handling precautions
- No issues of safety or effectiveness are raised by this change",FALSE,
FDA-2018-P-4306-0001_Citizen_Petition_from_Jill_H__Osborne_Redacted.pdf,11/8/2018,,"Jill H. Osborne, founder of the Interstitial Cystitis Network (IC Network)
",Not mentioned.,"- General reference to statutory authority under the Federal Food, Drug, and Cosmetic Act (specific provisions not filled in the form)
- 21 C.F.R. §§ 25.30–25.34 or 25.40 (environmental impact)","The petition urges the FDA to investigate and issue an alert concerning the possible link between long-term use of Pentosan Polysulfate (Elmiron) and macular disease, particularly pigmentary maculopathy.
","The petitioner requests that the FDA:
- Investigate the association between Elmiron and macular disease
- Issue an alert informing patients of vision risks
- Advise patients to monitor their vision and consider annual eye exams
- Recommend cessation of the drug if retinal disease is identified
- Suggest that patients consider alternative bladder therapies","- Cites a study published in Ophthalmology (May 2018) by Emory Eye Center identifying a unique pigmentary maculopathy in 6 women using Elmiron long-term (12–20 years)
- Reports from the IC Network’s patient survey (n=753) showed that 53% reported eye or retinal illnesses, including difficulty reading, blurry vision, and dimming vision
- Cited concerns that Elmiron’s toxicity may manifest only after chronic exposure, possibly being underrecognized due to misdiagnosis as age-related macular degeneration or other eye diseases
- Notes that an early Elmiron clinical trial of 2,499 patients already listed optic neuritis, amblyopia, and retinal hemorrhage as adverse events
- The goal is early recognition and prevention of vision loss or blindness among Elmiron users",FALSE,
FDA-2018-P-4338-0001_Citizen_Petition_from_PMRS.pdf,11/13/2018,,"Pharmaceutical Manufacturing Research Services, Inc. (PMRS)
",Not mentioned.,"- 505(q) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. § 10.30 (citizen petition procedures)","FDA’s prior approval of Voxzogo (morphine sulfate extended-release) oral tablets, and related labeling and risk management practices for opioid analgesics. PMRS comments on the misalignment between its own efforts to commercialize a morphine sulfate ER product with abuse-deterrent features and the FDA’s regulatory actions.
","PMRS requests that the FDA:
- Revoke the approval of current non-abuse-deterrent formulations of morphine sulfate extended-release (ER) tablets
- Require abuse-deterrent labeling and technology for all ER opioid formulations
- Reconsider PMRS’s ANDA (Abbreviated New Drug Application) for an abuse-deterrent morphine sulfate ER product","- PMRS argues that continued approval of non-abuse-deterrent ER opioids undermines public health, especially amidst the opioid crisis
- PMRS developed a product with validated abuse-deterrent properties (e.g., extraction resistance and deterrence to IV and nasal abuse)
- Claims unfair treatment and inconsistency in FDA’s actions approving other manufacturers’ less secure products while rejecting or stalling PMRS’s ANDA
- Points to FDA’s own policies and guidance that emphasize the transition to abuse-deterrent opioid products as a strategy to reduce misuse and diversion",FALSE,
FDA-2018-P-4340-0001_Citizen_Petition_from_Freyr_Inc_.pdf,11/14/2018,,Freyr Inc. ,Representing an unnamed client,"- Section 505(j)(2)(C) of the FD&C Act
- 21 C.F.R. §§ 10.20, 10.30, 314.93 (citizen petition and ANDA suitability regulations)
- 21 C.F.R. § 25.31 (environmental impact – categorical exclusion)","FDA’s regulatory stance on the suitability of a Tigecycline for Injection, 50 mg/vial formulation containing 82.6 mg of arginine as a stabilizer, which differs from the Reference Listed Drug (RLD) TYGACIL (which uses lactose monohydrate).",- Determine that the proposed Tigecycline formulation (with 82.6 mg of arginine) is suitable for submission as an ANDA (Abbreviated New Drug Application) under Section 505(j).,"- The proposed formulation uses the same Q1/Q2 composition as another FDA-approved equivalent product: FK’s (Fresenius Kabi) Tigecycline for Injection, 50 mg/vial (NDA 205645)
- FDA has previously approved pharmaceutical equivalents containing arginine (e.g., NDA 205645 by FK and NDA 211158 by Amneal)
- The proposed product would be pharmaceutically equivalent to these approved alternatives, and no new clinical investigations are required to establish safety or efficacy
- The product is a sterile parenteral injection intended for intravenous infusion, following FDA’s guidance for ANDA submissions",FALSE,
FDA-2018-P-4454-0001_Citizen_Petition_from_Bonumose_LLC.pdf,11/19/2018,,Bonumose LLC,Not mentioned.,"- 21 C.F.R. § 10.30 (citizen petition regulation)
- 21 C.F.R. § 170.30 (GRAS notification)
- 21 U.S.C. § 321(s) (definition of “food additive”)
- 21 U.S.C. § 348 (regulation of food additives)","FDA's handling of Generally Recognized as Safe (GRAS) notifications, specifically the lack of response or objections to certain GRAS notices regarding new low-calorie sugars such as tagatose.
","- Promptly respond to GRAS Notices, particularly GRN 765 (regarding tagatose)
- Affirmatively state that the use of tagatose in food is GRAS, based on scientific procedures
- Streamline the GRAS review process and increase transparency in reviewing GRAS notifications","- Tagatose is a naturally occurring, low-calorie sweetener with recognized safety and physiological benefits (e.g., low glycemic index, prebiotic effects)
- FDA’s failure to respond to GRN 765 (submitted March 2018) causes uncertainty and delays for food companies seeking to use tagatose
- Bonumose cites multiple published scientific studies supporting the safety of tagatose
- The petition emphasizes that FDA’s GRAS process lacks timely engagement, impacting innovation and public health benefits of healthier alternatives",FALSE,
FDA-2018-P-4490-0001_Citizen_Petition_from_Hyman__Phelps___McNamara__P_.pdf,11/21/2018,,"Hyman, Phelps & McNamara, P.C.","The law firm represents an undisclosed pharmaceutical company; the identity of the client is redacted from the public version of the petition.
","- 21 C.F.R. § 10.30 (citizen petition procedures)
- Section 505(j) of the FD&C Act (ANDA process)
- References to FDA’s Orange Book Preface and ANDA suitability petition requirements","FDA's regulatory pathway concerning approval of an ANDA for a generic version of a drug product that differs from the reference listed drug (RLD) in both dosage form and strength
","The petitioner requests that FDA:
- Refuse to approve any ANDA that differs in dosage form and strength from the RLD unless a suitability petition has first been approved
- Reiterate and enforce its requirement that ANDAs comply with statutory limitations and established preface guidance","- Approving ANDAs with differences in dosage form and strength without a suitability petition is inconsistent with statutory and regulatory provisions
- Such approvals may pose risks to public health and undermine regulatory integrity
- Past FDA statements and the Orange Book Preface affirm that both dosage form and strength must match unless a suitability petition is granted
- Preventing circumvention of proper procedures ensures fair competition and compliance with the law",FALSE,
FDA-2018-P-4549-0001_Citizen_Petition_from_Unichem_Pharmaceuticals__USA.pdf,11/28/2018,,Unichem Pharmaceuticals (USA) Inc.,"Unichem Pharmaceuticals (USA), Inc. is submitting on behalf of Unichem Laboratories Limited, indicating a corporate representation relationship
","- 21 C.F.R. § 10.25(a)
- 21 C.F.R. § 10.30 (citizen petition procedures)
- Section 505(j) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. § 25.31 (environmental impact exclusion)","FDA’s designation of a Reference Standard (RS) for Terbinafine Tablets, 250 mg, specifically the continued listing of LAMISIL® by Novartis as the RS, which is no longer available in the market.
","The petitioner requests that FDA:
- Designate an additional reference standard (RS) for Terbinafine Tablets in the Orange Book
- Preferably, designate Aurobindo Pharma’s product (ANDA 078297) as the RS due to its market leadership and availability","- The currently designated RS (LAMISIL®) is unavailable in the market, preventing required bioequivalence (BE) testing
- FDA guidance (Referencing Approved Drug Products in ANDAs) allows a new RS designation if the existing RS is inaccessible
- IMS sales data shows that Aurobindo’s product is the market leader among three available generic Terbinafine Tablets
- Designating a new RS will enable generic development and ANDA submission",FALSE,
FDA-2018-P-4590-0001_Citizen_Petition_from_Ascend_Laboratories__LLC.pdf,11/30/2018,,"Ascend Laboratories, LLC","Ascend Laboratories, LLC is acting as the U.S. Agent for Alkem Laboratories, Ltd., the manufacturer seeking action","- 21 C.F.R. §§ 10.25, 10.30 (citizen petition procedures)
- Sections 505(j) and 505(w) of the FD&C Act
- 21 C.F.R. §§ 314.122 and 314.161 (drug listing and withdrawal)
- 21 C.F.R. § 25.31 (environmental impact categorical exclusion)","FDA/DEA scheduling of cannabidiol (CBD) drug products, specifically the classification of synthetic CBD formulations like that proposed by Alkem as Schedule V controlled substances, consistent with the innovator drug Epidiolex.
","Ascend requests that the FDA/DEA:
- Assign Schedule V status to a generic version of Epidiolex (cannabidiol oral solution 100 mg/mL) manufactured using synthetic CBD
- Confirm its eligibility for ANDA (Abbreviated New Drug Application) submission","- The reference listed drug Epidiolex (approved June 25, 2018, NDA 210365) was rescheduled from Schedule I to Schedule V due to low abuse potential
- The proposed synthetic CBD formulation avoids contamination by tetrahydrocannabinols (THC) and results in equal or higher purity than natural CBD
- Synthetic route offers further reduced psychotropic THC content, minimizing abuse risk even more than the innovator’s product
- DEA precedent and Federal Register notice (Docket No. DEA–486) allow Schedule V designation for FDA-approved CBD products with ≤ 0.1% THC content",FALSE,"Missing in original spreadsheet, so completed in full here."
FDA-2018-P-4591-0001_Citizen_Petition_from_International_Maple_Syrup_In.pdf,11/1/2018,,"International Maple Syrup Institute
",Not mentioned.,"- 21 C.F.R. § 168.140 (Standard of Identity for Maple Sirup)
- Environmental references to 21 C.F.R. §§ 25.30, 25.31, 25.32, 25.33, 25.34, and 25.40","The petition seeks amendment of the Standard of Identity (SOI) for maple syrup currently defined under 21 C.F.R. § 168.140.
","The petitioner requests the FDA to:
- Revise the definition of pure maple syrup in §168.140(a)
- Remove optional ingredients listed in §168.140(b), including salt and chemical preservatives
- Eliminate the term “Maple Sirup” from the regulation and consistently use “Maple Syrup”","- The current federal definition is outdated and inconsistent with modern state-level maple syrup regulations
- A standardized North American definition is needed to support Codex certification
- Salt and chemical preservatives are no longer used in the industry; defoaming agents are processing aids, not ingredients
- Ensures the purity and integrity of maple syrup
- No anticipated opposition from public or industry stakeholders",FALSE,"Missing in original spreadsheet, so completed in full here."
FDA-2018-P-4642-0001_Citizen_Petition_from_Provetica_Animal_Health_LLC.pdf,11/20/2018,"Letterhead dated November 20, but stamp reflects December 3.",Provetica Animal Health LLC,Not mentioned.,"- Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act (FFDCA)
- 21 C.F.R. § 10.30 (citizen petition procedures)
- 21 C.F.R. § 25.30(h) (categorical exclusion from environmental assessment)
- 21 C.F.R. § 25.21 (environmental impact)","FDA’s determination of suitability for a generic animal drug application (ANADA) for a different dosage form than the approved reference listed drug, Atopica™ (cyclosporine capsules).
","The petitioner requests that FDA:
- Determine that an Abbreviated New Animal Drug Application (ANADA) is suitable for a non-encapsulated oral solution of cyclosporine that differs in dosage form from the reference listed drug (a capsule)","- The reference drug (Atopica™) is a gelatin capsule containing cyclosporine; the proposed generic is a non-encapsulated oral solution
- The petition references a previously approved suitability petition (FDA-2017-P-6968) for the same dosage change, approved by FDA on March 14, 2018
- The proposed generic matches the reference product in active ingredient, strength, administration route, and labeled dose
- The solution offers dose flexibility and may improve ease of administration for veterinarians and pet owners
- The product will be provided in calibrated dosing syringes and multiple bottle sizes to match therapeutic needs
- Labeling will align with the reference product categories and instructions",FALSE,"Missing in original spreadsheet, so completed in full here."
FDA-2018-P-4656-0001_Citizen_Petition_from_Animal_Legal_Defense_Fund.pdf,12/6/2018,,Animal Legal Defense Fund,Not mentioned.,"- 21 C.F.R. § 10.35 (petition to stay action)
- 21 C.F.R. § 10.31 (certification)
- Federal Food, Drug, and Cosmetic Act (FFDCA) – 21 U.S.C. § 360b(d), § 360b(i)
- Administrative Procedure Act (APA)
- National Environmental Policy Act (NEPA) – 42 U.S.C. § 4332(2), 40 C.F.R. §§ 1508.8, 1508.25, 1508.27, 1502.14
- Endangered Species Act (ESA) – 16 U.S.C. § 1536(a)(2), (c)(1); 50 C.F.R. § 402.01(b), § 402.12(c)","Approval of New Animal Drug Application (NADA) 141-508 for Experior™ (lubabegron) and its associated Environmental Assessment (EA) and Finding of No Significant Impact (FONSI)
","Stay the FDA’s approval of NADA 141-508 (Experior™) for an indefinite duration unless and until the FDA complies with applicable laws (APA, FFDCA, NEPA, ESA)
","The ALDF alleges several legal and scientific deficiencies:
- Failure to publish notice of approval in the Federal Register as required by the FFDCA
- Approval of a drug not proven safe or effective under the FFDCA
- Public health risks due to the drug’s impact on animal behavior and meat safety
- Failure to evaluate reasonable alternatives, cumulative effects, or impacts on animal health under NEPA
- No consultation with wildlife agencies as required by ESA
- Issuance of a FONSI despite acknowledged environmental uncertainties and omissions regarding groundwater contamination risks and manure management",FALSE,
FDA-2018-P-4661-0001_Citizen_Petition_from_Hyman__Phelps___McNamara__P_.pdf,12/6/2018,,"Hyman, Phelps & McNamara, P.C.",Representing an unnamed client,"- 21 C.F.R. § 10.25(a) and 10.30 (citizen petition procedures)
- Section 505(j) of the FDCA (ANDA requirements)
- 21 C.F.R. § 314.3 (definitions, including listed drug)
- 21 C.F.R. § 25.31 (categorical exclusion from environmental assessment)
- 21 C.F.R. § 10.30(b) (economic impact information)","FDA’s designation of the reference standard (RS) for Diclofenac Potassium Tablets, 50 mg under ANDA 075463, which is reportedly commercially unavailable.
","The petitioner requests that the FDA:
- Designate ANDA 075219 (also for Diclofenac Potassium Tablets, 50 mg) as a new reference standard (RS)
- Update the Orange Book to reflect this new designation","- The currently designated RS (ANDA 075463) is not commercially available, and its manufacturer is subject to an FDA Warning Letter for GMP violations
- Without an available RS, new generic applicants cannot conduct bioequivalence testing, effectively blocking competition
- An alternative ANDA (075219) is available and suitable to serve as a RS
- The original RLD (CATAFLAM) is discontinued but was not withdrawn for safety or effectiveness reasons
- Designating ANDA 075219 as a RS will restore a pathway for ANDA submissions and generic competition",FALSE,
FDA-2018-P-4664-0001_Citizen_Petition_from_Fresenius_Kabi_USA__LLC.pdf,12/7/2018,,"Fresenius Kabi USA, LLC",Not mentioned.,"- 21 C.F.R. § 10.30 (citizen petition procedures)
- Federal Food, Drug, and Cosmetic Act (unspecified provisions)
- 21 C.F.R. § 320.22(b) (waiver of bioequivalence for sterile injectable products)
- 21 C.F.R. § 25.31 (categorical exclusion from environmental impact assessment)
- 21 C.F.R. § 10.30(b) (economic impact analysis)","The FDA’s current therapeutic equivalence designation for Palonosetron Hydrochloride Injection; specifically, the petitioner comments on the absence of an “AP” therapeutic equivalence rating for their product (NDA 208109) relative to the RLD Aloxi® (NDA 021372).
","Request for the FDA to designate NDA 208109 (Palonosetron Hydrochloride Injection by FK USA) as therapeutically equivalent with an ‘AP’ rating to the RLD Aloxi® (Palonosetron Hydrochloride Injection, NDA 021372 by Helsinn Healthcare).
","- FK USA’s product is pharmaceutically and therapeutically equivalent to the RLD, with the same active ingredient, strength, dosage form, and route of administration.
- A side-by-side comparison table (page 2) shows identical indications and comparable excipients, differing only in minor tonicity and chelating agents (e.g., substitution of sodium chloride for mannitol and exclusion of edetate disodium dihydrate).
- FDA granted a waiver of in vivo bioequivalence testing under 21 C.F.R. § 320.22(b) since the product is a sterile intravenous solution.
- Stability data demonstrated the product’s safety and efficacy were not affected by formulation differences.
- The product relied on published literature and RLD data under the 505(b)(2) approval pathway. ",FALSE,
FDA-2018-P-4664-0004_Withdrawal_from_Fresenius_Kabi_USA_LLC.pdf,12/17/2021,"Date was incorrectly identified by ChatGPT, but date has been manually adjusted. ","Fresenius Kabi USA, LLC",Not mentioned.,Not applicable.,Not applicable.,"Withdrawal of the previously submitted citizen petition.

","The product (NDA 208109) is no longer distributed or marketed and has been moved to the discontinued section of the Orange Book, making the petition moot

",FALSE,
FDA-2018-P-4714-0001_Citizen_Petition_from_TherapeuticsMD__Inc_.pdf,12/11/2018,,"TherapeuticsMD, Inc.",Not mentioned.,"- 21 C.F.R. § 10.30 (citizen petition procedures)
- 21 U.S.C. § 355(b)(1) (drug approval provisions)
- 21 C.F.R. §§ 314.50, 314.94, 314.105, 314.127, and 320.22(b) (NDA/ANDA requirements and bioequivalence waivers)
- Section 505(b)(2) of the FDCA (application type used by the petitioner)
- 21 C.F.R. § 25.31(b) (categorical exclusion for environmental assessment)","FDA’s potential approval of ANDAs for generic versions of Imvexxy® (estradiol vaginal inserts) without requiring in vivo bioequivalence studies that include clinical evaluation of local estrogenic effects, particularly vaginal cytology parameters.","TherapeuticsMD requests the FDA to:
- Refuse to approve any ANDA referencing Imvexxy® unless it includes data showing therapeutic equivalence and local effects on vaginal tissue
- Require that such ANDAs include clinical data demonstrating local efficacy in treating dyspareunia due to VVA","- Imvexxy® delivers very low doses of estradiol directly to vaginal tissue, leading to localized effects, with minimal systemic absorption
- Bioequivalence based solely on systemic exposure (pharmacokinetics) would be insufficient to ensure therapeutic equivalence for a locally acting drug
- FDA precedent (e.g., Vagifem®) shows that local clinical efficacy data may be required
- Without local-effect data, generic products may not reliably deliver the same therapeutic benefit, particularly in treating dyspareunia
- Risk of inappropriate approval could compromise patient outcomes and public trust in regulatory oversight",FALSE,
FDA-2018-P-4769-0001_CITIZEN_PETITION__FROM_EXELA_PHARMA_SCIENCES__LLC_.pdf,12/16/2018,,"Exela Pharma Sciences, LLC",Not mentioned.,"- 21 C.F.R. § 10.25(a) and § 10.30 (Citizen Petition procedures)
- Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. § 314.3(b) (Therapeutic equivalence definition)
- 21 C.F.R. § 320.22 (Waiver of in vivo bioequivalence)
- 21 C.F.R. § 25.31 (Environmental impact – categorical exclusion)
- 21 C.F.R. § 10.30(b) (Economic impact statement)","Absence of a Therapeutic Equivalence (TE) Code for Exela’s GLYRX-PF (glycopyrrolate injection) in the FDA’s Orange Book, despite its bioequivalence to the reference listed drug (RLD), Robinul® (NDA 017558).
","The petitioner requests FDA to assign a TE Code “AP” to GLYRX-PF (both 0.2 mg/mL and 0.4 mg/2mL strengths) in the Orange Book
","- GLYRX-PF is pharmaceutically equivalent to Robinul®: same active ingredient, dosage form, route, and concentration
- The product was approved under 505(b)(2) and granted a bioequivalence waiver under 21 C.F.R. § 320.22
- The Orange Book’s own guidance permits assignment of an “AP” code to injectable aqueous solutions meeting required criteria
- Several ANDAs for glycopyrrolate injections already carry “AP” ratings, supporting the precedent
- Exela’s 0.4 mg/2mL formulation matches the strength and concentration of Robinul® (0.2 mg/mL), fulfilling bioequivalence and labeling alignment requirements",FALSE,
FDA-2018-P-4769-0004_Withdrawal_of_Petition_Docket_No__FDA_2018_P_4769.pdf,3/2/2021,"Date was incorrectly identified by ChatGPT, but date has been manually adjusted. ","Exela Pharma Sciences, LLC",Not mentioned.,Not applicable.,Not applicable.,"Withdrawal of the previously submitted citizen petition.

","Not mentioned. The letter simply states the petition is withdrawn without providing a reason

",FALSE,
FDA-2018-P-4812-0001_Citizen_Petition_from_Arent_Fox_LLP.pdf,12/19/2018,,Arent Fox LLP,Representing an unnamed client,"- 21 C.F.R. §§ 10.25(a), 10.30(b), 314.161, 314.122, 314.162
- Section 505(j) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. § 25.31 (Environmental impact - categorical exclusion)
- 21 C.F.R. § 25.40 (Environmental assessment)","The FDA’s listing of Nizoral® (Ketoconazole 2% topical cream, NDA No. N019084) in the Discontinued Section of the Orange Book without determining whether it was withdrawn for reasons of safety or effectiveness
","The petitioner requests the FDA to determine whether Nizoral® (Ketoconazole 2% topical cream, NDA N019084) has been voluntarily withdrawn from the market for safety or effectiveness reasons
","- NDA 019084 (Nizoral Cream) is still listed as the Reference Listed Drug (RLD) in the Orange Book.
- ANDA applicants need clarity on whether the product was withdrawn for regulatory or commercial reasons.
- A prior FDA denial of a similar citizen petition (FDA-2017-P-3468) indicates Teva’s ANDA is still in distribution, and FDA acknowledged Nizoral was moved to the discontinued section but did not clarify if for safety or effectiveness.
- The petitioner is unaware of any safety or efficacy issues leading to discontinuation",FALSE,
FDA-2018-P-4832-0001_Citizen_Petition_from_Goodwin_Procter_LLP__on_beha.pdf,12/21/2018,,Goodwin Procter LLP,"Submitted on behalf of Amneal Pharmaceuticals LLC
","- Federal Food, Drug, and Cosmetic Act (FD&C Act)
- 21 C.F.R. §§ 10.25, 10.30, 10.31, 314.70
- 21 C.F.R. § 314.3(b)
- 21 C.F.R. § 314.125(a)(4)
- 21 C.F.R. § 25.31
- Section 505(d)(4) of the FD&C Act, 21 U.S.C. § 355(d)(4)","- FDA's assignment of AB2 therapeutic equivalence rating to Euthyrox (levothyroxine sodium)
- FDA’s potential approval of supplemental NDAs for bulk/loose packaging of non-color-coded Euthyrox tablets","- Rescind AB2 ratings for Euthyrox in the Orange Book and assign BX ratings instead
- Refrain from approving any sNDAs for Euthyrox that allow bulk or loose packaging of non-color-coded tablets without sufficient safety data","- Euthyrox is a narrow therapeutic index (NTI) drug requiring precise dosage
- All dosage strengths of Euthyrox tablets are off-white, unlike other levothyroxine products that use color coding to differentiate strengths
- Risk of “look-alike” medication errors due to lack of color differentiation, especially if separated from original blister packaging
- Patient safety may be compromised, with potential for underdosing or overdosing
- FDA itself previously recommended color differentiation and acknowledged risks of color similarity in NTI drugs",FALSE,
FDA-2018-P-4851-0001_Citizen_Petition_from_Hetero_Labs_Limited.pdf,12/20/2018,,Hetero Labs Limited,Not mentioned.,"- 21 C.F.R. § 10.30 (Citizen Petition procedure)
- 21 C.F.R. § 314.161 (Determination of withdrawal for safety/effectiveness)
- 21 C.F.R. § 314.162 (Procedures for withdrawn drugs)
- 21 C.F.R. § 25.31 (Environmental impact exclusion)
- 21 C.F.R. § 10.30(b) (Economic impact info provision)","- Listing of Lupron® (Leuprolide Acetate) NDA 019010 in the Discontinued Section of the FDA Orange Book
- Lack of FDA determination on whether it was withdrawn for safety or effectiveness reasons","- That the FDA determine Lupron® (Leuprolide Acetate), NDA 019010, was not withdrawn for safety or effectiveness reasons
- That FDA publish this determination in the Federal Register and annotate the Orange Book accordingly","- Public searches yielded no evidence that Abbvie Endocrine Inc. withdrew Lupron® for safety or efficacy issues
- The drug is currently listed in the Discontinued Section but lacks an annotation clarifying that it was not withdrawn for safety/effectiveness
- There are no court decisions regarding product liability linked to this product
- Hetero seeks FDA confirmation to support an ANDA referencing Lupron® as the RLD
",FALSE,